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Mice pretreated with a mild toxic dose of acetaminophen (APAP)
acquire resistance to a second, higher APAP dose. This phenomenon is
termed APAP autoprotection and the exact mechanism by which such
resistance develops is not clearly known. Given the prevalence of APAPhepatotoxicity and the human health impact of this potentially hepatotoxic
agent, a further understanding of the mechanism(s) involved in such
protection are of considerable significance and could lead to new modalities
of treatment of acute drug-induced liver injury. The work presented in this
thesis investigates FMO3 gene expression during APAP-induced liver injury
as well as the functional significance of FMO3 over-expression during APAPinduced liver injury. Furthermore, FMO3 gene regulation during oxidative
stress conditions is also examined.
Acetaminophen treatment resulted in up-regulation of liver Fmo3
protein in male mice. Female mice express higher liver Fmo3 than males and
are highly resistant to APAP hepatotoxicity. Inhibition of Fmo3, by
methimazole, renders female mice susceptible to APAP-induced liver injury.
These findings are suggestive of a protective function for Fmo3. In addition to
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APAP, ANIT and BDL also increase Fmo3 gene expression in mice. Because
these hepatotoxicants also induce oxidative stress, we also investigated the
potential role of the oxidative stress sensor and transcription factor, NRF2, in
FMO3 gene regulation. Both in vivo and in vitro results show that
transcriptional regulation of FMO3 might not involve the NRF2-KEAP1
regulatory pathway.
Human liver can adapt to APAP-induced hepatotoxicity similar to our
APAP autoprotection mouse model. The last part of this dissertation
examined FMO3 gene induction in a human hepatoma cell line, HepaRG.
APAP induced FMO3 gene expression in HepaRG cells, and over-expression
of FMO3 protects cells against APAP-induced cytotoxicity. The unexpected
observation of a faster differentiation phenotype in HepaRG cells overexpressing FMO3 suggests that FMO3 may play an important role in cellular
differentiation.
Collectively, data presented in this thesis provide evidence for Fmo3
as a novel genetic determinant of APAP-induced liver injury. Furthermore, this
thesis describes a novel protective function for FMO3. Findings from HepaRG
cells suggest that FMO3 over-expression in response to APAP may be a
driving force for differentiation in regenerating hepatocytes.
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CHAPTER 1
Review of Literature
1.1 Liver Function and Structure
The structure and function of the liver is well understood. The
description that follows is adapted from Casarett and Doull’s Toxicology: The
Basic Science of Poison (Klaassen, 2008), Guyton and Hall: Textbook of
Medical Physiology (Hall, 2011), and Wheater’s Functional Histology (Young,
Lowe, Stevens and Heath, 2006).
Liver Function. The liver’s strategic location between the gastrointestinal
tract and the rest of the body helps to serve as a checkpoint for substances
arriving in portal veins. The liver has multiple functions involving nutrient
homeostasis (processing of carbohydrates, amino acids and lipids); storage
of glycogen, vitamins and iron; filtration of particulates like bacterial
endotoxins; protein synthesis including albumin, clotting factors and transport
proteins; bioactivation and detoxification of xenobiotics; and synthesis and
secretion of bile and cholesterol. Importantly, the liver is the main organ
where xenobiotics and endogenous compounds are metabolized into more
polar, water-soluble derivatives that can be easily excreted into urine and/or
bile.
Structural Organization of the Liver. The liver is the largest visceral organ,
as well as the largest gland in the body, representing 2.5 % of total body
weight. Blood flow into the liver sinusoids comes from the hepatic portal vein
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(60-70 %) and hepatic artery (30-40 %). The liver is therefore unusual in
having both arterial and venous blood supplies as well as a separate venous
drainage. The liver consists of various cell types: hepatocytes (parenchymal
cells), sinusoidal lining cells (endothelial cells, Kupffer cells, Ito cells and pit
cells), hematopoietic cells, nerve cells, and blood and lymphatic vessel cells.
Hepatocytes are the main functional cells in the liver. The majority of cells
lining the hepatic sinusoids are endothelial cells that are fenestrated and have
contractile and metabolic functions. Kupffer cells, which are resident
macrophages that form part of the monocyte-macrophage defense system,
phagocytize particles, detoxify endotoxin, secrete mediators of inflammation,
process antigens, and catabolize lipids and glycoproteins. Ito cells have dual
functions of vitamin A storage and production of extracellular matrix and
collagen. Lastly, pit cells are liver-specific natural killer (NK) cells that reside
mostly near portal veins.
The liver is structurally organized into polygon-shaped lobules
surrounded by connective tissue (Figure 1.1). Each lobule consists of a
central vein. Cords of hepatocytes and the intervening sinusoids extend
radially between the central vein and the periphery of the lobule. At the
corners of the lobule are the portal triads that are made up of a hepatic
arteriole, portal vein and bile duct. This lobular organization is most easily
appreciated in sections of pig liver. In human liver, lobules are not as well
defined by connective tissue although they still contain a central vein and are
surrounded by portal triads. Blood entering the portal tract via the portal vein
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and hepatic artery mixes as it enters the sinusoids, percolates along the cords
of hepatocytes and eventually flows into central veins, and exits the liver via
the hepatic vein. The lobule is thus divided into three regions known as
centrilobular, midzonal, and periportal. Even though the structural unit of the
liver can be considered as a conceptually simple hepatic lobule, the
physiology of the liver is more precisely represented by a unit structure known
as the hepatic acinus. The acinus is a roughly berry-shaped liver
parenchymal unit centered on the portal tract (comprising the terminal
branches of the portal vein and hepatic artery). The acinus is divided into
zone 1, 2, and 3. Zone 1 is closest to the portal tract (similar to the periportal
area) and receives blood rich in oxygen (9-13 %) and nutrients, while Zone 3
abuts the central vein (coincides with the centrilobular region) and receives
the least oxygen (4-5 %). Zone 2 is intermediate between Zone 1 and Zone 3
and coincides with the midzonal region.
In addition to the gradient in oxygen concentrations along the hepatic
sinus,

there

are

gradients

in

blood

bile

acid

concentrations

and

heterogeneities in protein levels within hepatocytes that generate gradients of
metabolic functions. For example, mitochondria-rich Zone 1 has high levels of
oxidative enzymes (fatty acid oxidation), gluconeogenesis and ammonia
detoxification to urea. Hepatocytes in Zone 3 contain high levels of esterases
and low levels of oxidative enzymes. Gradients of enzymes involved in the
bioactivation and detoxification of xenobiotics is seen along the acinus. For
example, greater amounts of cytochrome P450 proteins (CYP), particularly
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CYP2E1, are higher in Zone 3, and glutathione (GSH) levels are higher in
Zone 1. Hepatocytes in different zones exhibit differences in sensitivity to
chemical toxicity, which are dictated by zonal gradients in GSH, nutrients,
oxygen, and bioactivation enzymes.
Cords of hepatocytes are arranged radially around the central vein with
bile canaliculi between adjacent hepatocytes. The canaliculi are separated
from the intercellular space between hepatocytes by tight junctions that are
permeable to water, electrolytes, and some small organic cations. These tight
junctions are impermeable to anions such as bile acids (BA), glutathione, and
bilirubin-diglucuronide resulting in their high concentrations in bile. Canaliculi
form channels between hepatocytes that connect to a series of ducts in the
liver. The large extrahepatic bile ducts merge into the common bile duct. Bile
is modified and stored in the gall bladder before it is released into the
duodenum. It is important to note that several species including rats do not
have gall bladders.
1.2 Hepatic Metabolizing Systems. The liver is the main organ where a
majority of the xenobiotics are metabolized and eventually excreted. Blood
from the stomach and the intestine carrying ingested nutrients along with
drugs and environmental toxicants flow into the portal vein and then through
the liver before entering the systemic circulation. Hence, the liver is exposed
to high concentrations of these absorbed compounds. The goal of hepatic
metabolism is to eliminate endogenous intermediates and exogenous
chemicals by making it more polar and readily excreted through urine. The
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mammalian liver is equipped with enzyme systems that perform this function.
During the past six decades, a large body of knowledge has accumulated
documenting the role of xenobiotic-metabolizing enzyme systems in the
mediation of the toxic effects of drugs, environmental pollutants, and some
endogenous compounds. Here, some of these enzyme systems are briefly
discussed.
Conceptually, the drug metabolizing enzymes involved in xenobioticmetabolism or -biotransformation fall into three groups: Phase I, Phase II, and
Phase III reactions.

Phase I metabolism involves enzymes that catalyze

hydrolysis, reduction, or oxidation reactions by introducing functional groups
such as ‐OH, ‐NH2, ‐SH, or ‐COOH. Phase I metabolism usually results in
a small increase in water solubility. One of the most important enzyme
systems involved in Phase I metabolism is the microsomal CYP superfamily,
which to date includes fifty-seven identified enzymes in humans. Other Phase
I

enzymes

include

flavin-containing

monooxygenases

(microsomal),

carboxylesterases, epoxide hydrolases, etc.
Phase II conjugation reactions require cofactors (except acetylation
and methylation reactions) that react with functional groups that are either
already present on the molecule or are introduced/exposed during Phase I
metabolism. The Phase II drug metabolizing enzymes catalyze the coupling
of endogenous small molecules to xenobiotics that usually result in large
increases in water solubility so that they are more readily excreted. Phase two
enzymes include members of the UDP-glucuronysltransferase (microsomal),
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sulfotransferase (cytosolic), and GSH transferase (cytosolic, microsomal and
mitochondrial).
Phase III reactions result in the cellular efflux of polar xenobiotics by
membrane-bound transporters to either blood or bile. For the purposes of this
thesis, only three members of the ABCC transport family will be discussed:
multidrug resistance-associated proteins (Mrp) 2, 3, and 4. Mrp2 is
predominantly expressed at the hepatocyte canalicular membrane and is
responsible for the efflux of chemicals and metabolites into bile. Substrates
for Mrp2 include glucuronide and GSH conjugates. Mrp 3 and 4, on the other
hand, are basolateral efflux transporters that transport metabolites into the
blood. Transporters commonly exhibit broad and overlapping substrate
specificities.
The result of xenobiotic biotransformation is typically a reduction in
lipophilicity and toxicity. However, in some cases, metabolism can produce
reactive intermediates that can result in an enhancement of toxicity. Some of
these intermediate metabolites covalently bind to cellular macromolecules
(proteins and lipids) resulting in oxidative stress and eventually cellular death.
Examples of xenobiotic activation by CYP enzymes include acetaminophen
(APAP), carbon tetrachloride, benzene, and benzo[a]pyrene.
1.3 APAP Hepatotoxicity
Incidence. Acetaminophen, currently one of the most commonly used
analgesic and antipyretic agents in the U.S. and Great Britain, was first
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described more than a century ago. However, APAP-poisoning and APAPhepatotoxicity was first recognized in Great Britain (Davidson & Eastham,
1966) and later in the U.S. (McJunkin et al., 1976). APAP usage increased
after aspirin was implicated in over 80 % of Reye’s syndrome cases in
children. As APAP usage increased, the incidence of APAP-induced
hepatotoxicity also increased. In a retrospective study from 1994 to 1996,
APAP-induced hepatotoxicity comprised 20 % of acute liver failure (ALF)
cases in the U.S. (Schiodt et al., 1999). These numbers increased over time
and by the early 2000s nearly 50 % of ALF cases were due to APAP. Even
though this fraction has remained fairly constant over the past decade, it is
still a very prominent leading cause of acute liver failure accounting for more
that 50 % of all acute liver failure cases from all etiologies (Larson et al.,
2005; W. M. Lee, 2010). The potential for drug-related morbidity and
mortality, and the popularity of this drug, make it a significant human health
problem.
Metabolism. Upon administration of a therapeutic dose of APAP, a majority
of the parent compound (~90 %) undergoes Phase II metabolism in the liver
by glucuronidation and sulfation, and the metabolites (APAP-GLUC and
APAP-SUL) are safely excreted in urine or bile (Nelson, 1990). A small
portion of APAP (5-15 %) undergoes Phase I metabolism by several
members of the CYP superfamily including CYP2E1, 1A2, and 3A4. This
reaction results in the formation of a reactive metabolite, N-acetyl-pbenzoquinone imine (NAPQI), which by GSH conjugation is effluxed out into
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the bile (Mitchell et al., 1973; Mitchell et al., 1973; Zaher et al., 1998). The
GSH conjugate can further undergo cleavage to form a cysteine conjugate
(APAP-CYS) and subsequent acetylation to the mercapturic acid conjugate
(APAP-NAC). However, during APAP overdose, the Phase II pathways are
saturated and a large fraction of the drug undergoes metabolism by CYP
enzymes, generating more NAPQI. Once GSH stores are depleted,
unconjugated NAPQI can then exert it’s cytotoxic effect by causing oxidative
stress, covalent binding to thiol groups on macromolecules and/or lipid
peroxidation and mitochondrial dysfunction. (Cohen et al., 1997; Jaeschke &
Bajt, 2006; Patten et al., 1993).
Phase III metabolism of APAP includes transport of APAP-metabolites
into bile or urine for excretion and there is an overlap in metabolite transport
between transporters. While Mrp2 is responsible for the excretion of APAPGLUC conjugate into bile (Chen et al., 2003), Mrp3 is involved in the efflux of
APAP-GLUC into plasma. Mrp3 has a higher affinity for APAP-GLUC
compared to Mrp2 (Manautou et al., 2005). Mrp4 and the Breast cancer
resistance protein (Bcrp) are responsible for the transport of APAP-SUL
conjugate into plasma and bile, respectively (Zamek-Gliszczynski et al., 2005;
Zamek-Gliszczynski et al., 2006).
Protein Covalent Binding in APAP-Induced Cell Injury. As previously
mentioned, the CYP oxidative metabolite of APAP, NAPQI, is responsible for
cytotoxic effects of APAP. The earliest effect of NAPQI generation is profound
depletion of hepatocellular GSH (Mitchell et al., 1973). Once hepatocellular
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GSH levels are depleted, NAPQI reacts with thiol groups of protein leading to
protein adducts (Jollow et al., 1973; Potter et al., 1973). Using radioactively
labeled APAP, studies demonstrated that APAP binds irreversibly to hepatic
proteins

in

multiple

subcellular

compartments,

including

nucleus,

mitochondria, endoplasmic reticulum, and cytosol (Jollow et al., 1973; Potter
et al., 1973). Immunohistochemical studies further identified some of these
covalently modified proteins that are implicated in APAP-induced liver injury
(Cohen et al., 1997). Studies also demonstrated that APAP could inhibit
mitochondrial respiration and increase mitochondrial oxidative stress by
modifying mitochondrial proteins (Jaeschke, 1990; Meyers et al., 1988).
Although the covalent binding of proteins and APAP hepatotoxicity occur
concurrently, APAP-bound proteins are detectable in mice given non-toxic
doses of APAP. Conversely, antioxidant treatment that prevents APAP
hepatotoxicity does not alter covalent protein binding. These data suggest
that covalent binding is required but not sufficient for APAP-induced
hepatotoxicity.
Mechanism of Oxidative Stress Mediated Liver Pathophysiology.
Reactive Oxygen Species (ROS) are produced during metabolism. Under
normal physiological conditions, these pro-oxidants are detoxified by cellular
antioxidant

systems.

When

the

balance

between

pro-oxidants

and

antioxidants is disturbed, in favor of ROS generation to the cell’s capacity to
detoxify them, a state of oxidative stress ensues. During APAP overdose,
there is a significant elevation of GSH disulphide (GSSG) in cellular as well as
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mitochondrial compartments of hepatocytes (Jaeschke, 1990; Jaeschke et al.,
2012). Studies show that oxidative stress is an initiating event in APAP
hepatotoxicity (Bajt et al., 2004; Jaeschke, 2003). Mitochondrial dysfunction
generates superoxide that reacts with nitric oxide to form a potent oxidant and
nitrating

species,

peroxynitrite.

Immunohistochemical

analysis

shows

formation of lipid peroxide and nitrotyrosine adducts in liver during APAP
overdose. The oxidative stress caused by ROS and nitrogen species
increases intracellular calcium levels resulting in the opening of mitochondrial
membrane permeability transition (MPT) pores (Jaeschke & Bajt, 2006). ROS
also activates JNK MAPKinase pathway. Activated c-Jun N-terminal Kinase
(JNK) inactivates anti-apoptotic proteins Bcl-2 and Bcl-xL by phosphorylation.
The resulting increase in pro-apoptotic proteins results in an increase in
permeability of the mitochondrial membrane and triggers the release of
cytochrome C from mitrochondria to cytosol (El-Hassan et al., 2003; Ghosh et
al., 2010). This combination ultimately results in reduction of cellular
adenosine-tri-phosphate (ATP) and necrosis of the liver.
Transporter Expression During APAP-induced Liver Injury. Rodent
models are extensively used to investigate the mechanisms of APAP-induced
hepatotoxicity and the effect of APAP on hepatic transport protein expression.
Mrp2 and P-glycoprotein (Pgp) protein expression increases during APAPinduced liver injury in rat livers. This increased expression resulted in
increased biliary elimination of substrates such as dinitrophenyl- Sglutathione, oxidized glutathione, and digoxin. While the first two are
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substrates for Mrp2, the latter is a substrate for Pgp (Ghanem et al., 2004). A
comprehensive analysis of transporter expression performed previously in our
lab shows that APAP at toxic doses in mice increased expression of
basolateral (Mrp3, Mrp4) and canalicular (Mrp2) efflux transporters.
Simultaneously, APAP also decreased expression of basolateral uptake
transporters such as organic anion transporter polypeptide (Oatp)1a1 and
1b2 and sodium taurocholate-cotransporting polypeptide (Ntcp) (Aleksunes et
al., 2006; Campion et al., 2008). Additionally, it was also shown that the
increased Mrp3 and Mrp4 expression was localized to hepatocytes
surrounding the central vein, the region where APAP-induced damage is
localized (Aleksunes et al., 2006). Increases in hepatic efflux transporter
expression (MRP2, BCRP, MRP4 and MRP5) are also evidenced in human
liver samples obtained during liver transplantation after APAP overdose
(Barnes et al., 2007). APAP-GLUC is a substrate for Mrp3 (Manautou et al.,
2005; Slitt et al., 2003) and its altered expression due to toxic APAP pretreatment in rats alters the elimination of APAP-GLUC from bile to urine
(Ghanem et al., 2005). Although the impact of hepatic transport protein
induction during APAP hepatotoxicity is not clearly known, Aleksunes et al.
have demonstrated that in a mouse model of resistance to APAP-induced
hepatotoxicity termed “APAP autoprotection”, there is a significant induction
of the Mrp4 protein (Aleksunes et al., 2008). Mrp4 induction is localized to the
hepatocytes surrounding the central vein where proliferation following a mildly
toxic dose of APAP is confined. Further, colchicine (antimitotic agent)
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treatment blocked the hepatocelluar proliferation around the central vein as
well as induction of the Mrp4 protein, thus supporting the role of Mrp4 in
protection from APAP hepatotoxicity (Aleksunes et al., 2008).
1.4 Liver Injury Models and Mechanisms of Hepatotoxicity
Allyl Alcohol Hepatotoxicity
Mechanism of Allyl Alcohol-induced Liver Injury. Allyl alcohol (AlOH) is an
unsaturated alcohol used in the production of food flavoring agents, fire
retardants, organic chemicals, drugs, plastics, pesticides, and herbicides.
Exposure to AlOH occurs primarily in industries where AlOH is produced or
used. Since exposure to AlOH is limited, it does not pose a significant health
problem in humans. Today, AlOH serves as a useful experimental tool for
studying chemical-induced periportal hepatic necrosis (Reid, 1972). AlOH is
metabolized in the liver by alcohol dehydrogenase to its reactive metabolite,
acrolein (Badr, 1991). Humans are exposed to acrolein through cigarette
smoke, automobile exhaust, and oil burning. Acrolein is detoxified by
aldehyde dehydrogenase to acrylic acid or conjugated to glutathione. The
glutathione adducts can potentially be converted by CYP enzymes to
glycidaldehyde, a mutagen & carcinogen that produces oxidative stress and
lipid peroxidation in periportal hepatocytes. Glycidaldehyde also binds
covalently to cellular macromolecules leading to hepatocellular injury and
death (Burcham & Fontaine, 2001; Ohno et al., 1985). While some studies
suggest that alkylation of cellular proteins by acrolein is the initiating event in
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hepatotoxicity, some studies also suggest that AlOH-induced hepatotoxicity is
mediated by lipid peroxidation. The exact mechanisms of AlOH-induced
hepatotoxicity are not clearly known. However, it is believed that the periportal
necrosis induced by AlOH targets is due to high oxygen tension in these
regions, which allows for increased superoxide anion formation and lipid
peroxidation (Badr, 1991).
Transporter Expression During AlOH-induced Liver Injury. Our laboratory
has demonstrated that AlOH treatment decreases expression of uptake
transporters Oatp1a1 and 1b2 and Ntcp in mice. The reduction is
accompanied by increases in efflux transporters Mrp1, 2, 4 and 5 (Campion et
al., 2009). In this study, kupffer cell depletion enhanced AlOH-induced
hepatotoxicity, while there were no changes in hepatic transporter expression
(Campion et al., 2009).
Alpha-naphthylisothiocyanate Hepatotoxicity
Mechanism

of

Alpha-Naphthylisothiocyanate-induced

Liver

Injury.

Alpha-naphthylisothiocyanate (ANIT) is a hepatotoxicant used to model
intrahepatic cholestasis in rodents. It produces intrahepatic cholestasis dose
dependently (Capizzo & Roberts, 1971). Following oral administration, ANIT
reaches the liver through the portal vein. In the hepatocytes, ANIT is
conjugated with glutathione and transported into bile by the canalicular efflux
transporter, Mrp2. Upon crossing the canalicular membrane, the ANIT‐GSH
conjugate dissociates, yielding free GSH and ANIT in the bile. ANIT
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selectively causes damage to the bile duct epithelial cells leading to
cholestasis (Dietrich et al., 2001).
Transporter Expression During ANIT-induced Liver Injury. In mice, ANIT
decreases the expression of uptake transporters Ntcp, Oatp1a1, and
Oatp1b2, and increases expression of efflux transporter Mrp3, Organic solute
transporter β (Ostβ), Multidrug resistance protein 2 (Mdr2), Mrp2 and
ATPase, aminophospholipid transporter, class I, type 8B, member 1 (Atp8b1)
(Cui et al., 2009). Nuclear receptors, farnesoid X receptor (FXR) and
pregnane X receptor (PXR) regulate expression of hepatic uptake
transporters, basolateral, as well as canalicular transporters during ANIT
treatment. Nuclear receptor FXR regulates the canalicular and basolateral
transporters bile salt export pump (Bsep), Mdr2, Mrp2, Atp8b1, and Ostβ,
while PXR regulates Mrp2 (Cui et al., 2009). While Mrp3 expression in
response to ANIT treatment is regulated by oxidative stress responsive
transcription factor Nrf2 alone, Bsep mRNA expression is regulated by both
Nrf2 and FXR (Cui et al., 2009; Tanaka et al., 2009).
Biliary Obstruction Cholestasis
Mechanism of Bile Duct Ligation-induced Liver Injury. Obstructive
cholestasis is a complex disease characterized by decreased or impaired bile
flow

resulting

in

increased

biliary

pressure,

impaired

excretion

or

accumulation of bile salts and various other organic anions within
hepatocytes, oxidative stress and subsequent activation of proinflammatory
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cytokines. Common bile-duct ligation (BDL) is used to model extrahepatic
obstructive cholestasis in rodents. After BDL, the liver accumulates BAs and
other compounds such as bilirubin and bilirubin-glucuronide leading to liver
injury. Eventually, bile acid levels increase in liver, plasma, and urine.
Transporter Expression During BDL-induced Liver Injury. Transporters
transport BAs both from blood into liver and from liver into bile. Ntcp and
Oatps (Oatp1a1, 1a4 and 1b2) transport BAs into the liver, while transporters
such as Mrp2 and Bsep transport BAs out of the liver into bile, and Mrp3,
Mrp4 and Ostα/β transport BAs from liver into blood. BDL decreases
expression of hepatic uptake transporters such as Ntcp and Oatp1a1 and the
reduction corresponds to lower uptake of taurocholate in rat hepatocytes
(Gartung et al., 1996; Geier et al., 2005). In mice similar to rats, BDL
decreases expression of uptake transporters Ntcp, Oatp1a1, and 1b2 as well
as increases expression of efflux transporters Mrp1, 3, 4, and 5 (Slitt et al.,
2007). It is suggested that a decrease in uptake transporters is an adaptive
mechanism that will extract less BA from blood into liver thus reducing BA
levels in the hepatocytes. Similarly, up-regulation of efflux transporters during
BDL decrease BA levels in hepatocytes by enhancing clearance of bile acids
into the blood and urine.
Carbon Tetrachloride Hepatotoxicity
Mechanism of Carbon Tetrachloride-induced Liver Injury. Carbon
tetrachloride (CCl4), a non-polar solvent, was used for industrial and home
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use as a cleaning agent, degreasing agent, fire extinguisher, etc. Exposure to
CCl4 results in severe hepatotoxicity or nephrotoxicity, hence it is banned or
severely restricted from usage. Currently, CCl4 is used as a model
hepatotoxicant to study the mechanisms of liver injury such as fatty
degeneration, fibrosis, hepatocellular death, and carcinogenicity (Weber et
al., 2003). In the liver, CCl4 is bioactivated into tricholoromethyl radical (˙CCl3)
by Cyp (Cyp2e1, Cyp2b1 and Cyp2b2) dependent systems (Gruebele et al.,
1996). This ˙CCl3 radical readily reacts with oxygen to form a more reactive
free radical, trichloromethylperoxyl radical (CCl3OO˙). Free radicals generated
can also bind covalently to Cyp2e1 resulting in suicide inhibition. The toxic
effect mediated by CCl3OO˙ includes oxidation of membrane polyunsaturated
fatty acids resulting in lipid peroxidation. CCl3OO˙ can also covalently bind to
microsomal proteins, nucleic acids, and lipids resulting in generation of
superoxide and hydroxyl radicals (Tom et al., 1984). Lipid peroxidation alters
membrane permeability of cellular and subcellular structures resulting in loss
of cellular calcium and uncoupling of oxidative phosphorylation leading to
cellular degeneration and necrosis. The antioxidant defense machinery is also
affected following exposure to this toxin.
Transporter Expression During CCl4-induced Liver Injury. Similar to drug
metabolizing enzymes, transporters exhibit zonal distribution patterns. In rats,
basal expressions of Mdr mRNA and protein levels are higher in zone 1 and
lowest in zone 3. Following exposure to CCl4, Mdr1b and Mdr2 expression
increases in zone 1 and gradually extends to zone 3 (Nakatsukasa et al.,
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1993). Expression of some basolateral transporters such as Oatp1, 4, and
Ntcp decreases in rats exposed to CCl4 (Geier et al., 2002). Blockage of
TNFα signaling using the inhibitor etanercept inhibits CCl4-induced
downregulation of Oatp1a1, Oatp1a4, and Ntcp mRNA supporting the
concept that proinflammatory cytokines are one of the key regulators of
organic anion transporters (Geier et al., 2003). Previous work in our
laboratory reported a simultaneous increase in expression of sinusoidal efflux
(Mrp1 and Mrp4) and canalicular transport proteins (Mrp2) as well as a
decrease in expression of Ntcp and Mrp3 proteins in mice in response to CCl4
treatment (Aleksunes et al., 2006). This coordinated induction of efflux
transport proteins and reduction of uptake carriers suggests an adaptive
response by the liver for elimination of xenobiotics and oxidative stress
products that are generated during CCl4-induced liver injury.
1.5 Nrf2 Signaling Pathway
Oxidative stress is a steady-state level of oxidative damage in a cell,
tissue, or organ caused by reactive oxygen species (ROS). ROS are
transiently formed during the normal course of cellular metabolism, and
elevated levels damage cellular macromolecules including proteins, lipids,
mitochondrial, and nuclear DNA. Cells possess defense systems that protect
against oxidative stress. In prokaryotes, the transcription factors oxygen
response (OxyR) and superoxide response (SoxRS) sense the redox status
of the cell and during oxidative stress induce expression of defensive genes
(Zheng & Storz, 2000). Eukaryotic cells have similar mechanisms to protect
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against oxidative stress. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2 or
NFE2L2), heat shock protein (Hsp) activator protein 1 and nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) promote cell survival,
whereas activation of JNK, p38 kinase, and tumor protein-53 (TP53) lead to
cell cycle arrest and apoptosis.
Nrf2 belongs to the cap ‘n’ collar family of transcription factors that
share a conserved basic region-leucine zipper (bZIP) structure. Nrf2 was
identified during a screen for proteins that bind to the control region of the βglobin gene (Moi et al., 1994). Unlike p45-NF-E2 that is expressed only in
blood cells such as megakaryocyte, erythroid, and mast cells, Nrf2 is present
in a wide variety of tissues including liver, lung, intestine, and kidney.
Negative Regulation of Nrf2 Mediated by Keap1. Under basal conditions,
Nrf2 is largely bound to the cytoskeletal anchoring protein Kelch-like ECHassociated protein 1 (Keap1), also known as cytosolic Nrf2 inhibitor (INrf2) in
the cytoplasm. Keap1 exists as a dimer and retains Nrf2 in the cytoplasm.
Serine 104 of Keap1 is required for dimerization of Keap1, and mutations in
serine 104 leads to disruption of the Keap1 dimer and release of Nrf2 (Zipper
& Mulcahy, 2002). Amino acid sequence and domain structure-function
analyses show that Keap1 has broad-complex, tramtrack, bric-a-brac (BTB) /
poxvirus, zinc finger (POZ) domain, Kelch domain also known as the double
glycine repeat (DGR) domain, N-terminal region (NTR), Intervening region,
and C-terminal region (CTR) (Figure 1.2). The BTB/POZ domain serves as an
adapter for the cullin 3/ring box 1(cul3/Rbx1) E3 ubiquitin ligase complex and
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promotes ubiquitination of Nrf2 (Kaspar et al., 2009). On the other hand, the
DGR/Kelch domain binds to actin, allowing the scaffolding of Keap1 to the
actin cytoskeleton, which plays an important role in Nrf2 retention in the
cytosol. Thus, Keap1 is responsible not only for sequestering Nrf2, but also
for its normal proteosomal targeting and degradation.
Cytoplasmic Retention of Nrf2. Two nuclear export signals in the leucine
zipper and transactivation domains of Nrf2 are responsible for cytoplasmic
localization of Nrf2. One of these nuclear export signals is redox sensitive and
can be disabled in the presence of ROS allowing Nrf2 to translocate into the
nucleus (Aleksunes & Manautou, 2007). Evidence also suggests that
phosphorylation of Nrf2 is important for dissociation of Nrf2 from Keap1. More
recently,

it

has

been

demonstrated

that

phosphorylation

and

dephosphorylation of tyrosine 141 in Keap1 regulate its stability and
degradation, respectively. It is also shown that modification of critical
cysteines (Cys 151, Cys 273, and Cys 288) in Keap1 lead to a change in the
conformation

of

homodimerization

the
site,

BTB

domain

disrupting

by

Neh2

means

of

ubiquitination

perturbing
and

the

causing

ubiquitination of Keap1 (Kaspar et al., 2009). The switch of ubiquitination from
Nrf2 to Keap1 leads to Nrf2 nuclear accumulation.
Antioxidant Response Element and Nrf2. Ubiquitination of Keap1 occurs in
response to a variety of stimuli. Following ubiquitination of Keap1, Nrf2 is
released that translocates into the nucleus. The nuclear localization signal in
the basic region of Nrf2 stimulates its nuclear translocation. The basic region
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is also responsible for DNA binding, and the acidic region of Nrf2 is required
for transcriptional activation (Jaiswal, 2004). In the nucleus, Nrf2 binds to the
GTGACA***GC core sequence of antioxidant response element (ARE)
(Rushmore et al., 1991) and regulates ARE-mediated antioxidant gene
expression (Figure 1.3). ARE-mediated transcriptional activation requires
heterodimerization of Nrf2 with other bZIP proteins, including Jun (c-Jun, JunD, and Jun-B) and small Maf (MafG, MafK, and MafF) proteins.
The aforementioned Keap1:Nrf2 regulatory pathway is generally
thought to dictate subcellular localization of Nrf2 and activity. However,
questions regarding how Nrf2 maintains constitutive transcription of drug
metabolizing enzymes have prompted researchers to put forth alternative
models of Nrf2 signaling. One hypothesis includes the constitutive targeting of
de novo Nrf2 protein to the nucleus. In this model, there is continuous
shuttling of Keap1/cul3/Rbx1 complex into the nucleus, and this nuclear
import is mediated by Prothymosin- α (Niture & Jaiswal, 2009). This complex
inside the nucleus exchanges prothymosin-α with Nrf2 resulting in
degradation of Nrf2 (Kaspar et al., 2009).
Other regulatory mediators of Nrf2 include Bach1, which is a
transcription repressor. Bach1 heterodimerizes with small Maf proteins in the
absence of cellular stress and represses gene expression. In the presence of
oxidative stress, Bach1 is released from the Maf proteins and is replaced by
Nrf2. The activation of a delayed mechanism involving glycogen synthase
kinase 3β (GSK3β) controls the switching off of gene transcription by Nrf2
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activation. GSK3β is a serine/threonine kinase that phosphorylates Fyn (a
tyrosine kinase) leading to nuclear localization of Fyn. Fyn phosphorylates
Nrf2 resulting in nuclear export of Nrf2, binding with Keap1, and degradation
of Nrf2 (Kaspar et al., 2009).
Activation of Nrf2-Keap1 Regulatory Pathway in Liver Injury Models
Nrf2 and APAP-induced Hepatotoxicity. Nrf2 knockout mice are more
susceptible to APAP-induced liver injury compared to their wild-type
counterparts (Chan et al., 2001; Enomoto et al., 2001). This susceptibility of
Nrf2 knockout mice to APAP hepatoxicity is attributed to altered phase1 and
phase 2 metabolism of APAP in the liver, where Nrf2 knockout livers exhibit
lower Ugt1a6 activity, which is a detoxification pathway for APAP (Enomoto et
al., 2001). It is also demonstrated that Nrf2 knockout mice have an 85 %
lower Nqo1 activity compared to wild-type mice (Reisman et al., 2009). On
the other hand, mice with Keap1 deficient livers exhibit resistance to APAPinduced hepatotoxicity compared to Nrf2 knockout mice as well as their wildtype counterparts (Okawa et al., 2006; Reisman et al., 2009). Higher nuclear
accumulation of Nrf2 in Keap1 knockout livers markedly enhances the
constitutive expression of genes regulated by Nrf2 such as NAD(P)H:quinone
oxidoreductase-1 (Nqo1) (about 415 % compared to wild-type), glutathione Stransferase (Gst), and glutamate cysteine ligase catalytic subunit (Gclc)
(Okawa et al., 2006; Reisman et al., 2009).
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A low toxic APAP dose causes nuclear accumulation of Nrf2 in CD-1
mouse livers (Goldring et al., 2004). Nrf2 nuclear translocation in these mice
is accompanied by increased expression of Nrf2 dependent genes such as
heme oxygenase-1 (Hmox1) and Gclc. Similar studies confirmed the
induction of Nrf2 dependent genes Nqo1 and Hmox1 in liver (Aleksunes et al.,
2005; Aleksunes et al., 2006; Bauer et al., 2000; Chiu et al., 2002). NQO1
induction is also reported in human liver samples obtained from patients
during transplantation following APAP overdose (Aleksunes et al., 2006).
Taken together, Nrf2 not only regulates expression of enzymes that
metabolize APAP, but also alters the detoxification mechanism involved
during APAP-induced hepatotoxicity.
Nrf2 and AlOH-induced Hepatotoxicity. Liu et al. have demonstrated the
Nrf2 role in protection against AlOH-induced liver injury using Nrf2-null,
Keap1-knockdown (Keap1-KD), and Keap1-hepatocyte knockout (Keap1HKO) mice called “graded Nrf2 activation” model (Liu et al., 2013). While
there was lower plasma ALT activity in Keap1-HKO mice following AlOH
treatment, plasma ALT activity was not detectable in Keap1-KD mice.
Furthermore, Nrf2-null mice showed increased plasma ALT activity compared
to wild-type controls. Collectively, it can be concluded from this study that
Nrf2

activation

confers

moderate

protection

against

AlOH-induced

hepatotoxicity in mice (Liu et al., 2013).
Nrf2

and

ANIT-induced

hepatotoxicity.

ANIT

causes

intrahepatic

cholestasis and activates Nrf2 (Tanaka et al., 2009). This is evidenced by
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Nrf2 translocation and Nqo1 mRNA and protein induction. Surprisingly, the
authors did not see any difference in degree of liver injury in both wild-type
and Nrf2-null mice following ANIT treatment. This response was attributed to
compensatory alteration in Shp and Hnf1α signaling in Nrf2 knockout mice.
Activation of Nrf2 by oltipraz in Nrf2 knockout mice protected against ANITinduced liver injury (Tanaka et al., 2009).
Nrf2 and BDL-induced Hepatotoxicity. Cholestasis resulting from BDL
increased Nqo1 gene expression in mouse liver, and this increase is Nrf2dependent (Aleksunes et al., 2006). Consistent with this, Yamamoto’s group
showed that Nrf2 activation protects against BDL-induced liver injury in
Keap1-knockout mice, an animal model for Nrf2-activation (Okada et al.,
2009). In spite of the lack of Nqo1 induction in Nrf2 knockout mice liver, BDL
in Nrf2 knockout mice did not result in significant elevations of ALT activity
(Aleksunes et al., 2006; Weerachayaphorn et al., 2012). This discrepancy is
attributed

to

the

adaptive

compensatory

changes

involving

nuclear

transcription factors, including Fxr, Shp, Pxr, efflux bile acid transporters,
altered

GSH

levels,

and

bile

flow

rates

in

Nrf2

knockout

mice

(Weerachayaphorn et al., 2012). These multiple adaptations lessen the
susceptibility of Nrf2 knockout mice to BDL-induced liver injury. While the
levels of various isoforms of Gst’s, Gclc, and Gclm increase from day 1 to day
7 after BDL (Aleksunes et al., 2006; Yang et al., 2009), this transient increase
is followed by a fall to below baseline by day 14 that persists up to day 28
(Yang et al., 2009). This lack of expression of GSH synthetic enzymes during
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the later stages of cholestasis was shown to be due to the fall in Nrf2 nuclear
binding activity to ARE (Yang et al., 2009). Collectively, these studies
demonstrate the influence of Nrf2 on the regulation of bile acid homeostasis
in the liver as well as protection against BDL-induced liver injury.
Nrf2 and CCl4-induced Hepatotoxicity. CCl4 treatment results in induction of
oxidative stress (Ho-1) and detoxification (Nqo1) genes at 6 h and 24 h,
respectively (Aleksunes et al., 2005). A later report by Randle et al.
demonstrated that CCl4 administration results in Nrf2 nuclear translocation at
1 h, while severe hepatic necrosis was evident 24 h later (Randle et al.,
2008). As expected, in this study Nrf2 nuclear translocation was accompanied
by induction of Hmox1 24 h after CCl4 administration (Randle et al., 2008).
The Nrf2 role in CCl4-induced liver injury is further supported by the CCl4
study in Nrf2-null mice (Liu et al., 2013). In this study, Nrf2-null mice are more
susceptible to CCl4-induced hepatotoxicity compared to Keap1-KD or Keap1HKO mice. The Nrf2-mediated protection is attributed to induction of
antioxidant genes, suppression of inflammatory responses, and attenuation of
oxidative stress in the livers (Liu et al., 2013).
1.6 APAP Autoprotection
An experimental approach to modulate APAP hepatotoxicity in rodents
is through auto/heteroprotection. Autoprotection is resistance to toxicant reexposure following acute, mild injury with the same toxicant, whereas in
heteroprotection, the initial toxicant used is different from the second.
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Mehendale and his colleagues first demonstrated autoprotection in rats in the
early 1990’s with carbon tetrachloride (CCl4) (Thakore & Mehendale, 1991).
Previous studies conducted in our laboratory have demonstrated both
auto/heteroprotection in mice and that pre-treatment with various chemicals
reduce the severity of APAP toxicity in mice (Aleksunes et al., 2008;
Manautou et al., 1994). For instance, Manautou et al. show that peroxisome
proliferators such as clofibrate at subtoxic doses protect rodents from APAP
toxicity (APAP heteroprotection) (Manautou et al., 1994). Alternatively, APAP
at a mild toxic dose protects mice against hepatotoxicity from higher doses of
APAP (APAP autoprotection) (Aleksunes et al., 2008). This model of APAP
autoprotection was used to investigate the role of hepatobiliary drug
transporters during the development of resistance to APAP hepatotoxicity. In
this study, an increased expression of the sinusoidal efflux transporter Mrp4 is
evidenced in the hepatocytes localized to centrilobular areas where
compensatory hepatocellular proliferation following pre-treatment with mildly
toxic doses of APAP is confined. The protection occurs independently of
changes in bioactivation or detoxification of APAP.
The phenomenon of autoprotection is also seen in patients who are
repeatedly exposed to supratherapeutic doses of APAP. Shayiq et al., while
describing the incremental dose model of APAP autoprotection in mice,
introduced a clinical case where a physician addicted to prescription pain
medication reported tolerance to the combination product (containing opiod
and APAP) (Shayiq et al., 1999). The physician claimed to have consumed
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200 tablets per day in the later stages of his addiction (about 65 g APAP) with
no apparent liver damage. Another later study demonstrated a similar
phenomenon, where healthy adults given 4 g APAP per day over a period of
14 days showed elevations in plasma ALT activity around day 7 to 8 that
decreased by day 14 (Watkins et al., 2006). This shows an adaptation to
hepatocyte injury during repeated exposure to APAP. These clinical evidence
supports evaluation of mechanisms underlying APAP autoprotection.
Gene Expression Profiling in APAP Autoprotection Model
The utility of gene array analysis to address mechanistic toxicology
questions has been demonstrated in our lab (Moffit et al., 2007). Even though
our previous study demonstrated the role of the drug transporter Mrp4 in
APAP autoprotection (Aleksunes et al., 2008), a gene array analysis was
performed to identify any other differentially expressed genes resulting from
APAP pre-treatment that might also contribute to the development of
resistance to APAP hepatotoxicity upon re-exposure to this toxicant. A gene
array analysis revealed statistically significant genes unique to the APAP
autoprotection mouse model (mice pretreated and re-exposed to APAP) and
further analysis of these genes using the causal reasoning engine (CRE)
provided insights into the signaling pathways involving autoprotection
(O'Connor et al., 2014). Out of several noteworthy genes that were identified
to be differentially expressed in APAP autoprotected mice, Fmo3 was one of
them.
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1.7 Flavin-containing Monooxygenase-3
Flavin-containing monooxygenase (FMO) is one of the major
microsomal monooxygenase enzyme systems located in the membrane of
the endoplasmic reticulum. Mammalian FMO is an NADPH-dependent and
oxygen-dependent microsomal FAD-containing enzyme system that functions
as a nitrogen, sulfur, and phosphorus oxygenase (Rettie & Fisher, 1999).
Discovery of FMO Enzymes. Miller and his co-workers in the 1960’s
reported that liver microsomes contained enzymes that catalyzed the
NADPH- and O2-dependent oxidation of butter yellow and a number of other
azo dyes (Miller et al., 1960). Later, Ziegler studied the nature of enzymes
catalyzing the mixed function oxidation reactions. N-oxidation of N, Ndimethylaniline was selected as a model reaction to characterize enzymes in
liver microsomes and a high activity was observed in microsomes isolated
from pig liver. The Ziegler lab further purified the enzyme that catalysed the
NADPH- and O2-dependent N-oxidation of N, N-dimethylaniline in 1972 from
pig liver (Ziegler & Mitchell, 1972). This enzyme was called “mixed-function
amine N-oxidase” or “Ziegler’s enzyme” until 1979. Shortly after the isolation
of the enzyme from pig liver, Jollow and Cook demonstrated that it catalyzed
oxygenation of a wide range of xenobiotics that had no common structural
features (Ziegler et al., 1971; Ziegler & Poulsen, 1998). The list includes
inorganic and organic compounds and some of these compounds contain
functional groups bearing sulfur or selenium instead of nitrogen. Since the
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name “mixed-function amine N-oxidase” was restrictive, the enzyme was
given the name flavin-containing monooxygenase, abbreviated as FMO.
Biochemical Properties Unique to FMOs.
Thermal Stability and NADPH. With the exception of FMO2, placement of
microsomes in an argon environment at 55°C for 1 min in the absence of
NADPH decreases FMO activity by 85 % or more, while CYP activity is
reduced by 15 % or less (Cashman, 1999). NADPH stabilizes FMO activity
(Cashman, 1999).
Effect of Detergent. The FMO activity increases at Triton X-100
concentrations between 0.05-0.5 %. At concentrations above 0.5 %, the
enzyme activity decreases (Brunelle et al., 1997). Sodium cholate and fatty
acid at a low concentration inhibit FMO1 and FMO3, while sodium cholate at
a high concentation (1 %) does not inhibit FMO2 function (Krueger &
Williams, 2005).
Effect of pH. The optimal pH for animal and human FMO-mediated N- and Soxygenation is generally equal to or above pH 9.0. On the other hand,
maximum CYP activity is seen at pH 7.4 (Cashman, 1999).
Formation of a Relatively Stable Hydroperoxyflavoprotein Intermediate.
Among the flavoproteins that exist, FMO is distinct in its ability to form a
relatively stable hydroperoxyflavin intermediate. This is because the protein
environment of the FMO and the presence of NADPH protect the hydroperoxy
species from decomposing, reacting with apoprotein or disproportionating into
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reactive oxygen species. Thus, it does not expose the cell to the untoward
effects of oxidative stress. However, in the absence of NADPH, peroxyflavin
can decompose to hydrogen peroxide resulting in significant loss of enzyme
activity (Cashman, 1999).
Metabolite Prediction. Barring steric constraints, the metabolite produced by
an FMO of a particular substrate can be predicted based on the oxidation
product produced from the treatment of substrate with alkyl hydroperoxides or
peracids (Cashman, 1999).
Approaches

to

Distinguish

Between

FMO-

and

CYP-mediated

Metabolism.
The similarities and differences between the FMO and CYP enzymes
are summarized in Table 1.1. FMO and CYP have overlapping substratespecificity. There are a number of in vitro approaches to distinguish CYP
activity from that of FMO.
Thermal Inactivation. Heating the enzyme up to 50°C for 1 min in the
absence of NADPH results in the loss of 85 % of FMO activity, while retaining
85 % of CYP activity (Cashman, 2005).
pH of Incubation Mixture and Detergents. Performing microsomal
incubations at pH 8.4 to 9.4 generally abrogates CYP activity (Cashman,
2005). The presence of high concentrations of Emulgent 911 also abrogates
CYP activity (Cashman, 2005). Thus, solubilization of microsomes using
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detergents at elevated pH is another approach to selectively examine FMO
activity (Cashman, 1999).
NADPH and Enzyme-mediated Reactions. FMO-dependent reactions are
initiated by the addition of substrate to a previously pre-equilibrated
microsomal preparation containing NADPH, while CYP-dependent reactions
are initiated by the addition of NADPH (Cashman, 1999).
Metal Ions. FMO is relatively sensitive to metal ions, thus incubations should
be carried out in the absence of MgCl2 and in the presence of a chelating
agent (Cashman, 1999).
Inactivation of prosthetic group. While CYPs can be inactivated via
saturation of heme prosthetic group by carbon monoxide, FMOs are
unaffected by carbon monoxide (Krueger & Williams, 2005).
Inhibitors.
•

Chemical inhibitors: FMO inhibitors include methimazole (MMI),
thiourea and indole-3-carbinol (I3C), whereas CYP inhibitors include Nbenzylimidazole, aminobenzotriazole, and proadifen hydrochloride
(SKF-525).

•

Immunological inhibitors: Antibodies directed against FMOs and
NADPH-P450 reductase.

Molecular Biology Tools. Recombinant FMO and CYP enzymes.
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The Potential of Chemical Inhibitors in vivo and Knockout Mouse Lines.
In rodents, pretreatment with MMI or I3C has been demonstrated to block
FMO-mediated conversion of various compounds (Nace et al., 1997). MMI is
not a specific inhibitor, and inhibits thyroid peroxidase along with FMO. The
reactive intermediate of MMI metabolism, sulfenic acid, also inhibits CYP
activity. On the contrary, I3C induces CYP enzymes (Katchamart & Williams,
2001). These problems associated with FMO-inhibitor usage for evaluating
the FMO role in drug metabolism in vivo can be overcome by use of
engineered knockout mouse lines. To date, only one Fmo knockout mouse
line has been produced and this knockout mouse line lacks genes encoding
Fmo1, Fmo2, and Fmo4. Because the expression of Fmo3 in male mouse
liver is switched off during development, male mice are essentially void of the
Fmo3 protein. In the absence of functional Fmo3 protein in normal male mice,
there has been no need for developing a knockout model (Hernandez et al.,
2009; Shephard & Phillips, 2010).
The Mechanism of Catalysis. FMO and CYP both require NADPH and O2 as
cofactors for its catalytic activity. The mechanism of reactions catalysed by
FMO is different from that of the CYP-mediated metabolism. In CYP-mediated
metabolism, the first step is the addition of substrate to the enzyme, and
electron transfer follows this from the flavoprotein NADPH-CYP reductase to
the substrate-bound CYP. The catalytic cycle of FMO is shown in Figure 1.4.
In contrast to CYP, the first step in FMO-mediated metabolism is reduction of
the FAD by NADPH. This step is followed by the formation of a relatively
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stable intermediate, C4α-hydroperoxyflavin, by the addition of a molecular
oxygen to the reduced FAD. Therefore, when substrate is accepted by FMO,
the enzyme is in an active form (i.e. a cocked gun) ready to effect
oxygenations. CYP forms an unstable ferrous-O2 complex that is capable of
decomposing

to

generate

superoxide

anion

or

hydrogen

peroxide.

Oxygenation by FMO proceeds through an attack of the nitrogen atom (or any
other nucleophilic heteroatom) on the terminal hydroperoxyflavin oxygen atom
to produce the N-oxygenated substrate and the hydroxyflavo enzyme
species. Thus, one atom of molecular oxygen is transferred to the substrate
and the second to form water. The rate-limiting step of the catalytic cycle is
thought to be the breakdown of the FADOH pseudobase or the release of
NADP+. As this occurs after the substrate transformation, substrate binding
has no influence on Vmax (Cashman, 1999; Cashman, 2005).
FMO Ontogeny and Tissue Specificity in the Mouse and Humans. FMO
enzymes exhibit tissue-, species-, gender- and age-specificity in expression.
FMOs are expressed in the liver, lung, kidney, intestine, and brain. For the
purpose of this thesis, FMO expression in mouse liver will be discussed in
comparison to human liver. Cherrington et al. examined hepatic Fmo1, Fmo3,
and Fmo5 ontogeny in CD-1 mouse liver by western blotting and this was
quantified in a review by Hines (Cherrington et al., 1998; Hines, 2006).
Hepatic Fmo3 is undetectable at day 2 after birth in both male and female
mice. By day 14 after birth, the Fmo3 protein is detectable in both sexes and
is approximately about 50 % of adult female levels. On day 42 (young adult
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age), there is a gender-dependent dimorphism apparent, where male mice
express undetectable levels and female mice express very high levels of
hepatic Fmo3. This is consistent with other reports that show genderdependent dimorphism with respect to liver Fmo3 levels in B6C3F1 mice
(Ripp et al., 1999) as well as 129/SV mice (Janmohamed et al., 2004). Fmo5
on the other hand is expressed at very low levels in the fetus at gestation day
17, and by day 2, the levels are at adult values. Unlike Fmo3, no genderdependent dimorphism is seen with Fmo5. Fmo1 is detectable on gestation
day 15, and by day 17 of gestation, the levels reach adult values. By young
adult age, a gender-dependent dimorphism in liver Fmo1 expression is
evident, where male mice express detectable but lower Fmo1 compared to
females (Cherrington et al., 1998; Hines, 2006). Janmohamed et al. reported
tissue specificity and ontogeny of liver FMO mRNA levels in the 129/SV
mouse strain, measured by RNase protection assay and in situ hybridization
(Janmohamed et al., 2004). In this study, it was demonstrated that Fmo5
expression in female mouse liver is about 2- to 3-fold higher than Fmo3,
which in turn is 2-fold higher than Fmo1. On the contrary, hepatic Fmo3 is
expressed at undetectable levels in adult male mice. Little or no Fmo2 and
Fmo4 expression is seen in both sexes (Janmohamed et al., 2004). There is
a gradient for FMO expression in liver where Fmo1 and Fmo5 show a
decreasing concentration gradient from central vein to periportal areas.
Conversely, Fmo3 mRNA in female liver is localized to the periportal region.
Consistent with this, our results from immunohistochemical staining for the
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Fmo3 protein in female C57BL/6J mice livers also show a similar staining
pattern (Rudraiah et al., 2014).
FMO1 is the predominant FMO in fetal human liver, whereas FMO3 is
predominant in adults (Koukouritaki et al., 2002). Dolphin et al. provided the
first evidence of a developmental switch from FMO1 to FMO3 in human liver
(Dolphin et al., 1996). Although this study was the first to suggest a hepatic
FMO developmental switch in humans, Koukouritaki et al. demonstrated a
detailed ontogeny in FMO enzyme expression, and also that the FMO1 and
FMO3 are independently regulated during development (Koukouritaki et al.,
2002).
FMO Substrates Specificity. Different FMO enzymes exhibit broad and
overlapping substrate specificity. This property is in part attributed to the
formation of C4α-hydroperoxyflavin intermediate in the absence of the
substrate. Substrate specificity is determined more by access to the activated
flavin as opposed to specific binding at the active site (Hines, 2006; Poulsen
& Ziegler, 1995).
FMO1, 2, and 3 oxygenate a wide variety of nucleophilic tertiary and
secondary amines as well as sulfur-containing compounds compared to
FMO4 and FMO5. FMO5 has restricted substrate-specificity because it does
not form a stable intermediate (Ziegler, 2002). The substrate-specificity of
FMO5 is poorly defined, although is apparently distinct from FMO3. Because
of their limited substrate specificity and low expression levels in most tissues
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in humans, FMO4 and FMO5 currently are not thought to play an important
role in drug metabolism (Krueger & Williams, 2005).
In general, structural requirements for FMO substrates are as follows
(Krueger & Williams, 2005):
•

Any compound that contains a soft nucleophile and that is accessible
to the C4α-hydroperoxyflavin intermediate can be a substrate.

•

Compounds containing a single positive charge are excellent
substrates (e.g., cationic tertiary amines).

•

Negatively charged compounds are poor substrates with a few
exceptions, such as sulindac sulfide and lipoic acid.

•

Zwitterions and compounds with more than one positive charge are
typically not substrates.

Few examples for FMO substrates are presented in Table 1.2.
Transcriptional Regulation of FMO. Mammalian FMOs were considered
non-inducible by xenobiotics (Cashman & Zhang, 2002; Krueger & Williams,
2005). Thus, the transcriptional regulation of FMO involving stress activated
transcription factors or a receptor that binds ligand and interacts with DNA
was not studied as other forms of regulation. However, recent studies by
Celius et al. show that activation of the Aryl hydrocarbon (Ah) receptor by
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces Fmo3 mRNA in mice,
with marginal changes in protein levels (Celius et al., 2008; Celius et al.,
2010). Authors also show that the Fmo3 mRNA up-regulation by 3-
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methylcholanthrene (3MC) and benzo(a)pyrene (BaP) but not TCDD in Hepa1 cells is mediated by p53 and its binding to a p53-response element in the
promoter region of Fmo3 (Celius et al., 2010).
The hormonal effects on FMO activity have been described. Adult
female mice livers exhibit higher Fmo3 activity compared to male mice.
Gender-related differences in mouse liver Fmo3 activity are shown to be due
primarily to testosterone-dependent repression of the enzyme in male mice
(Duffel et al., 1981). Rat liver FMO is positively regulated by testosterone and
repressed by estradiol (Cashman & Williams, 1990; Cashman & Zhang, 2006;
Lemoine et al., 1991). Diurnal cortisol secretion also regulates FMO activity in
female mice (Dixit & Roche, 1984). In pregnant rabbits, plasma concentration
of progesterone and corticosterone is shown to regulate lung Fmo2 mRNA
and protein levels at day 15 and 28-31 (Hines et al., 1994). In cultured rat
hepatocytes, lipopolysaccharide and proinflammatory cytokines treatment
decreased FMO1 mRNA levels via a cGMP-independent destabilizing effect
of nitric oxide rather than decreased transcription (Ryu et al., 2004).
In humans, Lou and Hines demonstrated that hepatocyte nuclear
factor (HNF) 1α and HNF4α positively regulate, while Yin yang (YY1)
negatively regulate FMO1 expression (Luo & Hines, 2001). An upstream SNP
was also identified within the conserved core binding sequence for the YY1.
Transient expression assays showed that this SNP in YY1 could account for
two- to three-fold loss of FMO1 promoter activity, and genotype analysis
showed individuals of Caucasian, African, and Hispanic descent had 11 %, 13
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% and 30 % frequency, respectively (Hines et al., 2003). Klick and Hines also
demonstrated that binding of transcription factors such as nuclear factor-Y
(NF-Y), upstream stimulatory factor 1 (USF1), YYI and an unidentified GC
box to the regulatory domains upstream of the transcription start site are
important for constitutive FMO3 transcription regulation (Klick & Hines, 2007).
The pre-B-cell leukemia factor 2 (Pbx2) as a heterodimer with an unidentified
homeobox (Hox) isoform contributes to FMO3 developmental- and tissuespecific regulation (Klick & Hines, 2007). A later study by the same group
identified another element, CCAAT enhancer-binding protein β (C/EBPβ), as
being more distal to the transcription start site and this is shown to be
important for FMO3 developmental expression pattern (Klick et al., 2008).
Shimuzu et al. reported that HNF-4 and NF-Y could play crucial roles in
modulating the activity of the FMO3 expression in the Japanese population
(Shimizu et al., 2008).
Post-transcriptional Regulation of FMO. Post-transcriptional regulation of
FMO is not well understood. For example, not much is known about
enhancement of FMO mRNA stability or mechanisms regulating the stability
of FMO mRNA transcripts. Recent reports by Celius et al. showed an
increase in miRNA following TCDD treatment in C57BL/6J mice livers (Celius
et al., 2008). In silico analysis further predicted binding sites on mouse Fmo3
mRNA for the up-regulated miRNAs (mmu-miR203 and mmu-148a). The
authors concluded that a modest increase in FMO catalytic activity evidenced
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following TCDD treatment, in spite of a large increase in Fmo3 mRNA, is due
to targeted degradation of mRNAs by miRNAs (Celius et al., 2008).
FMOs have a consensus sequence for N-glycosylation, and mass
spectrometry studies have shown that FMO1 is selectively N-glycosylated at
Asn 120 (Korsmeyer et al., 1998). The highly conserved nature of this site
suggests that this region could be important in a structural or functional role in
enzyme action, but cDNA expression of FMOs in bacterial expression
systems show that enzyme activity does not require N-glycosylation
(Cashman & Zhang, 2006).
Physiological functions of FMO. The function of FMO is described
previously and is involved in the oxygenation of endogenous compounds and
xenobiotics. The importance of mammalian FMO in xenobiotic metabolism is
known, while its physiological role has not yet been identified, except for TMA
N-oxygenation. Trimethylamine (TMA) is an odorous compound formed by
gut bacteria and is responsible for a fish odor. In humans, a mutation in the
FMO3 results in failure to efficiently N-oxygenate TMA, leading to a genetic
disease known as trimethylaminuria.
FMO is involved in oxygenation of sulphur-containing endogenous
substrates such as cysteamine (reduced form) to cystamine (disulfide form)
(Poulsen, 1981).

Although the physiological role of cysteamine S-

oxygenation by Fmo3 is not clear, in the 1970s, Ziegler and Poulsen
suggested a role for FMO in protein disulphide bond formation through
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oxidation of cysteamine. It was also proposed that oxygenation of cysteamine
may be a significant source of disulphide, maintaining the cellular
thiol:disulphide potential in a cell (Ziegler et al., 1979). Further, Suh and
Robertus showed that yeast FMO serves as a modulator of cellular thiols and
maintains optimum redox potential within the endoplasmic reticulum, allowing
for proper folding of disulfide bond- containing proteins (Suh & Robertus,
2002).
The cytoprotective functions of Fmo3 and its possible involvement in
APAP autoprotection are summarized below. However, this is entirely
speculative at this point. The relationship between cellular thiol:disulphide
ratios and the regulation of metabolic reactions has been recognized for a
long time (Barron, 1953). Oxygenation of cysteamine during APAP
hepatotoxicity may serve to help control the overall thiol:disulphide redox
state of the cell, which in turn may modulate cellular metabolism and/or
activate signal transduction pathways leading to altered susceptibility to
APAP (or protection). It is also possible that oxygenation of cysteamine to
cystamine by Fmo3 and transport out of the cell may represent a detoxication
mechanism or protective function, since cysteamine is toxic to cells at
concentrations as low as 39 µM through the transition metal-dependent
formation of hydrogen peroxide (Jeitner & Lawrence, 2001).
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1.8 Summary
The project described in this thesis originated from a gene array
analysis on the APAP autoprotected mice livers performed previously. One of
the differentially expressed genes identified during analysis is Fmo3. For a
long time, Fmo3 was considered non-inducible by xenobiotics. Thus, the
mechanism(s) underlying Fmo3 gene induction by a xenobiotic is not well
studied. Apart from its role in drug metabolism and fish odor syndrome, the
physiological functions of Fmo3 are not currently known. The goal of this
project was to investigate the mechanistic role of Fmo3 gene expression
during APAP-induced hepatotoxicity. The results presented in this dissertation
show Fmo3 mRNA and protein induction during APAP hepatotoxicity in mice.
To verify that Fmo3 gene induction is not model-specific, Fmo3 gene
expression in other mouse models of hepatic injury was also investigated.
Since a common event for all hepatotoxicants tested is oxidative stress, the
oxidative stress transcription factor Nrf2 role in FMO3 gene expression was
examined. Similar to APAP autoprotection mouse model, human liver
acquires resistance to supratherapeutic doses of APAP. HepaRG cells were
employed to evaluate whether APAP-induced cytotoxicity induces FMO3
gene expression. The functional significance of FMO3 over-expression during
APAP hepatotoxicity was also evaluated both in vivo and in vitro.
In conclusion, this thesis clearly demonstrates Fmo3 as a genetic
determinant of APAP toxicity. Although many hepatotoxicants that result in
oxidative stress induces Fmo3 gene expression, both in vitro and in vivo
	
  

40	
  

studies demonstrate that FMO3 gene expression does not involve activation
of the NRF2-KEAP1 regulatory pathway. Results from human cell line studies
show that FMO3 over-expression alters susceptibility to APAP-induced
hepatotoxicity and that FMO3 may play an important role in cellular
differentiation. The cellular differentiation phenotype appears to be important
because the only gene altered in this cell line is FMO3 and differentiation is
happening in the absence of multiple gene expression changes that would
result in response to APAP (as in the autoprotection mouse model). With the
recent advancements showing a relationship between FMO3 gene expression
in humans, and the risk of atherosclerosis as well as ischemic stroke, a
complete understanding of the FMO3 over-expression function appear to be
important. This work not only emphasizes FMO3’s novel protective function,
but also its unexplored facets of function.
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Figure 1.1. Scheme showing structural organization of the liver lobule.
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Figure 1.2. Schematic drawing of various domains of Nrf (Nrf1, Nrf2, Nrf3)
and Keap1/INrf2 (Kaspar et al., 2009).
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Figure 1.3. A schematic representation of Nrf2-mediated gene transcription
(Bataille & Manautou, 2012).

	
  

44	
  

	
  
	
  
	
  

Figure 1.4. A schematic representation of catalytic cycle of FMO. S:
Substrate, S-O: Oxygenated substrate, Enz(Flox): Oxidized flavoprotein,
Enz(FlH2): Enzyme in reduced form, Enz(FlOOH): C4α-hydroperoxyflavin of
FAD, Enz(FlHOH): Hydroxyflavin of FAD (Cashman, 1995).
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Table 1.1 Similarities and differences between the FMO and CYP (Cashman,
2005; Hodgson et al., 1999).

FMO

CYP

Co-substrates

NADPH, O2

Coupled enzymes

None

Cellular location

Microsomes
AhR activators
(TCDD)**
(Celius et al., 2008 and
2010).

NADPH, O2
NADPH-P450 reductase
Cytochrome b5 *
Microsomes, mitochondria

Xenobiotic inducers

Inhibitors

Isoforms

Substrates
Oxygenation
Toxicity of
metabolites

Competitive substrates,
only
Few, only 11 known
currently. FMO6 to
FMO11 are
pseudogenes in humans
(Hines, 2006).
Some inorganics,
organic compounds with
N, S, Se, P heteroatoms
FMO oxygenates
compounds via a twoelectron mechanism
Usually non-toxic

Many, e.g. Phenobarbital,
TCDD
Competitive substrates and
mechanism based inhibitors,
e.g.SKF525A, piperonyl
butoxide
Many, over 3000 known
currently
Organic compounds with
and without N, S, Se, P
heteroatoms
Oxidizes compounds via a
sequential one-electron
processes
Greater prevalence for
generation of toxic
metabolite

* Cytochrome b5 is required only for some CYP isoforms and for
some substrates
** Activation of the Aryl hydrocarbon receptor (AhR) induces Fmo3
mRNA in mice, but with marginal changes in protein levels.
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Table 1.2 Substrates for FMO. Taken from (Hodgson et al., 1995; Krueger &
Williams, 2005; Ziegler, 1988).

Substrate
Endogenous substrates
Sulfur-containing

Nitrogen-containing
Exogenous substrates
Sulfur-containing
Nitrogen-containing

Phosphorus-containing
Selenium-containing
Inorganics
Boronic acid

	
  

Example
Cysteamine, Methionine, Lipoic acid,
S-farnesylcysteine, S-cysteine
conjugates, selenocysteine
conjugates
Trimethylamine, Tyramine,
Phenethylamine
Cimetidine, Albendazole, Sulindac
sulfide, Methimazole, Ethionamide,
Imipramine, Clozapine, Tamoxifen,
Chloro- and Bromo-pheniramine,
Zimeldine, Ranitidine, Benzydamine,
Olopatadine, Xanomeline, Pargyline,
Itopride, Nicotine
Fonofos, Diethylphenylphosphine,
Fenthion
2-selenylbenzanilide
HS-, I-, I2
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CHAPTER 2
Tolerance to Acetaminophen Hepatotoxicity in the Mouse Model of
Autoprotection is Associated With Induction of Flavin-containing
Monooxygenase-3 (FMO3) in Hepatocytes
2.1 Abstract
Acetaminophen (APAP) pretreatment with a hepatotoxic dose (400
mg/kg) in mice results in resistance to a second, higher dose (600 mg/kg) of
APAP (APAP autoprotection). Recent microarray work by our group showed
a drastic induction of liver flavin containing monooxygenase-3 (Fmo3) mRNA
expression in our mouse model of APAP autoprotection. The role of liver
Fmo3, which detoxifies xenobiotics, in APAP autoprotection is unknown. The
purpose of this study was to characterize the gene regulation and protein
expression of liver Fmo3 during APAP hepatotoxicity. The functional
consequences of Fmo3 induction were also investigated. Plasma and livers
were collected from male C57BL/6J mice over a period of 72 h following a
single dose of APAP (400 mg/kg) to measure Fmo3 mRNA and protein
expression. Although Fmo3 mRNA levels increased significantly following
APAP treatment, protein expression changed marginally. In contrast, both
Fmo3 mRNA and protein expression were significantly higher in APAP
autoprotected livers. Unlike male C57BL/6J mice, female mice have about 80times higher constitutive Fmo3 mRNA levels and are highly resistant to APAP
hepatotoxicity.
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APAP

with

the

FMO

inhibitor

methimazole rendered female mice susceptible to APAP hepatotoxicity, with
no changes in susceptibility detected in male mice. Furthermore, a human
hepatocyte cell line (HC-04) clone over-expressing human FMO3 showed
enhanced resistance to APAP cytotoxicity. Taken together, these findings
establish for the first time induction of Fmo3 protein expression and function
by xenobiotic treatment. Our results also indicate that Fmo3 expression and
function plays a role in protecting the liver from APAP-induced toxicity.
Although the mechanism(s) of this protection remains to be elucidated, this
work describes a novel protective function for this enzyme.

	
  

49	
  

2.2 Introduction
Acetaminophen (APAP) overdose is a leading cause of acute liver
failure in the U.S. and Great Britain, accounting for more than 50 % of all
acute liver failure cases from all etiologies (Larson et al., 2005; W. M. Lee,
2010). APAP is safe at therapeutic doses, where the majority of APAP
administered is glucuronidated or sulfated and the metabolites are safely
excreted into the urine and bile. Under these conditions, a small amount of
APAP also undergoes bioactivation by cytochrome P450 metabolism to
generate N-acetyl-p-benzoquinone imine (NAPQI), a reactive metabolite that
can be detoxified by hepatic glutathione (GSH). However, when NAPQI is
produced in large amounts, as in the case of APAP overdose, GSH stores are
depleted and NAPQI reacts with intracellular thiols, binds covalently to cellular
macromolecules, and produces oxidative stress, which ultimately results in
necrosis of centrilobular hepatocytes (Cohen et al., 1997; Hinson et al.,
2010). The growing concern over APAP-induced hepatotoxicity has prompted
extensive research aimed at devising measures to reduce the risk of APAP
heptotoxicity.
An experimental approach to modulate APAP hepatotoxicity in rodents
is through auto/heteroprotection. Autoprotection is resistance to toxicant reexposure following acute, mild injury with the same toxicant, whereas in
heteroprotection, the initial toxicant used is different from the second.
Mehendale and his colleagues first demonstrated autoprotection in rats in
early 1990’s with carbon tetrachloride (CCl4) (Thakore & Mehendale, 1991).
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Previous studies conducted in our laboratory have demonstrated both
auto/heteroprotection in mice and that pre-treatment with various chemicals
can reduce the severity of APAP toxicity in mice (Aleksunes et al., 2008;
Manautou et al., 1994). For instance, Manautou et al. showed that
peroxisome proliferators such as clofibrate at subtoxic doses protect rodents
from APAP toxicity (APAP heteroprotection) (Manautou et al., 1994).
Alternatively, APAP at a mild toxic dose protects mice against hepatotoxicity
from higher doses of APAP (APAP autoprotection) (Aleksunes et al., 2008).
This model of APAP autoprotection was used to investigate the role of
hepatobiliary drug transporters during the development of resistance to APAP
hepatotoxicity. In this study, an increased expression of the sinusoidal efflux
transporter Mrp4 (Multidrug resistance-associated protein 4) is evidenced in
the hepatocytes localized to centrilobular areas where compensatory
hepatocellular proliferation following pre-treatment with mildly toxic doses of
APAP is confined. The protection is shown to occur independently of changes
in bioactivation or detoxification of APAP.
The utility of gene array analysis to address mechanistic toxicology
questions has been demonstrated in our lab (Moffit et al., 2007). Even though
our previous study demonstrated the role of the drug transporter Mrp4 in
APAP autoprotection (Aleksunes et al., 2008), a gene array analysis was
performed to identify any other differentially expressed genes resulting from
APAP pre-treatment that might also contribute to the development of
resistance to APAP hepatotoxicity upon re-exposure to this toxicant. Gene
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array analysis revealed statistically significant gene expression changes
unique to the APAP autoprotection mouse model (mice pretreated and reexposed to APAP) and further analysis of these genes using causal
reasoning engine (CRE) provided insights into the signaling pathways
involved in autoprotection (O'Connor et al., 2014). Of several noteworthy
genes that were identified to be differentially expressed in APAP
autoprotected mice, Fmo3 is one of them. Fmo3 is unique in a way that it is
considered non-inducible (Cashman & Zhang, 2002), but Fmo3 mRNA
expression increased 20- and 7-fold at 4 and 24 h in the autoprotected group,
respectively (O'Connor et al., 2014). Although a role of Fmo3 in APAP
hepatotoxicity is not known, it was the most biologically plausible for playing a
role in autoprotection.
Fmo3 is a monooxygenase involved in drug-metabolism somewhat
similar to cytochrome P450 (CYP) in that it produces many of the same
metabolites, although its substrate specificity is much more limited. Fmo3 is
not known to metabolize APAP and most metabolic products of Fmo3 are
considered to be non-toxic (Krueger & Williams, 2005). Hepatic expression of
the Fmo3 gene is highly variable showing cell-, tissue-, gender- and
developmental stage-specific expression patterns (Hines, 2006; Janmohamed
et al., 2004; Koukouritaki et al., 2002). Mammalian Fmo3 is also considered
to be non-inducible (Cashman & Zhang, 2002). However, recent studies by
Celius et al. showed that activation of the Aryl hydrocarbon (Ah) receptor
induces Fmo3 mRNA in mice, with marginal changes in protein levels (Celius
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et al., 2008; Celius et al., 2010). To our knowledge, the current study is only
the second to document xenobiotic-dependent Fmo3 induction, the
importance of which is unknown. Further, the role of Fmo3 in APAP-induced
hepatotoxicity and/or autoprotection also is not known.

However, it is

intriguing that female mice, which contain approximately 80-times more
hepatic Fmo3 mRNA than males (Janmohamed et al., 2004), are much more
resistant to APAP hepatotoxicity compared to their male counterparts (Dai et
al., 2006).
The initial studies reported herein describe Fmo3 gene expression
during APAP-induced hepatotoxicity. To better understand an Fmo3 role in
protection against APAP hepatotoxicity, we further attempted to establish a
causal relationship between the two, i.e., Fmo3 gene expression and APAP
hepatotoxicity. Thus, the functional significance of Fmo3 over-expression
during APAP hepatotoxicity was evaluated. To date, there are no
commercially available Fmo3-specific knockout mice because the expression
of this enzyme in male mouse liver is switched off during development and
male mice are essentially void of Fmo3 protein. In the absence of functional
Fmo3 protein in normal male mice, there has been no need for developing a
knockout model (Hernandez et al., 2009; Shephard & Phillips, 2010). As an
alternative model to low Fmo3 function, inhibition of Fmo3 activity in female
mice was achieved using the FMO inhibitor, methimazole. Methimazole
(MMI), an antithyroid drug, is an FMO substrate and also a competitive
inhibitor that has been used to block FMO-mediated conversion of various
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compounds in animal models (Nace et al., 1997). Fmo3 and Fmo5 are among
the most abundant FMO enzymes in female mouse liver and MMI is not a
substrate for Fmo5 (Cherrington et al., 1998; Hines, 2006; Overby et al.,
1995; Zhang et al., 2007). Thus, with MMI, among all FMO enzymes, Fmo3
was predominantly inhibited. Taking advantage of this observation, we could
test the hypothesis that MMI inhibition of Fmo3 renders female mice
susceptible to APAP-induced hepatotoxicity. In addition to the in vivo Fmo3
inhibitor study, we also developed an in vitro transgene over-expression
system. We have established for the first time a stable cell line (Human
hepatocyte HC-04) that over-expresses human FMO3 protein. Using this
system, we could test the hypothesis that enhanced expression of FMO3
confers resistance against APAP-induced cytotoxicity.
FMO is involved in the oxygenation of sulphur-containing endogenous
substrates, e.g., catalyzing the conversion of cysteamine (reduced form) to
cystamine (disulfide form) (Poulsen, 1981). Although, the physiological role
of cysteamine S-oxygenation by Fmo3 is not clear, in the 1970s Zieglar and
Poulsen proposed that oxygenation of cysteamine may be a significant
source of disulphide, maintaining the cellular thiol:disulphide potential in a cell
(Ziegler et al., 1979). Upregulation of Fmo3 during APAP-induced
hepatotoxicity and oxygenation of cysteamine by Fmo3 may serve to help
control the overall thiol:disulphide redox state of the cell, which in turn may
modulate cellular metabolism and/or activate signal transduction pathways
leading to altered susceptibility to APAP (or protection). To reiterate, the
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objective of the current investigation was to characterize the gene regulation
and protein expression of liver Fmo3 during APAP-induced hepatotoxicity.
The functional consequences of Fmo3 induction were also investigated. To
our knowledge, this is the first report describing a novel protective function for
this drug-metabolizing enzyme.
2.3 Materials and Methods
Chemicals
Acetaminophen, propylene glycol, methimazole and reduced GSH
were purchased from Sigma-Aldrich (St Louis, MO). All other reagents were
of reagent grade or better.
Animals
Male and female C57BL/6J mice, 9-10 week old, were obtained from
Jackson Laboratories (Bar Harbot, ME). Upon arrival, mice were acclimated
for one week prior to experimentation. Mice were housed in a 12 h dark/light
cycle in a temperature and humidity controlled environment. Mice were fed
laboratory rodent diet (Harlan Teklad 2018, Madison, WI) ad libitum.
Dosing regimen 1. Following an overnight fast, male mice (n=6) were
treated with APAP (400 mg/kg, ip) in 50 % propylene glycol (PG) or vehicle.
Animals were sacrificed 24, 48 and 72 h after APAP treatment. Plasma and
liver were collected for measuring alanine amino transferase (ALT) activity,
Fmo3 mRNA and protein levels and enzyme activity.
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Dosing regimen 2. Following an overnight fasting male mice (n=6)
were treated with APAP (400 mg/kg, ip) in 50 % PG or vehicle. Animals were
treated with APAP (600 mg/kg, ip) in 50 % PG or vehicle, 48 h after the first
treatment. Animals were sacrificed and plasma and liver were collected after
24 h for analysis.
Dosing regimen 3. Following an overnight fast, female mice (n=6) were
administered a single dose of methimazole (MMI) (50 mg/kg, ip) in saline.
Animals were sacrificed and plasma and livers were collected at 0.5, 4, 12
and 24 h for analysis of hepatotoxicity and GSH content. A single group of
mice received a first dose of MMI (50 mg/kg, ip) and 12 h after the first dose,
mice were treated with a second dose of MMI (50 mg/kg, ip). Plasma and liver
were collected 12 h later for analysis.
Dosing regimen 4. Following an overnight fasting female or male mice
(n=6) were administered vehicle (saline) or MMI (50 mg/kg, ip). Animals were
treated with APAP (400 mg/kg, ip), 30 min later. The group receiving two
doses of MMI along with APAP received the first dose of MMI 30 min prior to
APAP treatment and the second dose of MMI at 12 h after the first dose. Mice
in the group receiving only the second MMI dose were treated with MMI 11.5
h after APAP treatment. At 24 h after APAP treatment, animals were
sacrificed and plasma and liver were collected for measuring ALT activity and
GSH levels in this group of mice.
All animal studies were performed in accordance with National Institute
of Health standards and the Guide for the Care and Use of Laboratory
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Animals. This work was approved by the University of Connecticut’s
Institutional Animal Care and Use Committee.
Alanine Aminotransferase (ALT) Assay
Plasma ALT activity was determined as a biomarker of hepatocellular
injury. Infinity ALT Liquid Stable Reagent (Thermo Fisher Scientific Inc.,
Waltham, MA) was used to determine ALT activity. Samples were analyzed
using a Bio-Tek Power Wave X Spectrophotometer.
RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRTPCR)
TRIzol reagent (Life Technologies, Carlsbad, CA) was used to extract
total mouse liver RNA. cDNA was then made using an M-MLV RT kit
(Invitrogen, Carlsbad, CA). Fmo3 mRNA expression was quantified by the
ΔΔCT method and normalized to two housekeeping genes, β-actin and
ribosomal protein S18. Data presented in this manuscript were normalized to
β-actin. Primer pairs were synthesized by Integrated DNA Technologies
(Coralville, IA) and are as follow: Fmo3 forward: 5′-GGA AGA GTT GGT
GAA GAC CG-3′, reverse: 5′-CCC ACA TGC TTT GAG AGG AG-3′.
Amplification was performed using an Applied Biosystems 7500 Fast RealTime PCR System. Amplification was carried out in a 20 μL reaction volume
containing 8 μL diluted cDNA, Fast SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA) and 1 μM of each primer.
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Preparation of Crude Membrane and Microsomal Fractions
Microsomes were isolated from livers as described previously
(Cashman & Hanzlik, 1981). Briefly, livers were homogenized in cold
homogenization buffer (0.1 M potassium phosphate, 0.1 mM dithiothreitol
(DTT), 2 % sucrose, pH 9.0) and homogenates were centrifuged at 10,000 x
g for 20 min at 4°C. The supernatant was then centrifuged at 100,000 x g for
60 minutes. The resulting pellet was washed and resuspended in 0.1 M
potassium phosphate buffer (pH 9.0) containing 1 mM EDTA and stored at 80°C. Protease inhibitor was added to all buffers before use. Protein
concentration was determined by the method of Lowry using Bio-Rad protein
assay reagents (Bio-Rad Laboratories, Hercules, CA).
Western Blot Analysis
For western blot analysis of Fmo3, microsomal proteins (10 μg) were
electrophoretically resolved using 10 % polyacrylamide gels and transferred
onto PVDF-Plus membrane (Micron Separations, Westboro, MA). A custommade rabbit anti-mouse Fmo3 primary antibody (GenScript USA Inc., NJ) was
used to detect Fmo3 with β-Actin as a loading control. Extensive
characterization of the reactivity and/or specificity of this antibody was carried
out. The antibody developed was specific for mouse Fmo3 protein. Blots
were then incubated with HRP conjugated secondary antibodies against
rabbit
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were

detected

using

a

chemiluminescent kit (Thermo Scientific, IL) followed by exposure to X-ray
film.
Enzyme Assay
Methimazole

(MMI)

metabolism

was

determined

spectrophotometrically by measuring the rate of MMI S-oxygenation via the
reaction of the oxidized product with nitro-5-thiobenzoate (TNB) to generate
5,5’-dithiobis(2-nitrobenzoate) (DTNB). The incubation mixture consisted of
50 mM sodium phosphate buffer (pH 9.0), 0.5 mM NADP+, 0.5 mM glucose6-phosphate, 1.5 IU/mL glucose-6-phosphate dehydrogenase, 0.06 mM
DTNB, 0.04 mM DTT and 100 to 150 μg/mL liver microsomes isolated from
mice. Reactions were initiated by the addition of different amounts of MMI
(substrate) and range of MMI concentrations used were between 1.25 and
800 μM. Incubations were done in duplicates. The disappearance of the
yellow color was measured spectrophotometrically at 412 nM and specific
activity (µM/min/mg) was determined using the molar extinction coefficient of
NADPH (28.2 mM-1cm-1).
Immunohistochemistry
Immunohistochemical detection of Fmo3 protein was performed on 5
μm liver sections from tissues fixed in 10 % neutral-buffered zinc formalin
followed by routine processing, paraffin embedding, sectioning and
rehydration. Antigen retrieval was performed via microwave (950 watt)
method in 10 mM sodium citrate buffer for 2 minutes at 100 % power and at
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30 % power for another 8 minutes. Endogenous peroxidase activity was
blocked with a 10 min incubation in 3 % H2O2, and avidin/biotin blocking was
performed using a commercially available kit from Vector Laboratories
(Burlingame, CA). Sections were incubated overnight with the previously
mentioned anti-mouse Fmo3 primary antibody at a dilution of 1:8000 followed
by Vector Laboratory’s biotinylated goat anti-rabbit secondary antibody for 30
min. Protein-antibody complexes were detected with the Vector Elite ABC
reagent and developed using a Vector ®Nova RED substrate kit for
peroxidase. Slides were counterstained with hematoxylin, and mounted in
“Protocol” mounting media (Fisher Scientific, IL).
GSH Assay
Total hepatic GSH concentrations were determined by the recycling
method as previously described (Rahman et al., 2006). Briefly, 15-25 mg of
liver tissue was added to 500 μL of 5 mM EDTA disodium salt in 0.1 M
potassium phosphate buffer containing protease inhibitors. Tissues were kept
on ice and homogenized by hand in a dounce homogenizer for 5-6 strokes.
Equal volumes of 0.67 mg/mL 5,5′ -dithio-bis(2-nitrobenzoic acid) (DTNB)
and 3.33 units/mL glutathione reductase (Sigma Aldrich, St. Louis, MO) in 0.1
M potassium phosphate buffer containing 5 mM EDTA disodium salt were
mixed and 120 μL was added to 20 μL of each liver homogenate in a 96 well
plate. Sixty μL of 0.67 mg/mL β-NADPH (Sigma) in 0.1 M potassium
phosphate buffer containing 5 mM EDTA disodium salt was then added to
each
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immediately

at

412

nm,

taking

measurements every 30 seconds for 2 minutes. The assay was performed in
duplicate for each sample and compared to a standard curve made from two
fold serial dilutions (211.2 nmol/mL to 1.65 nmol/mL) of a GSH standard
(Sigma).
Histopathology
Liver samples were fixed in 10 % neutral-buffered zinc formalin prior to
processing and paraffin embedding. Liver sections (5 μm) were stained with
hematoxylin and eosin. Sections were examined by light microscopy for the
presence and severity of necrosis and degeneration using an established
grading system (Manautou et al., 1994).
Lentiviral Vector Construction
The FMO3-T2A-luc lentiviral transfer vector was constructed by
modifying the FUdeltaGW-rtTA (obtained from K. Hochedlinger via Addgene,
Cambridge, MA, plasmid 19780) to replace the rtTA insert with a polylinker
designed to accommodate the human FMO3 ORF (Clone ID: 5175615 from
Open Biosystems, Waltham, MA). To allow for bicistronic expression of FMO3
and luciferase, sequence encoding the T2A peptide (Szymczak et al., 2004)
was inserted into the polylinker. The luciferase ORF from pGL4.10 vector
(Promega, Madison, WI) was cloned in frame with FMO3 and the T2A
sequence. Luciferase activity was used to normalize levels of FMO3 overexpression.
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Cell Culture and Transduction
The replication-defective virus was generated in HEK 293T cells and
concentrated as previously described (Maherali et al., 2008). HC-04 cells
were seeded 24 h prior to transduction in complete DMEM medium and then
infected with a series of volumes of untitered concentrate (100 µL, 50 µL, and
25 µL per well of a 6 well culture dish) overnight. Prior to, during, and after the
viral transduction, the cells were maintained in complete DMEM containing
0.05 mM riboflavin. Media was changed daily to prevent riboflavin
degradation.
Cell Culture and Treatment
HC-04 cells over-expressing human FMO3 (hFMO3-HC-04) and empty
vector (EV-HC-04) were maintained in DMEM supplemented with 10 mM
glucose, 10 % FBS, 0.05 mM riboflavin and 1 % antibiotic-antimycotic (100
units/mL penicillin G sodium, 100 µg/mL streptomycin sulfate, and 0.25 µg/mL
amphotericin B) in a 5 % CO2 and humidified environment (95 % relative
humidity) at 37°C. For APAP treatments, cells were seeded at 200,000 cells
per well in a 24-well plate. The following day, culture media was replaced with
media containing APAP (1 mM to 15 mM). Twenty-four hours later,
cytotoxicity was measured by the LDH assay. For MMI treatments, cells were
seeded at 200,000 cells per well in a 24-well plate. The next day, cells were
incubated in media containing 1 mM MMI for 30 min at 37°C. Thirty minutes
following incubation with MMI, culture media containing 15 mM APAP was
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added to wells. Cytotoxicity was measured using the LDH assay kit 24 h later.

LDH Leakage
As a measure of cytotoxicity following APAP treatment, percent lactate
dehydrogenase (LDH) leakage in all in vitro experiments was determined via
the Tox-7 kit. The assay was performed according to manufacturer’s
instructions (Sigma-Aldrich, St. Louis, MO).
Statistical Analysis
Results are expressed as means ± standard error (SE). Data were
analyzed using the Student’s t-test or ANOVA followed by a post-hoc test.
While Student’s t-test was used to compare means of two different treatment
groups, ANOVA was used to compare the means of more than two means of
different treatment groups that are normally distributed with a common
variance. Differences were considered significant at p<0.05.
2.4 Results
Time Course of Plasma ALT Activity and Fmo3 mRNA Levels After APAP
Treatment
Administration of 400 mg/kg APAP to male C57Bl/6J mice resulted in
elevation of plasma ALT levels (Figure 2.1A). Plasma ALT activity increased
to 191±18 and 219±47 IU/L at 24 and 48 h, respectively, following APAP
treatment (mean plasma ALT activity in control mice was 25±5 IU/L). By 72 h,
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plasma ALT activity is not statistically different from propylene glycol vehicle
controls indicating recovery from APAP-induced liver injury. Fmo3 mRNA
levels were quantified by qRT-PCR. The results in Figure 2.1B show that
Fmo3 mRNA levels increased by 5±2.6-and 23±5.6-fold, at 24 and 48 h
respectively, compared to the 0 h control group.
Time Course of Fmo3 Protein Expression After APAP Treatment
To examine the temporal changes in Fmo3 gene expression and
function following APAP treatment, Fmo3 protein levels were quantified by
western blotting and by measuring catalytic activity using MMI as substrate.
Representative blots and associated densitometric analysis are shown in
Figure 2.2A and 2.2B, respectively. Although the expression of Fmo3 protein
tended to increase by 1.1±0.3- to 1.6±0.2-fold between 24 and 72 h after
APAP, these increases are statistically significant only at 72 h. An alternative
method to quantitate Fmo3 protein induction is by measuring FMO catalytic
activity using MMI (Zhang et al., 2007). With APAP treatment, FMO specific
activity increased over time and this increase is statistically significant at 72 h
only

(24±1.5

2.2C).

µM/min/mg)(Fig.

immunohistochemical

analysis

of

Fmo3

Figure

protein

2.2D

localization.

shows
Cellular

localization of Fmo3 protein and degree of protein expression did not change
at 24 or 48 h, but marginally increased at 72 h after treatment with a single
dose APAP (400 mg/kg). Unlike Fmo3 mRNA levels that peaked at 48 h,
maximum Fmo3 protein expression is observed at 72 h following APAP
treatment. These data demonstrate that a single dose APAP (400 mg/kg)
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treatment results in a marginal, yet significant increase in Fmo3 protein levels
and activity at 72 h, the longest time-point tested.
Plasma ALT Activity and Fmo3 mRNA Expression in the Mouse Model of
APAP Autoprotection
Previous studies conducted in our laboratory demonstrated the
phenomenon of APAP autoprotection in mice, where mice receiving an initial
mild toxic dose of APAP are protected against hepatotoxicity from higher
doses (Aleksunes et al., 2008). To investigate Fmo3 gene expression in the
mouse model of APAP autoprotection, male C57BL/6J mice were pretreated
with either propylene glycol vehicle or 400 mg/kg APAP. Forty-eight hours
following pretreatment, mice were challenged with vehicle or a higher dose of
APAP (600 mg/kg). Plasma ALT activity and Fmo3 mRNA levels were
measured 24 h after the challenge dose (Fig. 2.3A and 2.3B respectively).
Plasma ALT levels in mice receiving vehicle pretreatment and APAP
challenge (600 mg/kg; VA) increased significantly to 1600±413 IU/L
compared to vehicle controls (VV). Likewise, ALT levels in mice pretreated
and challenged with APAP (AA; autoprotected group) increased significantly
to 230±69 IU/L compared to VV controls. However, the values are
significantly lower than in the VA group. Consistent with the single dose
APAP (400 mg/kg) study, APAP pretreated, vehicle challenged mice (AV)
have marginal increases in ALT values in comparison to VV controls. The
results in Figure 2.3B show Fmo3 mRNA levels in the mouse model of APAP
autoprotection. Fmo3 mRNA transcript levels in the AV and AA groups
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increased significantly by 39±5- and 70±11-fold, respectively, with APAP
autoprotected mice showing the greatest (70-fold) induction.
Fmo3 Protein Expression in the Mouse Model of APAP Autoprotection
Fmo3 protein expression is not normally detectable in adult male mice
livers because the expression of this enzyme is silenced during development
(Cherrington et al., 1998; Falls et al., 1997; Shephard & Phillips, 2010). To
determine if Fmo3 protein expression correlates with the mRNA expression
seen in APAP autoprotected male mouse livers, western blot analysis was
performed as described in Materials and Methods. Representative blots are
shown in Figure 2.4A and densitometric analysis of blots are shown in Figure
2.4B. As expected, no detectable hepatic Fmo3 protein is present in VV
control livers. Following treatment with APAP (dosing regimen 2) Fmo3
protein levels increased in both AV (p value 0.0743) and AA group (p value
0.041). However, the elevation is statistically significant only in APAP
autoprotected group (15±2-fold change). In agreement with protein
expression data, the MMI assay used to measure enzyme specific activity
shows an increase in activity to 16±2 and 42 ±5µM/min/mg in AV and AA
groups

of

mice,

respectively,

compared

to

vehicle

controls

(3±1µM/min/mg)(Fig. 2.4C). Figure 2.5 shows immunohistochemical analysis
of Fmo3 protein localization. Protein staining is localized to centrilobular
regions in both pretreated and autoprotected livers instead of its conventional
periportal localization seen in non-treated female livers. This distinct zonal
localization by APAP coincides with the area where damage and/or
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hepatocellular compensatory repair/proliferation occurs (Figure E/F and G/H,
respectively).
Effect of Methimazole Treatment on Liver in Mice
Methimazole is a drug used in the treatment of hyperthyroidism and is
a high affinity substrate and effective competitive inhibitor of the Fmomediated oxidation of various compounds (Nace et al., 1997). Later studies
described in this manuscript use MMI (50 mg/kg) to inhibit FMO activity in
female as well as male mice. MMI at higher doses can by itself deplete
hepatic GSH levels or cause hepatotoxicity in GSH-depleted mice (Mizutani
et al., 1999; Mizutani et al., 2000). To determine whether administration of
MMI by itself at doses used in our study results in hepatotoxicity, female mice
were administered either one or two doses of 50 mg/kg MMI. Animals were
sacrificed and plasma and livers were collected over a timecourse of 12 h for
liver toxicity analysis (dosing regimen 3). Plasma ALT activity increased to
39±4 IU/L at 12 h following a single dose MMI treatment compared to vehicle
controls (15±3 IU/L)(Fig. 2.6A). Even though the ALT activity increased
significantly at 12 h, these levels are below the normal physiological range for
hepatotoxicity (40-43 IU/L, as per the “Physiological Data Summary” provided
by The Jackson Laboratory for female C57BL/6J mice). Hepatic GSH levels
are shown in Figure 2.6B. GSH levels in livers from MMI treated mice are not
different from that in their vehicle treated controls. In support of ALT activity
data, histopathological analysis of H&E stained liver sections from MMI
treated mice do not show any signs of liver injury (Fig. 2.6C). Collectively
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these data suggest that MMI at two doses of 50 mg/kg does not result in
hepatotoxicity nor does it deplete hepatic GSH levels, one of the key
detoxification mechanisms involved during APAP exposure.
Immunohistochemical Analysis of Liver Fmo3 Protein Expression and
Localization in Naïve C57BL/6J Male and Female Livers
Female mice express about eighty times higher Fmo3 mRNA levels
compared to males (Janmohamed et al., 2004). To examine whether the
differences

in

mRNA

levels

translate

to

protein

levels,

an

immunohistochemical analysis for Fmo3 protein expression was performed in
naïve livers from male and female mice using our custom-made Fmo3
primary antibody. Consistent with the literature, Fmo3 protein expression and
its cellular localization is not detectable in male liver under basal conditions.
Strikingly, female livers express higher Fmo3 protein levels compared to male
mice. This Fmo3 expression is restricted to hepatocytes surrounding portal
veins (Figure 2.7).
Effect of Methimazole Treatment on APAP-induced Liver Injury in Female and
Male C57BL/6J Mice
As shown in Figure 2.7, female mice express higher Fmo3 protein
levels compared to their male counterparts. It has also been demonstrated
that female mice are much more resistant to APAP hepatotoxicity compared
to male mice (Dai et al., 2006). If Fmo3 plays a role in conferring tolerance to
APAP-induced hepatotoxicity in female mice, methimazole (FMO inhibitor)
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treatment should render female mice susceptible to APAP hepatotoxicity. To
investigate the effect of MMI treatment on APAP-induced hepatotoxicity in
female mice, groups of mice received APAP along with either one or two
doses of MMI (dosing regimen 4). Plasma ALT activity in female mice did not
change compared to vehicle controls following APAP (400 mg/kg) treatment
(Fig. 2.8A)(mean plasma ALT activity in control mice: 27±2 IU/L). APAP
treatment along with the first and second dose of MMI (1&2MMI/APAP),
significantly increased plasma ALT levels to 3343±802 IU/L. APAP treatment
with only the first dose (1MMI/APAP) of MMI also increased plasma ALT
values to 473±93 IU/L. Hepatic GSH levels also are shown in Figure 2.8B.
Liver GSH content measured at 24 h in mice receiving APAP alone show a
rebound increase to 72±3 nmol/mg protein compared to vehicle controls
(48±4 nmol/mg protein). On the other hand, all three groups of mice receiving
APAP and MMI co-treatment show significantly lower GSH levels
(1&2MMI/APAP: 19±7, 1MMI/APAP: 30±3 and APAP/2MMI: 37±2 nmol/mg
protein) compared to the group receiving APAP alone. This change correlates
well with higher plasma ALT activity in these three groups. The severity of
hepatocellular necrosis by APAP along with MMI was analyzed and graded
using a scale ranging from 0 to 5. Liver samples with grades greater than 2
are considered to have significant injury (Manautou et al., 1994). Results of
histopathological analysis are presented in Figure 2.8C and Table 2.1.
Examination of liver sections from the control group revealed normal
histology. Consistent with the plasma ALT activity, APAP (400 mg/kg)
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treatment resulted in a minimal amount of hepatocellular injury in female
mice. Even though the severity of APAP-related injury increased with MMI,
there is greater injury with two doses of MMI.
Fmo5 and Fmo3 are abundant FMO enzymes in female adult mouse
liver (Cherrington et al., 1998; Hines, 2006; Janmohamed et al., 2004). While
Fmo3 is abundant in female mice, male mice are void of Fmo3 (Cherrington
et al., 1998; Hines, 2006; Janmohamed et al., 2004). With the exception of
FMO5, MMI is a substrate for all FMO enzymes (Overby et al., 1995; Zhang
et al., 2007). Thus, with MMI we presume female hepatic Fmo3 is
predominantly inhibited. If the susceptibility of female mice to APAP-induced
hepatotoxicity is due to MMI inhibition of Fmo3 (demonstrated in Fig. 2.8A
and 2.8B), then we anticipate seeing no alteration in the susceptibility of male
mice to APAP hepatotoxicity with MMI administration. To investigate the
effect of MMI treatment on APAP-induced hepatotoxicity in male mice, groups
of mice received APAP along with either one or two doses of MMI (dosing
regimen 4). Administration of APAP (400 mg/kg) in saline to male mice
resulted in elevation of plasma ALT levels to 1794±222 IU/L compared to
vehicle controls (45±12 IU/L) (Fig. 2.8D). APAP co-administration with MMI
did not significantly change plasma ALT activity compared to APAP treated
male

mice

(1&2MMI/APAP:

1984±592,

1MMI/APAP:

2333±126

and

APAP/2MMI: 1530±328 IU/L). Hepatic GSH levels are presented in Figure
2.8E. Consistent with plasma ALT levels, hepatic GSH content following
APAP (400 mg/kg) treatment decreased significantly to 16±2 nmol/mg protein
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compared to vehicle controls (61±2 nmol/mg protein). Further, GSH levels did
not change significantly in all groups of mice that received APAP along with
one or two doses of MMI compared to the APAP only group (1&2MMI/APAP:
13±2, 1MMI/APAP: 11±2 and APAP/2MMI: 17±1 nmol/mg protein). These
data demonstrate that the susceptibility of female mice to APAP-induced
hepatotoxicity from MMI treatment is due to inhibition of hepatic Fmo3.
Establishment of Human Hepatocyte Cell Line (HC-04) Over-expressing
Human FMO3 (hFMO3-HC-04)
To further evaluate the functional significance of FMO3 overexpression during APAP hepatotoxicity, we developed a human hepatocyte
cell line (HC-04) that over-expresses human FMO3. Unlike HepG2 cells, HC04 cells express CYPs that bioactivate APAP to its toxic metabolite NAPQI
and also are susceptible to APAP-induced cellular toxicity (Lim et al., 2007).
Thus, this cell line is a good model for studying the protective effects of FMO3
gene expression during APAP-induced cytotoxicity. FMO3 was incorporated
into a bicistronic vector driven by the ubiquitin-C promoter, which allowed coexpression of FMO3 and luciferase (LUC) genes in transduced HC-04 cells.
We identified five clones that over-expressed human FMO3, of which three
were maintained as cell lines. Results from luciferase activity assays used to
measure the efficiency of transduction are presented in Figure 2.9A. The
clones expressed a 33±1-, 89±2- and 455±8-fold change in luciferase activity
as compared to the empty vector control (EV-HC-04). For convenience, these
clones are named Low- Mid-, and High-FMO3 expressing cell lines,
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respectively. FMO3 protein expression was confirmed by performing western
blotting using microsomal fractions isolated from EV expressing HC-04 cells
and all three FMO3-over-expressing HC-04 clones. Representative blots and
densitometric analysis are shown in Figure 2.9B. Following transduction,
Fmo3 protein levels increased by 5±0.1-, 10±0.3- and 33±0.5-fold in Low-,
Mid- and High-FMO3 expressing HC-04 cells, respectively. The specific
activity of over-expressed FMO3 protein increased to 75±1.2, 80±0.7 and
80±0.6 µM/min/mg in Low-, Mid- and High-FMO3 expressing HC-04 cells
respectively compared to EV-HC-04 controls (5 µM/min/mg) (Fig. 2.9C).
Effect of APAP Treatment in HC-04 Cells Over-expressing Human FMO3
(hFMO3-HC-04)
Cell culture and treatment is described in detail in the Materials and
Methods. Results are shown in Figure 2.10. The percent LDH leakage into
the media in Low-FMO3 expressing hFMO3-HC-04 cells in response to 1, 5,
10 and 15 mM APAP treatment is significantly lower (7, 10, 17and 24 %)
compared to empty vector controls (8, 13, 23 and 31 %), respectively. The
amount of LDH leakage does not change in Mid-FMO3 expressing cells and
is significantly greater (9, 14, 28 and 42 %) in High-FMO3 expressing cells
following 1, 5, 10 and 15 mM APAP treatment. Taken together, these data
suggest that over-expression of FMO3 protects against APAP-induced
cytotoxicity only in Low-FMO3 expressing cells. By contrast, APAP
cytotoxicity is aggravated in the High-FMO3 expressing clone.
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Effect of MMI Pretreatment During APAP-induced Cytotoxicity in HC-04 Cells
Over-expressing Human FMO3 (hFMO3-HC-04)
The amount of LDH leakage (%) into the media does not change with
MMI treatment (Fig. 2.11A). In response to 15 mM APAP treatment, the
percent LDH leakage into the media in Low-FMO3 expressing cells
decreased significantly to 25 % compared to EV controls (29 %)(Fig. 2.11B).
Following pretreatment with 1 mM MMI, the susceptibility of Low-FMO3
expressing cells to APAP-induced cytotoxicity restored to 29 %. On the
contrary, Mid- and High-FMO3 expressing cells did not exhibit any protection
against APAP-induced cytotoxicity. These cell lines also show enhanced
cytotoxicity during MMI pretreatment.
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Figure 2.1
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Figure 2.1 Plasma ALT activity and quantitative RT-PCR analysis of liver
Fmo3 transcripts following a single dose APAP treatment. Plasma and livers
were collected from mice 24, 48 and 72 h following APAP (400 mg/kg) or
vehicle treatments. (A) The data are presented as mean plasma ALT (IU/L) ±
SE. (B) RNA was isolated from livers and further cDNA was made using a
commercial MMLV-RT kit. The cDNA samples were analyzed by quantitative
RT-PCR using Fmo3 mouse-specific primers. Gene expression was
normalized to housekeeping gene β-Actin. Fmo3 mRNA expression are
presented as mean Fold Change ± SE. One-way ANOVA was performed
followed by the Dunnett’s post-test. Asterisks (*) represent a statistical
difference (p < 0.05) between 0 h vehicle and APAP-treated groups.
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Figure 2.2
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Figure 2.2 Analysis of liver Fmo3 protein expression following a single dose
APAP treatment by western blotting, enzyme activity assay as well as by
immunohistochemistry. After overnight fasting, mice received a single dose of
400 mg/kg APAP or vehicle.

Livers were collected at 24, 48 and 72 h

following APAP or vehicle treatments. Western blots for Fmo3 were
performed using liver microsomes from control and APAP-treated mice. A
custom-made rabbit anti-mouse Fmo3 primary antibody, described in
Materials and Methods section was used to detect Fmo3. Equal protein
loading (10 μg protein/lane) was confirmed by detection of β-actin.
Microsomal protein isolated from naïve female mouse liver was used as a
positive control indicated by “+” sign. The data are presented as blots (A) and
as mean Fmo3 protein expression (Fold Change) ± SE (B). FMO activity was
measured in liver microsomes from control and APAP-treated mice using
methimazole as substrate as described under Materials and Methods. Data
are presented as mean Specific Activity (μM/min/mg) ± SE (C). Asterisks (*)
represent a statistical difference (p < 0.05) between 0 h vehicle and APAPtreated groups. Immunohistochemical staining to detect Fmo3 was conducted
on zinc formalin fixed, paraffin-embedded liver sections from control and
APAP-treated mice. Immunochemical staining was performed with the same
antibody used for Western blotting. Representative images are shown (D).
Scale bar: 100 μm. (A) Vehicle-treated 0 h; (B) APAP-treated 24 h; (C)
APAP-treated 48 h; (D) APAP-treated 72 h.
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Figure 2.3
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Figure 2.3 Plasma ALT activity in the mouse model of APAP autoprotection.
Groups of mice were treated with vehicle or APAP 400 mg/kg. 48 h after
pretreatment, mice were challenged with vehicle or APAP 600 mg/kg. Plasma
and livers were collected 48 h following APAP challenge. (A) The data are
presented as mean plasma ALT (IU/L) ± SE. One-way ANOVA was
performed followed by the Dunnett’s post-test. While asterisks (*) represent a
statistical difference (p< 0.05) between VV group and VA groups, pound (#)
represent a statistical difference (p < 0.05) between VA and AA groups. (B)
RNA was extracted from livers and cDNA was prepared using a commercial
MMLV-RT kit as described in Materials and Methods. The cDNA samples
were analyzed for Fmo3 mRNA levels by quantitative RT-PCR using Fmo3
mouse-specific primers. Gene expression was normalized to housekeeping
gene β-Actin. Fmo3 mRNA expression are presented as mean Fold Change
± SE. One-way ANOVA was performed followed by the Dunnett’s post-test.
Asterisks (*) represent a statistical difference (p < 0.05) from VV groups and
pound (#) represent a statistical difference (p<0.05) between VA and AA
groups.
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Figure 2.4
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Figure 2.4 Analysis of liver Fmo3 protein expression in the mouse model of
APAP autoprotection by western blotting and enzyme activity assay. Dosing
regimen is described in detail in Materials and Methods section. Briefly,
groups of mice were administered with vehicle or APAP (400 mg/kg) and 48 h
later challenged with vehicle or APAP (600 mg/kg). Livers were collected 24 h
following the last treatment. Western blots for Fmo3 was performed using
liver microsomes from all groups of mice. A custom-made rabbit anti-mouse
Fmo3 primary antibody, described before was used to detect Fmo3. Equal
protein loading (10 μg protein/lane) was confirmed by detection of β-actin.
Microsomal protein isolated from naïve female mouse liver was used as a
positive control indicated by “+” sign. The data are presented as blots (A) and
as mean Fmo3 protein expression (Fold Change) ± SE (B). Liver microsomes
isolated from all groups of mice were used to measure FMO activity using
methimazole as substrate. Data are presented as mean Specific Activity
(μM/min/mg) ± SE (C). Asterisks (*) represent a statistical difference (p <
0.05) from VV groups.
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Figure 2.5
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Figure 2.5 Immunohistochemical analysis of liver Fmo3 protein expression
and localization in the mouse model of APAP autoprotection. Details of APAP
autoprotection treatment regimen are described in Materials and Methods.
Groups of mice were pretreated with vehicle or APAP (400 mg/kg) and
challenged with vehicle or APAP (600 mg/kg) 48 h later. Twenty-four hours
after the challenge dose livers were collected and fixed in zinc formalin and
paraffin embedded. Immunochemical staining to detect Fmo3 was performed
with the same antibody used for Western blotting. Representative images
from all groups of mice are shown at two magnifications. Scale bar: 100 and
500 μm. (A/B) VV – Vehicle pretreated and vehicle challenge group; (C/D) VA
– Vehicle pretreated and APAP (600 mg/kg) challenge group; (E/F) AV –
APAP (400 mg/kg) pretreated and Vehicle challenge group; (G/H) AA – APAP
(400 mg/kg) pretreated and APAP (600 mg/kg) challenge group liver sections.
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Figure 2.6
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Figure 2.6 Plasma ALT activity, hepatic GSH levels and histopathology of
liver sections after 50 mg/kg methimazole (MMI) treatment in female mice.
Dosing regimen is described in detail in Materials and Methods section.
Briefly, groups of mice were administered a single dose of MMI (50 mg/kg)
and plasma and livers were collected 0.5, 4, 12 and 24 h later. A single group
of mice received both the first and the second dose of MMI and 12 h after the
second dose, plasma and livers were collected for analysis. (A) The data are
presented as mean plasma ALT (IU/L) ± SE. (B) GSH levels are expressed
as GSH nmol/mg protein ± SE. One-way ANOVA was performed followed by
the Dunnett’s post-test. Asterisks (*) represent a statistical difference (p<
0.05) between vehicle and MMI-treated groups. (C) Histopathology of
formalin-fixed, paraffin-embedded liver sections from MMI treated mice.
Representative images are shown. Scale bar: 100 μm. (A) Control; (B) First
dose MMI-treated 0.5 h; (C) First dose MMI-treated 4 h; (D) First dose MMItreated 12 h; (E) First dose MMI-treated 24 h; (F) First and second dose MMItreated 12 h.

	
  

85	
  

Figure 2.7
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Figure 2.7 Immunohistochemical analysis of Fmo3 in naïve female and male
liver. Livers from untreated female and male mice were collected and fixed in
zinc formalin and paraffin embedded. Immunochemical staining of Fmo3 was
performed on paraffin sections using the custom-antibody used before.
Representative images are shown. Scale bar: 100 μm. (A) Female (B) Male
liver specimens.
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Figure 2.8
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Figure 2.8 Plasma ALT activity, hepatic GSH levels and histopathology of
liver sections after MMI intervention in APAP treated mice. Female or male
mice were treated with vehicle or APAP (400 mg/kg) or APAP along with MMI
(50 mg/kg). The first dose of MMI was administered 30 min prior to APAP
treatment and the second dose 12 h after the first dose. 24 h after APAP
treatment, plasma and livers were collected for analysis. (A) The data from
female mice are presented as mean plasma ALT (IU/L) ± SE. (B) GSH levels
in female mice livers are expressed as GSH nmol/mg protein ± SE. One-way
ANOVA was performed followed by the Dunnett’s post-test post-test.
Asterisks (*) represent a statistical difference (p< 0.05) compared to vehicle
treated group and pound (#) represent a statistical difference (p<0.05) from
APAP treated group. (C) Histopathology of formalin-fixed, paraffin-embedded
liver sections after MMI intervention in APAP treated female mice.
Representative images are shown. Scale bar: 100 μm. (A) Vehicle – Vehicle
treated group; (B) APAP – APAP (400 mg/kg) treated group; (C) 1&2
MMI/APAP – APAP (400 mg/kg) with both the first and second dose MMI (50
mg/kg) treated group; (D) 1 MMI/APAP – APAP (400 mg/kg) with the first
dose MMI (50 mg/kg) treated group; (E) APAP/2MMI – APAP (400 mg/kg)
with the second dose MMI (50 mg/kg) treated group. (D) The data from male
mice are presented as mean plasma ALT (IU/L) ± SE. (E) GSH levels in male
mice livers are expressed as GSH nmol/mg protein ± SE. One-way ANOVA
was performed followed by the Dunnett’s post-test. Asterisks (*) represent a
statistical difference (p< 0.05) compared to vehicle treated group.
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Figure 2.9
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Figure 2.9 Establishment of HC-04 cells over-expressing human FMO3
(hFMO3-HC-04). Lentiviral vector construction and transduction are described
in detail in Materials and Methods section. (A) Luciferase activity to measure
the efficiency of transduction in hFMO3-HC-04 clones. The data are
presented as mean luciferase activity/mg protein (Fold Change) ± SE. (B)
Western blot for Fmo3 was performed using microsomal protein isolated from
empty vector (EV), Low-, Mid- and High-FMO3 expressing cell lines. Rabbit
anti-human FMO3 primary antibody was used to detect FMO3 protein
expression. Equal protein loading (10 μg protein/lane) was confirmed by
detection of β-actin. The data are presented as blots as well as mean FMO3
protein expression (Fold Change) ± SE. (C) Microsomes isolated from EV
expressing HC-04 cells and all three FMO3-over-expressing HC-04 clones
were used to measure FMO activity using methimazole as substrate. Data are
presented as mean Specific Activity (μM/min/mg) ± SE Protein. One-way
ANOVA was performed followed by the Dunnett’s post-test. Asterisks (*)
represent a statistical difference (p< 0.05) compared to EV controls.
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Figure 2.10
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Figure 2.10 Effect of APAP treatment in HC-04 cells over-expressing human
FMO3 (hFMO3-HC-04). Empty vector, Low-, Mid- and High-FMO3 expressing
cell lines were treated with a range of APAP concentrations from 1 mM to 15
mM. 24 h later, percent LDH leakage into the medium was measured using a
commercial kit. The data are presented as mean LDH leakage (%) ± SE.
Two-way ANOVA was performed followed by the Bonferroni’s post-test.
Asterisks (*) represent a significant decrease (p< 0.05) compared to EV
controls and pound (#) represent a significant increase (p<0.05) compared to
EV controls.
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Figure 2.11
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Figure 2.11 Effect of MMI pretreatment during APAP-induced cytotoxicity in
HC-04 cells over-expressing human FMO3 (hFMO3-HC-04). Empty vector,
Low-, Mid- and High-FMO3 expressing cell lines were incubated with MMI (1
mM) for 30 min before APAP (15 mM) treatment. 24 h after APAP treatment,
percent LDH leakage into the medium was measured. The data are
presented as mean LDH leakage (%) ± SE. Two-way ANOVA was performed
followed by the Bonferroni’s post-test. Asterisks (*) represent a significant
decrease (p<0.05) compared to APAP treated EV control and pound (#)
represent a significant increase (p<0.05) compared to respective APAP
treated EV and hFMO3-HC-04 cell lines.
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TABLE 2.1
Histopathological Analysis of Livers after MMI Intervention in APAP Treated
Mice. Liver sections were examined for severity of degenerative and necrotic
changes in centrilobular region as described previously (Manautou et al.,
1994). Liver samples with grades greater than 2 are considered to have
significant injury.

Data were rank ordered prior to statistical analysis.

Asterisks (*) represent a statistical difference (p<0.05) from vehicle control
group and pound (#) represent a statistical difference (p<0.05) from APAP
treated group.
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Histological Grade
Treatment Group

Percent >2
0

1

2

3

4

5

Control

5

0

0

0

0

0

0

APAP

0

5

0

0

0

0

0

0

0

0

1

1

2

100

1MMI / APAP*

0

0

4

1

0

0

20

APAP / 2MMI

0

5

0

0

0

0

0

1&2MMI / APAP*
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2.5 Discussion
The mechanism of APAP-induced cellular and liver organ toxicity is
multifactorial and complex (Jaeschke & Bajt, 2006; Jaeschke et al., 2012).
Examining novel genes and pathways differentially regulated in experimental
models of xenobiotic hepatotoxicity resistance can provide novel avenues to
develop new modalities of treatment for liver diseases. Our laboratory has
previously developed a mouse model of APAP autoprotection for studying the
mechanisms of hepatic injury/recovery (Aleksunes et al., 2008). This study
also elucidated the role of efflux transporter MRP4 and compensatory cellular
proliferation in protecting against APAP-induced hepatotoxicity in this model
of APAP autoprotection. However, it is possible that factors other than MRP4
also can contribute to the development of APAP toxicity tolerance. A gene
array analysis recently conducted in our lab provided insights into signaling
pathways potentially involved in APAP autoprotection (O'Connor et al., 2014).
Fmo3 was among the genes with the most significant change in APAP
autoprotected mice. Even though a role of Fmo3 expression in APAP
hepatotoxicity is not known, it was the most biologically plausible for playing a
role in autoprotection.
In this study, we investigated the hepatic expression of Fmo3 protein
during APAP-induced hepatotoxicity. Historically, Fmo3 was considered to be
a non-inducible drug-metabolizing enzyme (Cashman & Zhang, 2002;
Cashman & Zhang, 2006; Hines, 2006; Krueger & Williams, 2005). However,
recent studies show that activation of the Ah receptor induces Fmo3 mRNA
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levels (Celius et al., 2008; Celius et al., 2010). In these studies, although
there is a very large increase in Fmo3 mRNA levels, protein levels measured
by methimazole oxidation show only modest increases in protein function.
Similarly, our results show that the dramatic elevation in liver Fmo3 mRNA
expression following administration of a single APAP dose is accompanied by
marginal increases in Fmo3 protein expression and catalytic activity. It is
worth noting that the Fmo3 mRNA expression is variable between studies,
which is again similar to the observations with ligand dependent activation of
AhR and Fmo3 mRNA expression (Celius et al., 2008). These differences in
expression cannot be due to diurnal variation in basal expression because
animals were dosed and tissue harvested at approximately the same time of
the day every time we conducted independent studies. Fmo3 is subject to
hormone regulation (Cherrington et al., 1998; Falls et al., 1997; Janmohamed
et al., 2004), and such, 9 to 10 weeks old mice were used in the current
study. Irrespective of the level and degree of increased Fmo3 mRNA
expression following a single dose APAP treatment, increases in protein
expression remained marginal.
In contrast to what was observed with a single APAP hepatotoxic dose,
both liver Fmo3 mRNA and protein expression are significantly higher in mice
treated with the APAP autoprotection regimen (pre- and post-APAP
treatment). In agreement with greater Fmo3 protein expression, Fmo3
catalytic activity and centrilobular zonal expression also are significantly
greater in the APAP autoprotection group. These findings suggest the
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regulation of Fmo3 gene expression (transcriptional and/or translational) is
different under the conditions of treatment with a single APAP dose versus an
autoprotection treatment regimen. Because the level of damage from a mildly
toxic dose of APAP is minimal, the need for restoration of balance in cellular
processes may also be less. Thus all mRNA transcribed in response to the
minimally toxic APAP exposure may not be translated into functional protein.
In contrast, after an autoprotected dosing regimen, the initial exposure to a
mildly toxic APAP dose would prime the tissue for faster recovery from reexposure to a second toxic insult. Indeed, the possibility exists that at least a
portion of the dramatic increases in Fmo3 protein observed with the second
APAP dose results from rapid translation of Fmo3 mRNA stabilized in
ribonucleoprotein complexes. Such translational control has been well
documented in other systems where a rapid response to a potentially toxic
exposure occurs (e.g., translation of stored ferritin mRNA in response to iron
exposure). This overall concept is well accepted and referred to by some
scientists as “hormesis”. The precise cellular and molecular events leading to
this adaptation is not known. Moreover, immunohistochemical analysis of
APAP autoprotected livers show the Fmo3 expression is localized to the
hepatic centrilobular regions, where APAP induced damage and/or
hepatocellular compensatory repair/proliferation occurs, instead of the
conventional periportal localization seen in female livers. This expression
pattern is again suggestive of a potential Fmo3 role in the development of
APAP hepatotoxicity resistance via an unknown cytoprotective function.
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Female mice exhibit higher Fmo3 gene expression than male mice
(Cherrington et al., 1998; Hines, 2006; Janmohamed et al., 2004), and are
much more resistant to APAP hepatotoxicity compared to males (Dai et al.,
2006). Our findings with the FMO inhibitor methimazole in female mice
demonstrate that MMI inhibition of Fmo3 makes female mice susceptible to
APAP-induced hepatotoxicity. The caveats of any inhibitor study are the
specificity of inhibition as well as potential off target effects exhibiting toxicity
comparable to that seen in males. Historically, MMI is known to interfere with
the synthesis of thyroid hormones by inhibiting the enzyme, thyroperoxidase
and is capable of inhibiting other enzymes involved in oxygenation reactions
such as FMO and CYP dependent monooxygenases (Hunter & Neal, 1975). If
MMI was contributing to changing female mice susceptibility to APAP
hepatotoxicity by inhibiting CYP-dependent metabolism, we would have
anticipated seeing less liver damage. Clearly, this is not the case because
MMI treatment makes female mice sensitive to APAP hepatotoxicity. This is
quite remarkable since C57BL/6J female mice are quite resilient to APAP
hepatotoxicity. Undesirable side effects such as cholestasis can develop from
MMI treatment due to extrathyroidal actions in humans (Schmidt et al., 1986).
However,

a

cholestatic

liver

is

less

susceptible

to

APAP-induced

hepatotoxicity in mice (Silva et al., 2006). Lastly, MMI at higher doses can
deplete hepatic GSH levels or in GSH-depleted mice induce centrilobular
necrosis (Mizutani et al., 1999; Mizutani et al., 2000). However, under the
conditions used in the current study, MMI treatment alone does not result in

	
  

101	
  

GSH depletion or hepatotoxicity in mice. Furthermore, MMI treatment in male
mice did not alter APAP-induced hepatotoxicity negating any potential nonspecific functions of MMI. Collectively, these results suggest that the
susceptibility of female mice to APAP hepatotoxicity following MMI treatment
is the result of inhibiting Fmo3 function.
To further study the importance of FMO3 over-expression, we
established an in vitro over-expression system using HC-04 cells. While the
percent LDH leakage into the media in Low-FMO3 expressing hFMO3-HC-04
cells in response to APAP treatment is significantly lower compared to empty
vector controls, the amount of LDH leakage by APAP does not change in the
Mid-FMO3 expressing clone and is significantly greater in High-FMO3 cells.
Taken together, these data suggest that over-expression of FMO3
significantly alters susceptibility to APAP induced cytotoxicity. Even though
the percent protection from APAP cytotoxicity in the Low-FMO3 expressing
clone is only about 20 percent, one must keep in mind that FMO3 overexpressing cells are a mono cell culture. The possible contribution from other
cell types, such as Kupffer cells and endothelial cells known to play an
important role in signaling mechanisms should not be overlooked. The data
also suggest that there is a threshold for FMO3 over-expression in protecting
against APAP-induced cytotoxicity. This is evidenced by the enhanced APAP
cytotoxicity in the High-expressing FMO3 cells. MMI treatment did not result
in elevation of basal LDH leakage into the medium in all FMO3-overexpressing clones. This suggests that MMI by itself at doses used in vitro did
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not result in cytotoxicity. Inhibition of FMO3 activity by MMI in all three Low-,
Mid- and High-FMO3 expressing cell lines resulted in rescue of sensitivity to
APAP in Low-FMO3 expressing cell line compared to EV controls. Since
High-FMO3 expressing cells exhibit greater LDH leakage in comparison to EV
controls following APAP treatment (threshold for FMO3 over-expression), one
might anticipate seeing lower APAP cytotoxicity following MMI co-treatment.
Considering this is not the case, it is possible that MMI at 1mM concentration
results in inhibition of FMO3 activity in Low-FMO3 expressing cell line but is
metabolized in High-FMO3 expressing cells. To emphasize, MMI is a
substrate for Fmo3 as well as a competitive inhibitor with IC50 value of
60.2±16.2 µM (Attar et al., 2003; Rettie & Fisher, 1999).
FMO is involved in oxygenation of phosphorus, nitrogen and sulphurcontaining xenobiotics. FMO’s also are involved in the oxidation of
endogenous substrates such as cysteamine to cystamine (Poulsen, 1981).
Although, the physiological role of FMO3 cysteamine S-oxygenation is not
clear, Zieglar and Poulsen proposed in the 1970’s that FMO might be
involved in protein disulphide bond formation through oxidation of cysteamine.
It was also proposed that oxygenation of cysteamine may be a significant
source of disulphide, maintaining the cellular thiol:disulphide potential in a cell
(Ziegler et al., 1979). Further, Suh and Robertus showed that yeast FMO
serve as a modulator of cellular thiols and maintains optimum redox potential
within the endoplasmic reticulum, allowing for proper folding of disulfide bondcontaining proteins (Suh & Robertus, 2002). The cytoprotective functions of
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Fmo3 and its possible involvement in APAP autoprotection are summarized
below. The relationship between cellular thiol:disulphide ratios and the
regulation of metabolic reactions has been recognized for a long time (Barron,
1953). Oxygenation of cysteamine during APAP hepatotoxicity may serve to
help control the overall thiol:disulphide redox state of the cell, which in turn
may modulate cellular metabolism and/or activate signal transduction
pathway leading to altered susceptibility to APAP (or protection). Oxygenation
of cysteamine to cystamine by Fmo3 and transport out of the cell also may
represent a detoxication mechanism or protective function, because
cysteamine is toxic to cells at concentrations as low as 39 µM through the
transition metal-dependent formation of hydrogen peroxide (Jeitner &
Lawrence, 2001). To investigate whether oxygenation of cysteamine to
cystamine by Fmo3 is important during APAP hepatotoxicity, follow-up
studies

will

measure

the

total

hepatic

cysteamine

and

cystamine

concentrations in the mouse model of APAP autoprotection.
In the present study, up-regulation of Fmo3 gene expression in the
mouse APAP autoprotection model and its role in protecting against APAPinduced cytotoxicity or hepatotoxicity has led to the conclusion that Fmo3 is
important for development of resistance to APAP-induced hepatotoxicity. The
phenomenon of autoprotection is also seen in patients who are repeatedly
exposed to supratherapeutic doses of APAP (Shayiq et al., 1999; Watkins et
al., 2006). These clinical data suggest that human liver can adapt to APAPinduced hepatotoxicity similar to that seen in our APAP autoprotection mouse
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model. C57BL/6J wild type mice are commonly used for studies of APAP
hepatotoxicity and the mechanisms of toxicity in these animals are not
completely understood. Although, key events such as NAPQI formation, GSH
depletion, protein arylation, peroxynitrate formation and mitochondrial
damage play an important role in APAP hepatotoxicity (Cohen et al., 1997;
Hinson et al., 2010; Jaeschke & Bajt, 2006; Jaeschke et al., 2011; McGill et
al., 2012). Even though primary human hepatocytes are the gold standard
tool for studying APAP hepatotoxicity mechanisms, they have major
drawbacks. The availability of these cells is limited, and the drug response
can vary significantly due to differences in donors. Most importantly, the
lifespan of primary human hepatocytes is short and they undergo changes in
CYP expression levels over time in culture. Hepatoma cell lines like HepG2
express very low CYP levels compared to primary human hepatocytes or
human liver especially those that are involved in the metabolism of APAP
(Rodriguez-Antona et al., 2002). Using the more recently available human
hepatoma cell line, HepaRG, which expresses a more normal spectrum of
drug metabolizing enzymes, studies have demonstrated that the mechanistic
features of APAP-induced hepatotoxicity are the same as reported for human
hepatocytes and mouse liver in vivo (McGill et al., 2011). Thus, it is very likely
that the phenomenon of APAP autoprotection seen in human might also
involve FMO3 over-expression. Although this is a subject of current
investigation in our laboratory the mere fact that the protein once thought to
be non-inducible is being induced following treatment with a commonly used,
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over-the-counter drug like acetaminophen is quite alarming. Importantly, one
also must be concerned about the number of other drugs that are coadministered with APAP and are FMO3 substrates.

	
  

106	
  

CHAPTER 3
Differential FMO3 Gene Expression in Various Liver Injury Models
Involving Hepatic Oxidative Stress in Mice
3.1 Abstract
Flavin-containing monooxygenase-3 (FMO3) catalyzes metabolic
reactions similar to cytochrome P450 monooxygenase however, most
metabolites of FMO3 are considered non-toxic. Recent findings in our
laboratory demonstrated Fmo3 gene induction following toxic acetaminophen
(APAP) treatment in mice. The goal of this study was to evaluate Fmo3 gene
expression in diverse other mouse models of hepatic oxidative stress and
injury. Fmo3 gene regulation by Nrf2 was also investigated using Nrf2
knockout (Nrf2 KO) mice. In our studies, male C57BL/6J mice were treated
with toxic doses of hepatotoxicants or underwent bile duct ligation (BDL, 10d).
Hepatotoxicants included APAP (400 mg/kg, 24 to 48 h), alpha-naphthyl
isothiocyanate (ANIT; 50 mg/kg, 2 to 48 h), carbon tetrachloride (CCl4; 10 or
30 µL/kg, 24 and 48 h) and allyl alcohol (AlOH; 30 or 60 mg/kg, 6 and 24 h).
Because oxidative stress activates nuclear factor (erythroid-derived 2)-like 2
(Nrf2), additional studies investigated Fmo3 gene regulation by Nrf2 using
Nrf2 knockout (Nrf2 KO) mice. At appropriate time-points, blood and liver
samples were collected for assessment of plasma alanine aminotransferase
(ALT) activity, plasma and hepatic bile acid levels, as well as liver Fmo3
mRNA
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mRNA

expression

increased

significantly by 43-fold at 12 h after ANIT treatment, and this increase
translates to a 4-fold change in protein levels. BDL also increased Fmo3
mRNA expression by1899-fold, but with no change in protein levels.
Treatment of mice with CCl4 decreased liver Fmo3 gene expression, while no
change in expression is detected with AlOH treatment. Nrf2 KO mice are
more susceptible to APAP (400 mg/kg, 72 h) treatment compared to their
wild-type (WT) counterparts, which is evidenced by greater plasma ALT
activity. Fmo3 mRNA and protein expression increased in Nrf2 KO mice after
APAP treatment. Collectively, not all hepatotoxicants that produce oxidative
stress alter Fmo3 gene expression. Along with APAP, toxic ANIT treatment in
mice markedly increases Fmo3 gene expression. While BDL increases Fmo3
mRNA expression, protein level does not change. The discrepancy with Fmo3
induction in cholestatic models, ANIT and BDL, is not entirely clear. Results
from Nrf2 KO mice with APAP suggest that the transcriptional regulation of
Fmo3 during liver injury may not involve Nrf2.
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3.2 Introduction
Drug-induced liver injury (DILI) is a significant challenge for both drug
development and clinical care. It accounts for more than 50 % of all acute
liver failure cases in the U.S. (Larson et al., 2005; W. M. Lee, 2010). Many
chemicals, such as acetaminophen (APAP), carbon tetrachloride (CCl4) and
allyl alcohol (AlOH) have been used to model hepatotoxicity relevant to
human exposure. Alpha-naphthyl isothiocyanate (ANIT) and bile duct ligation
(BDL) on the other hand are used to model cholestasis, a pathological
condition caused by impairment of hepatic bile flow. While ANIT produces
intrahepatic cholestasis, BDL produces extrahepatic cholestasis. With APAP
and CCl4, the parent compound is metabolized by cytochrome P450 (CYP) to
generate reactive metabolites, N-acetyl-p-benzoquinone imine (NAPQI) and
tricholoromethyl radical (˙CCl3), respectively. AlOH in turn is metabolized in
the liver by alcohol dehydrogenase to its reactive metabolite, acrolein. The
glutathione adduct of acrolein is converted by CYPs to glycidaldehyde.
Toxicity resulting from these reactive metabolites is multifactorial and includes
lipid peroxidation, generation of oxidative stress, altered cellular redox status
and protein adduct formation (Burcham & Fontaine, 2001; Cohen et al., 1997;
Jaeschke et al., 2012; Ohno et al., 1985; Tom et al., 1984). During
cholestasis resulting from either BDL or ANIT treatment, increase in bile acid
concentration stimulates production of reactive oxygen species eventually
leading to hepatocellular necrosis and apoptosis (Sokol et al., 1995; Trauner
et al., 1998).
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The role of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) role as a
master defense against hepatotoxicity produced by various chemicals has
been investigated in several studies. Nrf2 belongs to the cap ‘n’ collar family
of transcription factors that promotes transcription of a battery of
cytoprotective genes (Aleksunes & Manautou, 2007; Kensler et al., 2007).
Under basal conditions, Nrf2 is largely bound to the cytoskeletal anchoring
protein Kelch-like ECH-associated protein 1 (Keap1) also known as cytosolic
Nrf2 inhibitor in the cytoplasm. In response to oxidative stress, Nrf2 is
released from Keap1 and translocates to the nucleus. In the nucleus, Nrf2
binds to the GTGACA***GC core sequence of the antioxidant response
element (ARE) (Rushmore et al., 1991) and promotes ARE-mediated
antioxidant gene expression.
A low toxic APAP dose causes nuclear accumulation of Nrf2 in mouse
liver, which is accompanied by increased expression of Nrf2 dependent
cytoprotective genes such as heme oxygenase-1 (Hmox1), NAD(P)H:quinone
oxidoreductase-1 (Nqo1) and glutamate cysteine ligase catalytic subunit
(Gclc) (Aleksunes et al., 2005; Aleksunes et al., 2006; Bauer et al., 2000;
Chiu et al., 2002; Goldring et al., 2004). Similar results have been reported
with ANIT, BDL, CCl4 and AlOH, other models of hepatic oxidative stress
used in the present study (Aleksunes et al., 2005; Aleksunes et al., 2006; Liu
et al., 2013; Randle et al., 2008; Tanaka et al., 2009). On the other hand, Nrf2
KO mice are more susceptible to APAP-induced liver injury compared to their
wild-type counterparts (Chan et al., 2001; Enomoto et al., 2001). Likewise,
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Nrf2 KO mice are also more susceptible to CCl4- and AlOH-induced
hepatoxicity compared to wild-type mice (Liu et al., 2013). However, Nrf2-null
mice do not exhibit any difference in susceptibility to either BDL or ANIT
treatment (Tanaka et al., 2009; Weerachayaphorn et al., 2012). This
response is attributed to the adaptive compensatory changes involving
nuclear transcription factors, including Fxr, Shp, Pxr and Hnf1α, efflux bile
acid transporters, altered GSH levels and bile flow rates in Nrf2 KO mice
(Tanaka et al., 2009; Weerachayaphorn et al., 2012). Collectively, the models
of hepatic injury selected for the current study not only result in hepatic
oxidative stress but also activate the Nrf2-Keap1 regulatory pathway.
Despite Fmo3 being considered non-inducible, studies with aryl
hydrocarbon receptor (AhR) agonists in mice show liver Fmo3 gene induction
(Celius et al., 2008; Celius et al., 2010). A recent gene array analysis
performed in our laboratory also demonstrated Fmo3 gene induction in the
APAP autoprotection mouse model (mice receiving a low hepatotoxic APAP
dose that become resistant to a subsequent higher APAP dose) (O'Connor et
al., 2014). Unlike with AhR agonists that result in marginal increases in Fmo3
protein expression in mouse liver, we show significant increases in Fmo3
protein levels in APAP autoprotected mice (Rudraiah et al., 2014). Fmo3
induction by other hepatotoxicants that produce oxidative stress is not
currently known.
In human liver, transcription factors regulating constitutive FMO3
expression as well as those involved in developmental expression pattern are
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extensively studied (Klick & Hines, 2007; Klick et al., 2008; Shimizu et al.,
2008). Because the mammalian FMOs were considered non-inducible by
xenobiotics (Cashman & Zhang, 2002; Krueger & Williams, 2005), the
transcriptional regulation of FMO involving stress-activated transcription
factors or receptors that bind ligands and interact with DNA was not studied
as other forms of regulation. Thus, little is known about the transcriptional
regulation of Fmo3 in response to toxicant exposure. Recently, Celius et al.
show that the Fmo3 mRNA up-regulation by 3-methylcholanthrene (3MC) and
benzo(a)pyrene (BaP) but not TCDD in Hepa-1 cells is mediated by p53 and
its binding to a p53-response element in the promoter region of Fmo3 (Celius
et al., 2010).
Differentially expressed genes in the APAP autoprotection model were
further analyzed using Causal Reasoning Engine (CRE), a recently
developed computational platform (O'Connor et al., 2014). CRE analysis
provides hypotheses on the upstream molecular events that best explain
gene expression profiles based on prior biological knowledge. CRE analysis
of differentially expressed genes in APAP autoprotection study supports an
induction of the Nrf2 pathway (O'Connor et al., 2014). Additionally, the 5'flanking region of the mouse Fmo3 contains multiple copies of the ARE
(Celius et al., 2008). Therefore, the purpose of the present study was to
investigate liver Fmo3 gene expression under oxidative stress conditions
involving activation of the Nrf2-Keap1 regulatory pathway. Mice were dosed
with hepatotoxicants APAP (400 mg/kg, 24 to 48 h), ANIT (50 mg/kg, 2 to 48
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h), CCl4 (10 or 30 µL/kg, 24 and 48 h) or AlOH (30 or 60 mg/kg, 6 and 24 h)
or underwent sham surgery or bile duct ligation (10 d). Doses selected for
hepatotoxicants are based upon previous studies conducted in our laboratory
resulting in oxidative stress and tissue injury. The inclusion of multiple timepoints

following

hepatotoxicants

exposure

enabled

comprehensive

characterization of temporal changes in Fmo3 in relation to injury and
recovery. Further, in order to investigate whether Nrf2 mediates Fmo3 gene
expression, Nrf2 KO mice were employed. APAP was used as a model
toxicant in the Nrf2 KO mice study. From these experiments, it is concluded
that not all hepatotoxicants that produce oxidative stress in mice induce liver
Fmo3 gene expression. Toxic ANIT treatment, along with the previously
demonstrated APAP treatment, markedly increases Fmo3 gene expression.
While BDL increases Fmo3 mRNA expression, protein levels do not change.
APAP treatment induces Fmo3 gene expression in Nrf2 KO mice liver
suggesting that the transcriptional regulation of Fmo3 might not involve Nrf2.
3.3 Materials and Methods
Chemicals
Acetaminophen, alpha-naphthyl isothiocyanate, carbon tetrachloride,
allyl alcohol, propylene glycol and corn oil were purchased from SigmaAldrich (St Louis, MO). All other reagents were of reagent grade or better and
commercially available.
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Animals
Male C57BL/6J mice (9- to 10-week old) were purchased from Jackson
Laboratories (Bar Harbor, ME) for this study. Upon arrival, mice were
acclimated for one week prior to experimentation. Mice were housed in a
temperature-, light- and humidity-controlled environment. Mice were fed
laboratory rodent diet (Harlan Teklad 2018, Madison, WI) ad libitum.
Experimental Design 1. Following an overnight fast, male mice (n=6)
were treated with APAP (400 mg/kg in 50 % propylene glycol, ip, 24, 48 and
72 h), ANIT (50 mg/kg in corn oil, po, 2, 4, 8, 12, 24 and 48 h), CCl4 (10 or 30
µL/kg in corn oil, ip, 24 and 48 h), AlOH (30 or 60 mg/kg in saline, ip, 6 and 24
h) or vehicle. At the end of each experiment, animals were sacrificed at the
specified time-points for each hepatotoxicant and plasma and livers were
collected for analysis. BDL liver samples were obtained from a previously
described cohort (Donepudi et al., 2012). Briefly, sham or BDL surgery was
performed under phenobarbital-induced anesthesia (65 mg/kg, ip). The
surgeries were performed at the University of Rhode Island, College of
Pharmacy animal facility with IACUC approval. Serum and liver were
collected 10 d after surgery for analysis.
Experimental Design 2. Following overnight fasting, male Nrf2 KO mice
and their wild-type counterparts (C57BL/6J) were treated with APAP (400
mg/kg, ip) in 50 % PG or vehicle. Plasma and livers were collected 72 h after
APAP treatment for analysis.
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All animal studies were performed in accordance with National Institute
of Health standards and the Guide for the Care and Use of Laboratory
Animals. This work was approved by the University of Connecticut’s
Institutional Animal Care and Use Committee.
Alanine Aminotransferase (ALT) Assay
Plasma or serum ALT activity was determined as a biochemical
indicator of hepatocellular injury. Infinity ALT Liquid Stable Reagent (Thermo
Fisher Scientific Inc., Waltham, MA) was used to determine ALT activity.
Briefly, 100 µL of reagent was added to 10 µL serum or plasma samples, and
absorbance was measured spectrophotometrically at 340 nm using a Bio-Tek
Power Wave X Spectrophotometer. ALT activity (IU/L) was determined using
the molar extinction coefficient of NADH (6.3 mM-1cm-1).
Total Bile acid Assay
Total bile acids were extracted from whole liver homogenates using a
t-butanol extraction method. Briefly, livers were homogenized in extraction
solution (1:1, water: t-butanol) and bile acids extracted overnight at room
temperature in the dark. Blood levels of total bile acid and hepatic bile acid
levels were measured using a spectrophotometric bile acid assay kit
(Bioquant, San Diego, CA) according to manufacturer’s protocol.
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RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRTPCR)
Total RNA was extracted from mouse liver samples using TRIzol
reagent (Life Technologies, Carlsbad, CA) according to the manufacturer’s
instructions. Total RNA was then reverse-transcribed into cDNA using an MMLV RT kit (Invitrogen, Carlsbad, CA). Fmo3 mRNA expression was
quantified by the ΔΔCT method and normalized to two housekeeping genes,
β-actin and ribosomal protein S18. Data presented were normalized to βactin. Primer pairs were synthesized by Integrated DNA Technologies
(Coralville, IA) and are as follow: Fmo3 forward: 5′-GGA AGA GTT GGT
GAA GAC CG-3′, reverse: 5′-CCC ACA TGC TTT GAG AGG AG-3′.
Amplification was performed using an Applied Biosystems 7500 Fast RealTime PCR System. Amplification was carried out in a 20 μL reaction volume
containing 8 μL diluted cDNA, Fast SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA) and 1 μM of each primer.
Preparation of Microsomal Fraction and Western Blot Analysis
Microsomes were isolated from livers as described previously
(Cashman & Hanzlik, 1981; Rudraiah et al., 2014) and stored at -80°C until
use. Protein concentration was determined by the method of Lowry using BioRad protein assay reagents (Bio-Rad Laboratories, Hercules, CA). For
western blot analysis, microsomal proteins (10 μg) were electrophoretically
resolved using 10 % polyacrylamide gels and transferred onto PVDF-Plus
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membrane (Micron Separations, Westboro, MA). Membranes were blocked
with 5 % non-fat powdered milk in tris buffered saline containing 0.05%
tween-20 (TBS-T) for 8 h. A rabbit anti-mouse Fmo3 primary antibody
(GenScript USA Inc., NJ) (1:5000) was used to detect Fmo3 with β-actin as a
loading control. Blots were then incubated with HRP conjugated secondary
antibodies against rabbit IgG (1:2000) (Sigma-Aldrich, St Louis, MO). Proteinantibody complexes were detected using a chemiluminescent kit (Thermo
Scientific, IL) with visualization using GeneMate blue autoradiography film
(Bioexpress, Kaysville, UT).
Enzyme Assay
Methimazole

(MMI)

metabolism

was

determined

spectrophotometrically by measuring the rate of MMI S-oxygenation via the
reaction of the oxidized product with nitro-5-thiobenzoate (TNB) to generate
5,5’-dithiobis(2-nitrobenzoate) (DTNB). The incubation mixture consisted of
50 mM sodium phosphate buffer (pH 9.0), 0.5 mM NADP+, 0.5 mM glucose-6phosphate, 1.5 IU/mL glucose-6-phosphate dehydrogenase, 0.06 mM DTNB,
0.04 mM dithiothreitol and 100 to 150 μg/mL liver microsomes isolated from
mice. Reactions were initiated by the addition of different amounts of MMI
(substrate), with a concentration range from 1.25 to 800 μM. Incubations were
done in duplicates. The disappearance of the yellow color was measured
spectrophotometrically at 412 nm and specific activity (μM/min/mg) was
determined using the molar extinction coefficient of NADPH (28.2 mM-1cm-1).
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Statistical Analysis
The statistical significance between groups was determined using the
Student’s t-test, one-way ANOVA with Dunnett’s post-hoc test or two-way
ANOVA followed by the Bonferroni’s post-hoc test. While Student’s t-test was
used to compare means of two different treatment groups, ANOVA was used
to compare the means of more than two treatment groups that are normally
distributed with a common variance. All statistical analysis was performed
using GraphPad Prism version 4.00 for Macintosh (GraphPad Software, Inc.,
San Diego, CA). Data are presented as mean ± standard error (SE), with
p<0.05 considered statistically significant.
3.4 Results
Plasma ALT Activity in the Mouse Liver Injury Models
The hepatotoxicity of APAP (400 mg/kg) at 24, 48 and 72 h as
assessed by plasma ALT activity has been reported previously (Rudraiah et
al., 2014). Briefly, APAP increased plasma ALT activity to 191±18 and
219±47 IU/L at 24 and 48 h, respectively (mean plasma ALT activity in control
mice was 25±5 IU/L). Plasma ALT activity is not statistically different from
vehicle controls by 72 h, indicating recovery from APAP-induced liver injury.
Plasma ALT activity in all mouse models of liver injury is shown in Figure 3.1.
ANIT increased ALT activity at 12 h (182±9 IU/L), which continued to increase
at 24 and 48 h (715±126 IU/L and 781±45 IU/L, respectively) compared to
vehicle control group (9±1 IU/L). BDL for 10 d results in an elevation of ALT
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activity to 185±10 IU/L. A high CCl4 dose (30 µL/kg) increased plasma ALT at
24 and 48 h to 6367±1135 and 397±111 IU/L, respectively. A low CCl4 dose
(10 µL/kg) also increased plasma ALT activity at 24 and 48 h to 757±106 and
416±68 IU/L, respectively. The greatest increase in plasma ALT with both
doses of CCl4 is observed at 24 h. While AlOH treatment (low dose, 30
mg/kg) did not result in significant increases in ALT levels at 6 h and 24 h
(36±4 and 73±24 IU/L, respectively), a high AlOH dose (60 mg/kg) results in
significantly higher ALT levels at both 6 h and 24 h (153±50 and 4440±2428
IU/L, respectively). The associated histopathological damage with all
hepatotoxicants has been reported previously (Aleksunes et al., 2005;
Aleksunes et al., 2006; Campion et al., 2009; Donepudi et al., 2012; Rudraiah
et al., 2014). With acute toxicity models, plasma ALT activity lesser than 1000
IU/L is usually associated with a minimal to mild hepatocellular damage
(histological grade of 2 or less than 2), and an ALT activity higher than 1000
IU/L is associated with moderate, marked or severe hepatocellular damage
(histological grade of 3, 4, or 5) (Aleksunes et al., 2008; Manautou et al.,
1994). Alternatively, a 10 d BDL with an associated ALT activity of less than
200 IU/L, exhibit a chronic hepatocellular damage involving fibrosis (Donepudi
et al., 2012).
Hepatic Fmo3 mRNA Expression in the Mouse Liver Injury Models
Fmo3 mRNA levels were quantified by qRT-PCR and the results are
presented in Figure 3.2. Fmo3 mRNA expression following 400 mg/kg APAP
treatment has been previously reported (Rudraiah et al., 2014). Briefly, Fmo3
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mRNA levels increased by 5±2.6-and 23±5.6-fold, at 24 and 48 h after APAP,
respectively, compared to the 0 h control group. ANIT increased Fmo3 mRNA
levels as early as 2 h after treatment. This increase peaked and is statistically
significant only at 12 h (43±10-fold increase), compared to 0 h vehicle control
group. BDL also increased Fmo3 mRNA expression by 1899±625-fold,
compared to sham operated mice. Both the low and high dose of CCl4
decreased Fmo3 mRNA levels at both time points examined, and this
decrease is statistically significant only at 48 h (10 µL/kg: 0.2±0.06-fold and
30 µL/kg: 0.2±0.08-fold). No change in liver Fmo3 mRNA levels is observed
with AlOH treatment.
Hepatic Bile Acid Concentrations in the Mouse Liver Injury Models
To determine the extent of cholestasis induced by different
hepatotoxicants used in the current study, total hepatic bile acid levels were
measured (Figure 3.3). As expected ANIT increased hepatic bile acid levels
to 1.7±0.2 and 1.6±0.4 µmol/g at 24 and 48 h, respectively, compared to 0 h
vehicle control group (0.2±0.02 µmol/g). BDL also increased hepatic bile acid
concentrations to 19.49±0.85 µmol/g compared to sham operated group
(10.61±1.65 µmol/g). No significant changes were observed in mice treated
with APAP, CCl4 and AlOH.
Total bile Acid Concentrations in the Blood in the Mouse Liver Injury Models
Bile acid concentration in plasma is also a biomarker of cholestasis. In
order to determine the extent of cholestasis, plasma bile acid levels were also
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quantified in all mouse models of liver injury (Figure 3.4). Plasma bile acid
concentration increased in ANIT treated mice at 24 and 48 h to 210±20 and
330±128 µmol/L, respectively, compared with vehicle treated mice (2±0.2
µmol/L). Bile duct ligation significantly increased serum bile acid levels to
1359±142 µmol/L compared to sham operated mice (86±11 µmol/L).
Significant increases in plasma bile acid concentrations are seen in high dose
CCl4 treated mice at both 24 and 48 h (112±15 µmol/L and 29±2 µmol/L,
respectively). Exposure to APAP and AlOH did not result in any significant
change in plasma bile acid levels.
Fmo3 Protein Expression in the Mouse Liver Injury Models
Temporal expression of the Fmo3 protein following exposure to
hepatotoxicants and BDL were quantified by western blotting. Representative
blots and associated densitometric analyses are shown in Figure 3.5. Fmo3
protein increase following APAP treatment has been previously reported
(Rudraiah et al., 2014). Although the expression of Fmo3 protein tended to
increase by 1.1±0.3- to 1.6±0.2-fold between 24 and 72 h after APAP, the
increase is statistically significant only at 72h. Consistent with Fmo3 mRNA
changes evidenced with ANIT treatment, Fmo3 protein levels also tend to
increase as early as 2 h. However, this increase is significant only at 12 h
(3.5±0.9-fold) compared to 0 h vehicle treated group. Fmo3 protein levels
decreased to 0.7±0.08- and 0.3±0.1-fold at 24 and 48 h, respectively, after
exposure to ANIT. Conversely, in spite of the dramatic increase in Fmo3
mRNA levels after BDL, Fmo3 protein levels did not change. No significant
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changes in Fmo3 protein expression are observed with CCl4 or AlOH
treatment.
Plasma ALT Activity and Fmo3 mRNA Levels After APAP Treatment in WildType and Nrf2 Knockout Mice
All models of hepatic injury used in the current study activate the Nrf2Keap1 regulatory pathway. Furthermore, CRE analysis of differentially
expressed genes in our APAP autoprotection study supported an induction of
the Nrf2 pathway (O'Connor et al., 2014). To investigate whether Nrf2
mediates Fmo3 gene expression, APAP was used as a model toxicant for
Nrf2 activation in Nrf2 KO and WT mice. Mice were administered a 400 mg/kg
APAP dose for 72 h. Dose and time-point selected were based on our single
dose APAP study performed previously (Rudraiah et al., 2014), where a 400
mg/kg APAP treatment increased Fmo3 protein levels at 72 h. Administration
of 400 mg/kg APAP to male C57BL/6J WT mice did not result in significantly
different plasma ALT values at 72 h from vehicle controls. This is consistent
with the previously reported results, indicating recovery from APAP-induced
liver injury and increased Fmo3 protein expression in WT mice (Rudraiah et
al., 2014). In contrast, plasma ALT activity is elevated at 72 h in Nrf2 KO mice
receiving the same dose of APAP (176±12 IU/L) compared to vehicle control
group (23±5 IU/L) (Figure 3.6A). This is again consistent with the literature
and confirms that Nrf2 plays an important role not only in the magnitude of
toxicity, but also in the degree and rate of recovery from APAP-induced liver
injury. Fmo3 mRNA levels were quantified by qRT-PCR. The results in Figure
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3.6B show that there is no change in Fmo3 mRNA levels at 72 h in wild-type
mice administered 400 mg/kg APAP. This is again consistent with previous
reports, where maximal Fmo3 mRNA expression is seen at 48 h after APAP
administration and returns to normal by 72 h (Rudraiah et al., 2014). Notably,
Fmo3 mRNA expression is significantly higher in Nrf2 KO mice 72 h after
APAP treatment by 140±43-fold change compared to vehicle control group.
Fmo3 Protein Expression After APAP Treatment in Wild-Type and Nrf2
Knockout Mice
To examine the temporal changes in Fmo3 gene expression following
APAP treatment in WT and Nrf2 KO mice, Fmo3 protein levels were
quantified by western blotting and by measuring catalytic activity using MMI
as substrate. Representative blots and associated densitometric analysis are
shown in Figure 3.7A. Consistent with increased Fmo3 mRNA expression in
Nrf2 KO mice administered APAP (400 mg/kg) at 72 h, Fmo3 protein levels
are also significantly higher (5.1±1.3-fold) compared to vehicle control group.
Measuring FMO catalytic activity using MMI can also quantitate Fmo3 protein
induction (Zhang et al., 2007). FMO specific activity increased significantly in
Nrf2 KO livers (48±6 µM/min/mg) at 72 h after APAP compared to vehicle
controls of either genotype (Figure 3.7B).
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Figure 3.1
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Figure 3.1 Plasma ALT activity in mice treated with hepatotoxicants or BDL.
Male C57BL/6J mice were treated with ANIT (50 mg/kg, po, 2,4,8,12,24 & 48
h), CCl4 (10 & 30 µL/kg, ip, 24 & 48 h), AlOH (30 & 60 mg/kg, ip, 6 & 24 h) or
BDL (10 d). Plasma was collected from mice at various time points following
hepatotoxicant treatment or the appropriate vehicle. The data are presented
as mean plasma ALT (IU/L) ± SE. One-way ANOVA, t-test or two-way
ANOVA was performed, appropriately, followed by the Dunnett’s posttest for
One-way ANOVA and the Bonferroni posttest for two-way ANOVA. Asterisks
(*) represent a statistical difference (p < 0.05) between vehicle-treated and
hepatotoxicant-treated group.
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Figure 3.2
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Figure 3.2 Quantitative RT-PCR analysis of liver Fmo3 transcripts after
hepatotoxicant treatment or BDL. Livers were collected from mice sacrificed
at respective time-points (2,4,8,12,24 & 48 h for ANIT; 24 & 48 h for CCl4; 6
& 24 h for AlOH; and 10 d for BDL). RNA was isolated and cDNA was made
using a commercial MMLV-RT kit. The cDNA samples were analyzed by
quantitative RT-PCR using Fmo3 mouse-specific primers. Gene expression
was normalized to the housekeeping gene β-actin. Fmo3 mRNA expression
is presented as mean Fold Change ± SE. One-way ANOVA, t-test or two-way
ANOVA was performed, appropriately, followed by the Dunnett’s posttest for
One-way ANOVA and the Bonferroni posttest for two-way ANOVA. Asterisks
(*) represent a statistical difference (p < 0.05) between vehicle-treated and
hepatotoxicant-treated or BDL group.
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Figure 3.3
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Figure 3.3 Hepatic bile acid levels after hepatotoxicant administration or BDL.
Livers were collected at the end of each study (24, 48 & 72 h for APAP;
2,4,8,12,24 & 48 h for ANIT; 10 d for BDL; 24 & 48 h for CCl4; and 6 & 24 h
for AlOH). Liver total bile acids were measured spectrophotometrically using a
commercial bile acid assay kit. Hepatic total bile acids are expressed as
mean hepatic bile acids (μmol/g) ± SE. One-way ANOVA, t-test or two-way
ANOVA was performed, appropriately, followed by the Dunnett’s posttest for
one-way ANOVA and the Bonferroni posttest for two-way ANOVA. Asterisks
(*) represent a statistical difference (p < 0.05) between vehicle-treated and
hepatotoxicant-treated or BDL group.
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Figure 3.4
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Figure 3.4 Blood levels of Total Bile acid in the mouse models of liver injury.
Mice were administered APAP (400 mg/kg, ip, 24, 48 & 72 h), ANIT (50
mg/kg, po, 2,4,8,12,24 & 48 h), CCl4 (10 & 30 µL/kg, ip, 24 & 48 h), AlOH (30
& 60 mg/kg, ip, 6 & 24 h) or BDL (10 d). Blood was collected and the plasma
or serum (for BDL) was isolated by centrifugation. Total bile acid levels were
measured spectrophotometrically using a commercial bile acid assay kit.
Total bile acids are expressed as mean total bile acids (μmol/L) ± SE.
Student’s t-test, one-way ANOVA, or two-way ANOVA was performed,
appropriately, followed by the Dunnett’s posttest for one-way ANOVA and the
Bonferroni posttest for two-way ANOVA. Asterisks (*) represent a statistical
difference (p < 0.05) between vehicle-treated and hepatotoxicant-treated or
BDL group.
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Figure 3.5
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Figure 3.5 Analysis of liver Fmo3 protein expression in the mouse models of
liver injury by western blotting. Western immunoblots for Fmo3 were
performed using liver microsomes from control and hepatotoxicant-treated or
BDL mice. A custom-made rabbit anti-mouse Fmo3 primary antibody,
described in Materials and Methods was used to detect Fmo3. Fmo3 protein
levels were normalized to β-actin loading control. Microsomal proteins
isolated from naïve female mouse liver was used as a positive control
(indicated by “+” sign). The data are presented as blots and as mean Fmo3
protein expression (Fold Change) ± SE. One-way ANOVA, t-test or two-way
ANOVA was performed, appropriately, followed by the Dunnett’s posttest for
One-way ANOVA and the Bonferroni posttest for two-way ANOVA. Asterisks
(*) represent a statistical difference (p < 0.05) between vehicle-treated and
hepatotoxicant-treated or BDL group.
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Figure 3.6
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Figure 3.6 Plasma ALT activity and quantitative RT-PCR analysis of liver
Fmo3 transcripts following a single dose APAP treatment in wild-type and
Nrf2-knockout mice. Plasma and livers were collected from mice 72 h
following APAP (400 mg/kg) or vehicle treatment. (A) The data are presented
as mean plasma ALT (IU/L) ± SE. (B) RNA was isolated from livers and
cDNA samples were analyzed by quantitative RT-PCR using Fmo3 mousespecific primers. Gene expression was normalized to the housekeeping gene
β-actin. Fmo3 mRNA expression are presented as mean Fold Change ± SE.
One-way ANOVA was performed followed by the Dunnett’s post-test.
Asterisks (*) represent a statistical difference (p < 0.05) between vehicletreated group and APAP-treated group and pound (#) represent a statistical
difference (p<0.05) compared with APAP-treated wild-type mice.
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Figure 3.7
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Figure 3.7 Analysis of liver Fmo3 protein expression following a single dose
APAP treatment in wild-type and Nrf2-knockout mice by western blotting and
enzyme activity assay. After overnight fasting, groups of wild-type and Nrf2
knockout mice received a single dose of 400 mg/kg APAP or vehicle. Livers
were collected 72 h following APAP or vehicle treatments. Western blots for
Fmo3 was performed using liver microsomes from control and APAP-treated
mice. Equal protein loading (10 μg protein/lane) was confirmed by detection
of β-actin. Microsomal proteins isolated from naïve female mouse liver were
used as a positive control indicated by “+” sign. The data are presented as
blots and as mean Fmo3 protein expression (Fold Change) ± SE (A). FMO
activity was measured in liver microsomes from control and APAP-treated
mice using methimazole as substrate. Data are presented as mean Specific
Activity (μM/min/mg) ± SE (B). Asterisks (*) represent a statistical difference
(p<0.05) between vehicle-treated group and APAP-treated group and pound
(#) represent a statistical difference (p<0.05) compared with APAP-treated
wild-type mice.
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3.5 Discussion
FMO3 is a microsomal enzyme involved in the oxygenation of lipophilic
substrates to more polar metabolites. Substrates include nitrogen-, sulfur- and
phosphorous-containing drugs and xenobiotics, and most metabolic products
of Fmo3 are considered to be non-toxic (Krueger & Williams, 2005). Although
FMOs were discovered in the 1960s (Miller et al., 1960) and further purified in
1972 (Ziegler & Mitchell, 1972), it was not until 2008 that enzyme induction by
xenobiotics was demonstrated (Celius et al., 2008; Celius et al., 2010). In
these studies, in spite of a very large increase in Fmo3 mRNA level by AhR
agonist treatment, only a modest increase in protein level and function was
reported. A gene array analysis performed in our laboratory also
demonstrated Fmo3 gene induction in the mouse model of APAP
autoprotection (O'Connor et al., 2014). In this APAP autoprotection mouse
model, we show a significant increase in Fmo3 protein expression and
function (Rudraiah et al., 2014). Constitutive Fmo3 expression in a female
mouse liver is localized in the areas surrounding the periportal region
(Janmohamed et al., 2004; Rudraiah et al., 2014). Following APAP exposure,
the Fmo3 protein expression in APAP autoprotected livers is observed in the
centrilobular regions where APAP-induced damage and/or hepatocellular
compensatory proliferation is detected. Furthermore, we show that the
enhanced expression of Fmo3 confers resistance against APAP-induced
hepatotoxicity in mice (Rudraiah et al., 2014).
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In the present study, the effect of various other hepatotoxicants on
Fmo3 gene expression in male C57BL/6J mouse liver was examined. A
unifying theme for all hepatotoxicants used in our study is the oxidative
stress. These models of oxidative stress used are very well studied with
respect to activation of Nrf2-Keap1 regulatory pathway. This has been
repeatedly demonstrated in our laboratory and in the literature (Aleksunes et
al., 2005; Aleksunes et al., 2006; Aleksunes et al., 2006; Bauer et al., 2000;
Chiu et al., 2002; Goldring et al., 2004; Liu et al., 2013; Randle et al., 2008;
Tanaka et al., 2009). Thus, we were confident that the treatments selected
result in oxidative stress and therefore the need for measuring markers of
oxidative stress for each experimental group of hepatotoxicity was not
deemed necessary.
Coincidentally, all of the hepatotoxicants selected produce cholestasis,
with the exception of AlOH (Donepudi et al., 2012; Tanaka et al., 2009;
Weerachayaphorn et al., 2012; Yamazaki et al., 2013). Furthermore,
perturbation of bile acid homeostasis has been demonstrated to be an early
event in the pathogenesis of drug induced liver injury (Yamazaki et al., 2013).
To determine whether accumulation of bile acids is a signaling event
regulating Fmo3, we measured total hepatic and plasma bile acid levels.
Consistent with the literature, ANIT and BDL increased plasma and hepatic
bile acid concentrations. A high CCl4 dose did not significantly alter liver bile
acid levels, but significantly increased plasma bile acid concentration. APAP
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tended to increase both hepatic and plasma bile acid concentrations, but this
is not statistically significant.
In general, ANIT and BDL-mediated damage significantly increased
liver Fmo3 mRNA expression. While CCl4-mediated liver injury significantly
decreased Fmo3 mRNA expression, no change in expression is evidenced
with AlOH. Fmo3 mRNA expression in response to ANIT treatment precedes
serum and hepatic bile acid accumulation and the maximal Fmo3 expression
(both mRNA and protein) parallels the mild hepatocellular damage observed.
This observation argues against the concept that hepatic bile acid
accumulation is a pre-requisite for Fmo3 gene expression changes in the
ANIT model. With BDL, unlike ANIT, Fmo3 mRNA induction is associated
with higher serum and hepatic bile acid levels, but protein level does not
change. Since tissues were analyzed 10 days after BDL, we do not have a
sense of what the temporal relationship is between hepatic bile acid
accumulation and elevated Fmo3 mRNA induction. This relationship deserves
further attention based on the discussion of FXR signaling that can be found
below.
Overt ANIT-induced hepatocellular damage at 24 and 48 h decreased
Fmo3 gene expression and the decease is statistically significant at 48 h
compared to the 12 h ANIT-treated group. This observation with respect to
the relationship between plasma ALT level and Fmo3 gene expression is
consistent with our results with APAP hepatotoxicity. We have demonstrated
in our APAP autoprotection mouse model that the APAP (400 mg/kg)
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pretreated group as well as the autoprotected group (APAP pretreatment: 400
mg/kg, APAP challenge: 600 mg/kg) exhibit average plasma ALT values of
about 250 IU/L and Fmo3 protein induction. The group that receives a toxic
APAP dose of 600 mg/kg exhibits much greater average plasma ALT activity
of about 1600 IU/L, but no Fmo3 gene induction (Rudraiah et al., 2014).
One key feature that is consistent with APAP-, BDL- and ANIT-induced
liver injury and enhanced Fmo3 gene expression is the magnitude in plasma
ALT elevations. Mild ALT elevation is the common feature for all three models
where Fmo3 mRNA induction is observed. Although BDL is a chronic injury
model, it is well known that the ALT values do not correlate well with the
severity of liver damage particularly during fibrotic hepatocellular necrosis
(Kallai et al., 1964). A similar clinical feature is also seen in cases of primary
biliary cirrhosis (BDL models primary biliary cirrhosis in humans) (Hohenester
et al., 2009). The lack of Fmo3 protein detection during BDL may be due to
signal dilution by fibrotic liver tissue. It is also possible that under oxidative
stress conditions some proteins involved in translation are oxidized in vivo
inhibiting translation (Shenton et al., 2006). To add to this complexity, in spite
of lower plasma ALT activity at 24 h (low dose CCl4), and 48 h (both high and
low dose CCl4) with CCl4, there is down-regulation of Fmo3 gene expression.
In AlOH-treated livers, lower plasma ALT activity did not show any change in
Fmo3 gene expression. This is suggestive of an unknown underlying
mechanism unique to APAP, ANIT, and BDL, which is contributing to Fmo3
mRNA induction. Studies are necessary to investigate the regional distribution
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of Fmo3 protein expression during ANIT- and BDL-induced liver injury to
determine whether the protein expression in these models is localized to the
portal vein, where ANIT- and BDL-induced hepatotoxicity is confined.
Collectively, these data suggest that there is a threshold for degree of hepatic
injury that results in increased Fmo3 mRNA and protein expression. More
specifically, these data suggest that acute moderate or mild hepatotoxicity is
optional for Fmo3 induction, while chronic, severe hepatotoxicity is not.
As discussed before, all models of hepatic injury used in the current
study result in hepatic oxidative stress and activate the Nrf2-Keap1 regulatory
pathway. Importantly, CRE analysis of differentially expressed genes in our
APAP autoprotection study supported an induction of the Nrf2 pathway
(O'Connor et al., 2014). Additionally, Celius et al. showed that the 5'-flanking
region of the mouse Fmo3 contains multiple copies of the ARE (Celius et al.,
2008). Promoter analysis of mouse Fmo3 promoter (7 kb length) using
MatInspector software (Genomatix, Munich, Germany), also showed an ARE
at about 3 kb from the transcription start site (data not shown). We also found
two other binding sites for Bach1, at 600 bp and 2 kb from the Fmo3
transcription start site (data not shown). Bach1 is a regulatory mediator of
Nrf2, in that it is a transcription repressor. Bach1 heterodimerizes with small
Maf proteins in the absence of cellular stress and represses gene expression.
In the presence of oxidative stress, Bach1 is released from the Maf proteins
and is replaced by Nrf2 (Kaspar et al., 2009). Thus, using APAP as a model
toxicant for Nrf2 activation, Fmo3 gene expression was evaluated in Nrf2 KO
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mice. Compared to APAP-treated wild-type mice, Nrf2 KO mice exhibit
persistent and significant hepatocellular damage 72 h after APAP
administration. Nrf2 KO mice are not only more susceptible to APAP-induced
hepatocellular necrosis, but also fail to recover from injury as rapidly as the
WT mice. This is consistent with the literature that describes Nrf2 as a master
regulator

of

many

cytoprotective

genes

involved

in

APAP-induced

hepatotoxicity (Aleksunes et al., 2005; Aleksunes et al., 2006; Bauer et al.,
2000; Chiu et al., 2002; Goldring et al., 2004). Finally, Fmo3 gene induction
by APAP treatment in Nrf2 null mice suggests that the transcriptional
regulation of Fmo3 does not involve this transcription factor. The persistent
mild hepatocellular injury and oxidative stress in Nrf2 KO mice most likely
activates other signaling mechanisms involved in Fmo3 gene induction.
Future studies will investigate the role of other nuclear receptors in
Fmo3 gene induction. Particularly, farnesoid X receptor (FXR) role in Fmo3
gene induction during APAP hepatotoxicity is worth investigating. FXR is one
of the major bile acid sensors in the liver (Chiang, 2002) and plays a
protective role during cholestasis development. Recently, it is shown that
activation of FXR induces Fmo3 protein function (Bennett et al., 2013).
Activation

of

FXR

also

provides

protection

against

APAP-induced

hepatotoxicity (Lee et al., 2010). In addition, we discovered three binding sites
for farnesoid X receptor-response element (FXRE) at about 1.6, 2.1 and 3.3
kb from the transcription start site on the mouse Fmo3 promoter (data not
shown). Although, Pregnane X receptor (PXR) is also a bile acid sensor, no

	
  

143	
  

binding sites for PXR were found on promoter analysis and furthermore, PXR
activation sensitizes APAP-induced hepatotoxicity (Cheng et al., 2009; Guo et
al., 2004).
In conclusion, this study comprehensively characterizes for the first
time temporal changes in Fmo3 gene expression during different conditions
known to impart hepatic oxidative stress. In particular, we show that toxic
ANIT and BDL significantly alter Fmo3 mRNA expression, but only Fmo3
protein with ANIT. The reason for this discrepancy is not yet clear or easy to
rationalize. It is possible that Fmo3 is also protective during other chemicalinduced liver injury including ANIT. Even though the exact mechanism of
Fmo3 gene expression or its role in protecting against toxicant-induced liver
injury is not yet clear, the observed toxicity threshold for Fmo3 gene
expression is intriguing. This work advances the lack of knowledge with
regard to the inducibility of Fmo3 and its potential protective role in druginduced liver injury.
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CHAPTER 4
Establishment and Characterization of HepaRG Cell Line OverExpressing Human Flavin-containing Monooxygenase-3 (FMO3)

4.1 Abstract
Flavin-containing monooxygenase (FMO) is a drug metabolizing
enzyme system similar to cytochrome P450 (CYP). FMO and CYP exhibit
similar cellular localization and substrate specificity, but a different catalytic
cycle. FMOs were considered to be non-inducible by xenobiotics, but recently
we demonstrated liver Fmo3 gene induction and protein expression during
APAP hepatotoxicity. The role of FMO3 in APAP-induced hepatotoxicity is not
known. The goal of the present study was to investigate FMO3 gene
expression, and its role in APAP-induced cytotoxicity in vitro using HepaRG
cells. HepaRG cells have been recently used as a human in vitro model for
studying mechanisms of APAP hepatotoxicity. In this study, exposure of
HepaRG cells to APAP resulted in a significant increase in FMO3 gene
expression as we see in vivo. To determine the functional significance of
FMO3 induction during APAP toxicity, we developed a HepaRG cell line overexpressing human FMO3 (hFMO3-HepaRG). Clonal selection from a
heterogeneous population of hFMO3-HepaRG cells resulted in two
homogenous cell lines. Expression of FMO3 in these clones was confirmed
by qRT-PCR, western blotting and by a catalytic activity assay. Notably, the
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hFMO3-HepaRG clones had a faster rate of differentiation that was
dependent on the expression level of FMO3 compared to EV controls.
Consistent with a faster rate of differentiation in these clones, rifampicininduced CYP3A4 expression was also greater. In agreement with our
postulated role for FMO3 as genetic determinant of APAP toxicity, the low
hFMO3-HepaRG clone exhibits greater tolerance to APAP-induced (1, 5, 10
and 15 mM) cytotoxicity. In the high hFMO3-HepaRG clone, LDH leakage is
significantly lower only at 1 and 5 mM APAP, while at a higher APAP
concentrations, LDH leakage is significantly greater than in empty vector
controls. Taken together, our results suggest that changes in FMO3 gene
expression not only alter HepaRG cell phenotype, evidenced by an
expression level-dependent greater rate of cell differentiation, but also alter
susceptibility to APAP-induced cytotoxicity.
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4.2 Introduction
Acetaminophen is one of the most commonly used over-the-counter
analgesic and antipyretic agent in the U.S. and Great Britain. It was first
described more than a century ago. However, APAP-poisoning and APAPhepatotoxicity was first recognized in 1960s in Great Britain (Davidson &
Eastham, 1966) and later in the U.S. (McJunkin et al., 1976). APAP usage
increased after aspirin was implicated in over 80 % of Reye’s syndrome
cases in children. As APAP usage increased, the incidence of APAP-induced
hepatotoxicity also increased. In a retrospective study from 1994 to 1996,
APAP-induced hepatotoxicity comprised 20 % of all cases of acute liver
failure (ALF) in the U.S. (Schiodt et al., 1999). These numbers increased over
time and by the early 2000s, nearly 50 % of all ALF cases were due to APAP
use and misuse. APAP toxicity is still a very prominent cause of liver toxicity,
accounting for more that 50 % of all ALF from all etiologies (Larson et al.,
2005; Lee, 2010). The potential for drug-related morbidity and mortality, and
the popularity of this drug, make it a significant human health problem.
Until

recently,

the

consensus

was

that

Flavin-containing

monooxygesnases (FMOs) were not inducible (Cashman & Zhang, 2002;
Krueger & Williams, 2005). However, recently Celius et al. show that
activation

of

the

Aryl

hydrocarbon

(Ah)

receptor

by

2,3,7,8-

tetrachlorodibenzo-p-dioxin (TCDD) induces Fmo3 mRNA in mice, with
marginal changes detected in protein levels (Celius et al., 2008; Celius et al.,
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2010). Previous work in our laboratory has also documented induction of
Fmo3 gene expression in an APAP autoprotection mouse model (mice
pretreated with APAP acquires resistance to APAP re-exposure) (O'Connor et
al., 2014; Rudraiah et al., 2014). Furthermore, we also demonstrated an
association between Fmo3 expression and protection against APAP-induced
hepatotoxicity (Rudraiah et al., 2014). More specifically, female mice express
much greater Fmo3 protein levels in liver compared to their male
counterparts. In fact, Fmo3 protein expression in normal male mouse liver is
undetectable by immunochemical techniques (Rudraiah et al., 2014).
Coincidentally, female mice are highly resistant to APAP hepatotoxicity (Dai
et al., 2006). Taking advantage of this sex-dependent difference in liver Fmo3
expression in C57BL/6J mice, we demonstrated that administration of the
FMO inhibitor methimazole (MMI) renders female mice susceptible to APAPinduced hepatotoxicity (Rudraiah et al., 2014). Results from FMO3-overexpressing human hepatocyte cell line (HC-04) also supports the conclusion
that Fmo3 is important for development of resistance to APAP-induced
hepatotoxicity.
The human liver, similar to our APAP autoprotection mouse model, can
adapt to APAP-induced hepatotoxicity (Shayiq et al., 1999; Watkins et al.,
2006). In these studies, individuals developed tolerance to hepatotoxicity
following repeated exposure to supratherapeutic doses of APAP. Although
the clinical data suggest that the human liver can adapt to APAP-induced
hepatotoxicity similar to that seen in our APAP autoprotection mouse model,
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the mechanism for this adaptation is not known. Unlike C57BL/6J mouse liver
where Fmo3 expression is negligible, FMO3 is the predominant FMO enzyme
in the adult human liver with levels comparable to CYP3A4 (Koukouritaki et
al., 2002). Furthermore, inducibility of FMO3 in the human liver has not been
reported.
The HepaRG cell line, derived from a hepatoma in a female patient, is
a recently developed in vitro system for studying hepatotoxicants. HepaRG
cells are bipotent progenitors, that differentiate into hepatocyte-like cells and
biliary epithelial-like cells (Cerec et al., 2007; Parent et al., 2004). HepaRG
expresses a more normal spectrum of drug metabolizing enzymes similar to
primary human hepatocytes and human liver tissues, unlike other hepatoma
cell lines such as HepG2 (Hart et al., 2010). HepG2 cells express very low
cytochrome P450 (CYP) levels compared to primary human hepatocytes or
human liver, particularly those involved in APAP metabolism. McGill et al.
have demonstrated that many of the mechanistic features of APAP-induced
hepatotoxicity in mouse hepatocytes and HepaRG cells are very similar. In
addition, APAP-induced cytotoxicity as well as key mechanistic events
occurring in HepaRG cells are consistent to that seen in mouse hepatocytes
(McGill et al., 2011). Thus, the goal of the current study was to investigate
FMO3 gene expression in HepaRG cells and to determine the functional
significance of FMO3 over-expression during APAP-induced cytotoxicity.
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4.3 Materials and Methods
Chemicals
All chemicals were obtained from Sigma-Aldrich (St Louis, MO) and
were of reagent grade or better.
Cell Culture and Treatment
HepaRG cells, growth supplement and differentiation medium
supplement were obtained from Biopredic International (Saint-Gregoire,
France). Cells were maintained in Williams E medium supplemented with 1X
glutamax, 0.05 mM riboflavin, growth or differentiation supplement and 1 %
antibiotic-antimycotic (100 units/mL penicillin G sodium, 100 µg/mL
streptomycin sulfate, and 0.25 µg/mL amphotericin B) in a 5 % CO2 and
humidified environment (95 % relative humidity) at 37°C. HepaRG cell line
differentiation was performed according to manufacturer’s protocol and is
presented as a flowchart in Figure 4.1. Briefly, HepaRG cells were grown at
high density in growth medium for 14 d. Cell differentiation was induced by
maintaining cells in the differentiation medium for an additional 14 to 21 d.
The medium was renewed every 3 d. The cells were maintained for up to four
weeks after differentiation for use.
For all treatments, HepaRG cells were seeded at 4x105 cells/well in a
24-well plate. For rifampicin treatment, cells were cultured in induction
medium (Biopredic International) containing 10 µM rifampicin (diluted from
1000X rifampicin stock in DMSO) for 24 h. Cells were harvested in TRIzol
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reagent for RNA isolation. For APAP treatment, culture media was replaced
with tox medium (Biopredic International, Saint-Gregoire, France) containing
APAP (concentrations ranging from 1 mM to 15 mM). Cells were harvested
for measuring LDH leakage, RNA- or microsomal-protein isolation 24 h later.
For MMI treatment, cells were incubated in tox medium containing 1 mM MMI
for 30 min at 37 °C. Following incubation with MMI, culture medium containing
5 mM APAP was added to wells. Cytotoxicity was measured using the LDH
assay kit, 24 h later. All experiments were performed in triplicates and
repeated at least three times.
Preparation of Microsomal Fractions for Western Blot Analysis
Microsomes were isolated from cells as described previously
(Rudraiah et al., 2014). Protein concentration was determined by the method
of Lowry using Bio-Rad protein assay reagents (Bio-Rad Laboratories,
Hercules, CA). Microsomal proteins (10 μg) were electrophoretically resolved
using 10 % polyacrylamide gels and transferred onto PVDF-Plus membrane
(Micron Separations, Westboro, MA). A rabbit anti-human FMO3 primary
antibody (BD Gentest, NJ) at a 1:500 dilution was used to detect FMO3, with
β-Actin as loading control. Blots were then incubated with horseradish
peroxidase (HRP) conjugated secondary antibodies against rabbit IgG
(Sigma-Aldrich, St Louis, MO). Protein-antibody complexes were detected
using a chemiluminescent kit (Thermo Scientific, IL) with visualization using
GeneMate blue autoradiography film (Bioexpress, Kaysville, UT).
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RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRTPCR)
TRIzol reagent (Life Technologies, Carlsbad, CA) was used to extract
total RNA from cells and cDNA was made using the M-MLV RT kit
(Invitrogen, Carlsbad, CA). mRNA expression was quantified by the ΔΔCT
method and normalized to the housekeeping gene, β-actin. Primer pairs were
synthesized by Integrated DNA Technologies (Coralville, IA), and the primer
sequences are presented in Table 1. Amplification was performed using an
Applied Biosystems 7500 Fast Real-Time PCR System. Amplification was
carried out in a 20 μL reaction volume containing 8 μL of diluted cDNA, Fast
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and 1
μM of each primer.
Lentiviral Vector Construction, Transduction and Clonal Selection
The FMO3-T2A-luc lentiviral transfer vector was constructed as
described previously (Rudraiah et al., 2014). The replication-defective virus
was generated in HEK 293T cells and concentrated as previously described
(Rudraiah et al., 2014). HepaRG cells were seeded to confluency prior to
transduction in HepaRG growth medium in a 24 well plate. The cells were
then infected with a series of volumes of untitered concentrate (40 μL, 20 μL,
and 10 μL per well) for three days. Prior to, during, and after viral
transduction, cells were maintained in HepaRG growth medium containing
0.05 mM riboflavin. Media was changed every 3 days. Clonal selection from
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heterogeneous hFMO3-HepaRG cells was performed by the method of
dilution. Differentiation of selected clones was performed according to
manufacturer’s protocol described previously in this section.
Enzyme Assay
FMO3 enzyme activity assay was performed using methimazole (MMI)
as substrate as described previously (Rudraiah et al., 2014). Briefly, MMI
metabolism was determined spectrophotometrically by measuring the rate of
MMI S-oxygenation via the reaction of the oxidized product with nitro-5thiobenzoate (TNB) to generate 5,5’-dithiobis(2-nitrobenzoate) (DTNB). The
incubation mixture consisted of NADPH generating system and 100 to 150
μg/mL microsomal protein in sodium phosphate buffer (pH 9.0). Reactions
were initiated by the addition of different amounts of MMI. The range of MMI
concentrations were between 1.25 and 800 μM. Specific activity (µM/min/mg)
was determined using the molar extinction coefficient of NADPH (28.2 mM1

cm-1).

LDH Leakage
Percent lactate dehydrogenase (LDH) leakage was determined via the
Tox-7 kit (Sigma-Aldrich, St. Louis, MO) as a measure of cytotoxicity following
APAP treatment. The assay was performed according to manufacturer’s
instructions.
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FMO3 Knockdown by shRNA
FMO3 short hairpin RNA (FMO3 shRNA) (sc-72256-SH) and
scrambled shRNA (sc-108060) plasmids were obtained from Santa Cruz
Biotechnology. Differentiated EV-HepaRG and hFMO3-HepaRG clones were
plated at 40 to 80 % confluency 24 h prior to tansfection. FMO3 shRNA and
scrambled shRNA plasmid transfection was performed using TransIT-TKO®
Transfection Reagent (Mirus, Madison, WI) according to manufacturer’s
instructions. Following transfection, cells were harvested at 72 h to isolate
RNA and protein. Stable shRNA knockdown of FMO3 was verified by qRTPCR and western blot analysis for FMO3 mRNA and protein expression,
respectively. All experiments were performed in triplicates and repeated at
least three times. Representative results are reported.
Statistical Analysis
Results are expressed as mean ± standard error (SE). Data were
analyzed using the Student’s t-test or ANOVA followed by a post-hoc test.
While Student’s t-test was used to compare means of two different treatment
groups, ANOVA was used to compare the means of more than two means of
different treatment groups that are normally distributed with a common
variance. All statistical analysis was performed using GraphPad Prism version
4.00 for Macintosh (GraphPad Software, Inc., San Diego, CA). Differences
were considered significant at p<0.05.
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Table 4.1. Primer Sequences for Quantitative RT-PCR
Gene

Primer Sequences

ABCC2

Forward: 5'- TGG TTA TGG AGG CTG CAT CT -3'

(MRP2)

Reverse: 5'- CAT ACA GGC CCT GAA GAG GA -3'

ABCC3

Forward: 5'- GAC CCA CAG GTA GAT GCA GG -3'

(MRP3)

Reverse: 5'- AGC TCG GCT CCA AGT TCT G -3'

ABCC4

Forward: 5'- CCT TGC AAC TCC TCT CCA AG -3'

(MRP4)

Reverse: 5'- ATC TGC TCA CGC GTG TTC TT -3'
Forward: 5'- CTT CGT AAA CCA GTG GCA GG -3'

CYP1A2
Reverse: 5'- AGG GCT TGT TAA TGG CAG TG -3'
CYP2E1

Forward: 5'- GAC CAC CAG CAC AAC TCT GA -3'
Reverse: 5'- CCC AAT CAC CCT GTC AAT TT -3'
Forward: 5'- TTT TGT CCT ACC ATA AGG GCT TT -3'

CYP3A4
Reverse: 5'- CAC AGG CTG TTG ACC ATC AT -3'
Forward: 5'- TTG TAA ATG CTA GCC CTG CC -3'
FMO3
Reverse: 5'- CTG TCT GGA AGA GGG GCT G -3'
Forward: 5'- CAA GGA CGT TCT CAA GTG GG -3'
GCLC
Reverse: 5'- CTT TCT CCC CAG ACA GGA CC -3'
Forward: 5'- CTG AAG GAC TTC ATC TCC CG -3'
GSTM1
Reverse: 5'- CCC AGA CAG CCA TCT TTG AG -3'
Forward: 5'- GTT GGT GGA ATC AAC TGC CT -3'
UGT1A1
Reverse: 5'- TTG ATC CCA AAG AGA AAA CCA -3'
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4.4 Results
CYP3A4 Transcript Constitutive and Inducible Expression Profiles in HepaRG
Cells
To examine the constitutive and inducible CYP3A4 mRNA expression
in HepaRG cells, undifferentiated (early and late) and differentiated, HepaRG
cells were treated with 10 µM rifampicin or vehicle for 24 h. CYP3A4 mRNA
levels were quantified by qRT-PCR. The results in Figure 4.2 show that
CYP3A4 mRNA levels with vehicle treatment increased by 2.8±0.5-and
6.3±0.8-fold, in late-undifferentiated and differentiated HepaRG cells,
respectively, compared to the early-undifferentiated HepaRG cells. Following
treatment with rifampicin, CYP3A4 mRNA expression increased by 12.5±1.1-,
56.6±2.3-, and 172.4±8.9-fold in early-undifferentiated, late-undifferentiated
and differentiated HepaRG cells, respectively, in comparison with vehicle
treated early-undifferentiated HepaRG cells.
FMO3 Gene Expression Following APAP Treatment in HepaRG Cells
To evaluate the FMO3 gene expression after APAP treatment in
HepaRG cells, differentiated HepaRG cells were treated with 1, 2.5 or 5 mM
APAP or vehicle for 24, 48 and 72 h. APAP-induced cytotoxicity was
measured by measuring percent LDH leakage into the culture media. The
results are shown in Figure 4.3A. The percent LDH leakage into the medium
did not change significantly with 1 mM APAP treatment at 24, 48 or 72 h.
While percent LDH release with 2.5 mM APAP increased significantly at 24
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and 48 h by 7.5±0.2 and 8.7±0.1 %, respectively, the values are not
statistically significant at 72 h compared to respective control treatment. At all
time-points tested (24, 48 and 72 h), 5 mM APAP treatment significantly
increased the amount of LDH release in HepaRG cells to 8.5±0.3, 14.6±0.2,
and 20.7±0.7 %, respectively. Then, the temporal FMO3 transcript expression
after APAP treatment was evaluated. FMO3 mRNA expression in HepaRG
cells exposed to APAP is presented in Figure 4.3B. FMO3 mRNA levels
increased significantly by 2±0.35-, 2.1±0.3-, and 2±0.34- fold change in
response to 1, 2.5 and 5 mM APAP, respectively, at 24 h. While FMO3 mRNA
transcript levels peaked with 1 mM APAP treatment at 48 h by 3±0.4-fold
change, the levels are not statistically significant at 72 h. No change is FMO3
mRNA expression is seen with all three doses at 72 h. To investigate if the
increase in FMO3 transcripts translates into protein, we performed western
blotting. Representative blots and densitometric analysis of blots are shown in
Figure 4.3C. FMO3 protein is abundantly expressed in HepaRG cells (vehicle
controls). Following treatment with 5 mM APAP, FMO3 protein levels
increased significantly by 1.5±0.05- and 1.4±0.1-fold change at 24 and 48 h,
respectively, compared to vehicle control. FMO3 protein levels decreased
significantly at 72 h with 1, 2.5 and 5 mM APAP treatment compared to
vehicle control. These data demonstrate that a single dose APAP treatment
results in a significant increase in FMO3 protein levels in the human
hepatoma cell line, HepaRG cells.
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Establishment of Human Hepatoma Cell Line (HepaRG) Over-expressing
Human FMO3 (hFMO3-HepaRG)
We developed a HepaRG cell line over-expressing human FMO3 to
evaluate the functional significance of FMO3 over-expression during APAPinduced cytotoxicity. The FMO3 expression vector we used previously
(Rudraiah et al., 2014) to over-express FMO3 in the human hepatocyte cell
line (HC-04) was used again to over-express FMO3 in HepaRG cells. The
expression vector is a bicistronic vector driven by the ubiquitin-C promoter,
which allowed co-expression of the FMO3 and luciferase (LUC) genes in
transduced HepaRG cells. Twelve clones were picked from a heterogenous
population of hFMO3-HepaRG cells. Out of twelve clones selected, two
clones were maintained for further studies. The clones expressed a 152±13and 1031±12.6-fold change in luciferase activity, compared to the empty
vector control (EV-HepaRG) (Figure 4.4A). For convenience, these two
hFMO3-HepaRG clones are termed the Low-hFMO3-HepaRG and HighhFMO3-HepaRG cell line, respectively. FMO3 mRNA expression is shown in
Figure 4.4B. FMO3 mRNA levels increased by 6.5±0.8- and 25±0.9-fold
change in Low- and High-hFMO3-HepaRG cell line, respectively, compared
with EV control. FMO3 protein expression was confirmed by performing
western blotting and from FMO3 enzyme activity assay using microsomal
fractions isolated from EV and both FMO3-over-expressing HepaRG clones.
Representative blots, densitometric analysis of western blot and the specific
activity of over-expressed FMO3 protein are shown in Figure 4.4C, 4.4D and
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4.4E, respectively. Fmo3 protein levels increased by 3.2±0.1- and 5±0.04-fold
in Low-, and High-FMO3 expressing HepaRG cells, respectively. Consistent
with western blotting results, the specific activity of over-expressed FMO3
protein also increased to 98±1.5, and 150±8.7 μM/min/mg in Low-, and HighFMO3 expressing HepaRG cells, respectively, compared to EV-HepaRG
control (64.4±5.2 μM/min/mg).
Phenotypic Characteristics of hFMO3-HepaRG Cells in Culture
Representative phase-contrast micrographs of hFMO3-HepaRG Cells
in culture are shown in Figure 4.5. hFMO3-HepaRG cells exhibit a strikingly
faster rate of differentiation (formation of colonies of granular epithelial cells)
compared to empty vector control cells. This is evident by the appearance of
colonies of granular epithelial cells in the High-hFMO3-HepaRG clone as
early as 14 d while cells are still in growth medium. (Figure 4.5C). Empty
vector and Low-hFMO3-HepaRG also differentiate but at slower rates. At all
stages of differentiation, there is a consistent, expression level-dependent
increase in rate of differentiation of hFMO3-HepaRG cells.
Transcript Expression of Transporters, Bioactivation- and DetoxificationEnzymes for APAP in hFMO3-HepaRG Cells
Untreated hFMO3-HepaRG cell lines were characterized with respect
to the expression of genes critical in APAP bioactivation, transporters and
detoxification pathways by qRT-PCR. Results are shown in Figure 4.6. No
significant change in CYP1A2 expression is seen in both hFMO3-HepaRG
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cell lines compared to EV controls. However, CYP2E1 mRNA levels
increased by 5.3±0.1- and 14.2±0.2-fold change in Low- and High-hFMO3HepaRG cell line, respectively. Among all bioactivation gene expression
tested, the increase in CYP3A4 mRNA is highest by a fold change of 11±0.4
and 53±2.2 in Low- and High-hFMO3-HepaRG cell line, respectively,
compared to EV control. The expression of phase II enzyme, UDP
glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) also increased
significantly by 2.7±0.3-fold change in High-FMO3 expressing clone while no
change in expression was evidenced in the Low-FMO3 expressing clone.
The expression of Glutamate-cysteine ligase (GCLC) and glutathione Stransferase µ1 (GSTM1) showed a decreasing trend in both clones. This
decrease is statistically significant only with GCLC in the High-FMO3
expressing HepaRG cells. While the expression of ATP-binding cassette,
sub-family

C/multidrug

resistance-associated

protein

(ABCC/MRP)

particularly MRP3 and MRP4 tended to decrease with increasing FMO3
expression, this was not statistically significant. MRP2 expression on the
other hand increased significantly in high-FMO3 expressing clone by
3.3±0.14-fold change compared to EV control.
CYP3A4 Transcript Constitutive and Inducible Expression Profiles in hFMO3HepaRG Cells
To determine the CYP3A4 transcript constitutive and inducible
expression in hFMO3-HepaRG cells, undifferentiated (early and late) and
differentiated hFMO3-HepaRG cells were treated with 10 µM rifampicin or
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vehicle for 24 h. CYP3A4 mRNA levels were quantified by qRT-PCR. mRNA
levels are presented as graphs (4.7A and 4.7B) and tabulated in Figure 4.7C.
The results in Figure 4.7A show CYP3A4 constitutive mRNA levels at
undifferentiated (early and late) and differentiated stages. CYP3A4 mRNA
expression is significantly higher in High-hFMO3-HepaRG cells at both lateundifferentiated and differentiated stages. Following treatment with rifampicin,
CYP3A4 mRNA expression further increases significantly by 140.7±22- and
884.9±48.1-fold change in late-undifferentiated and differentiated in HighhFMO3-HepaRG cells, respectively, compared to respective EV-HepaRG
controls (Figure 4.7B). These results are consistent with the faster rate of
differentiation phenotype observed in hFMO3-HepaRG cell lines. Collectively,
these data suggest that there is a correlation between FMO3 expression and
differentiation in HepaRG cells that over-express human FMO3 protein and
function.
Effect of FMO3 Over-expression on APAP-induced Cytotoxicity in HepaRG
Cells
The basal LDH leakage in vehicle treated High-hFMO3-HepaRG clone
is significantly lower (6 %) than the EV-HepaRG cells (15 %) (Figure 4.8A). In
Figure 4.8B, the basal LDH leakage in significantly lower in both the Low- and
the High-hFMO3-HepaRG clones (13 % and 6 %) compared to EV controls
(20 %). This suggests that FMO3 over-expression contributes to a
characteristic cellular ability to resist stress.
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To evaluate the functional significance of FMO3 over-expression
during APAP-induced cytotoxicity, EV-HepaRG and hFMO3-HepaRG cells
were treated with 1, 5, 10 and 15 mM APAP for 24 h. The percent LDH
leakage into the media in response to these four concentrations of APAP in
Low-FMO3 expressing HepaRG cells is significantly lower (13, 16, 23 and 24
%) compared to empty vector control (18, 22, 27 and 28 %). The percent LDH
leakage in High-FMO3 expressing cells following 1 and 5 mM APAP
treatment is significantly lower (8 and 11 %) than in EV cells, while higher
LDH values (33 %) are seen at 15 mM APAP than in EV cells treated with the
same concentration of APAP (Figure 4.8A). Taken together, these data
suggest that over-expression of FMO3 protects against APAP-induced
cytotoxicity in the Low-hFMO3-HepaRG clone. By contrast, High-hFMO3HepaRG cells are protected against lower APAP concentrations, but APAP
cytotoxicity is aggravated at higher APAP concentrations with high FMO3
expression.
The amount of LDH leakage (%) into the media does not change with
only MMI treatment, compared with vehicle treated EV- and hFMO3-HepaRG
cell lines. The percent LDH leakage in response to 5 mM APAP treatment
increased significantly to 25 % in EV-HepaRG cells compared with vehicle
treated EV-HepaRG cells (20 %). While no change in LDH leakage was
observed in Low-hFMO3-HepaRG cells in response to APAP, percent LDH
leakage increased in High-hFMO3-HepaRG cells to 11 % compared with
vehicle treated High-hFMO3-HepaRG cells (8 %). The percent LDH leakage
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in both Low- and High-hFMO3-HepaRG clones after APAP is significantly
lower compared to APAP treated EV controls (Figure 4.8B). Following
pretreatment with 1 mM MMI, APAP-induced cytotoxicity increased to 17 % in
Low-FMO3 expressing cells and to 16 % in High-FMO3 expressing clone
compared to only APAP-treated Low- and High-hFMO3-HepaRG clones. No
change in LDH leakage is observed in MMI pretreated, APAP-treated EV cells
compared with only APAP-treated EV cells. This data suggests that inhibition
of FMO3 activity by MMI in Low-, and High-FMO3 expressing clones resulted
in rescue of sensitivity to APAP only in Low-FMO3 expressing cell line
compared to EV controls.
Effect of Short Hairpin RNA Interference (FMO3-shRNA) on FMO3 mRNA
and Protein Expression in EV and FMO3 Over-expressing HepaRG Cell Lines
To knockdown FMO3 gene expression in EV, Low-, and High-FMO3
expressing HepaRG cells, differentiated clones were transfected with FMO3shRNA or scrambled-shRNA for 72 h. qRT-PCR and western blot analysis of
FMO3 was performed 72 h after transfection (Figure 4.9). FMO3 mRNA
expression decreased significantly to 0.25-, 0.5- and 0.67-fold change which
represents a 75, 46.2 and 33.7 % decrease, respectively, in EV-, Low- and
High-hFMO3-HepaRG cells, compared to their respective scrambled-shRNA
transfected cells (Figure 4.9A). Representative western blots are shown in
Figure 4.9B and densitometric analysis of western blot is shown in Figure
4.9C. FMO3 protein expression in EV-HepaRG cells following FMO3-shRNA
transfection decreased significantly to 0.18-fold change which represents a
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82.4 % decrease, compared to scrambled-shRNA. In Low- and High-hFMO3HepaRG clones, FMO3 protein expression also decreased significantly to
0.25- and 0.44-fold change, which represents a 74.8 and 56.3 % decrease,
respectively, compared to scrambled-shRNA transfected controls (Figure
4.9C). These data shows that the FMO3 knockdown using shRNA
interference in hFMO3-HepaRG and EV-HepaRG clones was successful.
Effect of FMO3 Knockdown on APAP-induced Cytotoxicity in hFMO3HepaRG Cells
To determine whether FMO3 knockdown in hFMO3-HepaRG cells
restores their susceptibility to APAP-induced cytotoxicity, FMO3-shRNA and
scrambled-shRNA transfected cells were treated with 5 mM APAP for 24 h. In
response to 5 mM APAP treatment, the percent LDH leakage into the medium
increased significantly to 33 % in EV-HepaRG cells compared with control
treated EV-HepaRG cells (26 %) (Figure 4.10). APAP treatment also
increased percent LDH leakage in Low- and High-hFMO3-HepaRG clones to
31 and 30 %, respectively, compared to vehicle treated controls (25 % in
Low- and 23 % in High-hFMO3-HepaRG cells). Even though the percent LDH
leakage increased in hFMO3-HepaRG clones, the values were significantly
lower only in the High-hFMO3 expressing clone compared with 5 mM APAP
treated EV-HepaRG cells. Although, the cytotoxicity trend in response to
APAP treatment is similar to that seen in Figure 4.8A, the overall percent LDH
leakage is higher due to sub-confluent number of differentiated cells used in
this study.
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Transfection of scrambled-shRNA or FMO3-shRNA further increased
the percent LDH leakage in all three EV- and hFMO3-HepaRG cell lines. No
significant change in LDH leakage in scrambled-shRNA transfected, APAP
treated cells is observed in comparison with scrambled-shRNA transfected
cells. Furthermore, percent LDH leakage in FMO3-shRNA transfected cells
exposed to APAP increased in Low- and High-hFMO3 HepaRG cells
compared to scrambled shRNA transfected APAP treated cells. Together
these data suggests that FMO3 knockdown in Low- and High-hFMO3HepaRG cells restores their susceptibility to APAP-induced cytotoxicity.
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Figure 4.1
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Figure

4.1

HepaRG

cell

line

differentiation

protocol

flowchart.

Undifferentiated HepaRG cells are maintained in growth medium from Day 0
(HepaRG Undifferentiated early) to Day 14 (HepaRG Undifferentiated late).
On Day 0, HepaRG cells appear elongated with clear cytoplasm. During
proliferation period cells appear as a homogenous cell population with an
epithelial phenotype showing no regular structural organization. When the
cells reach confluency, they undergo progressive morphological changes
acquiring a granular cytoplasm. From Day 15 to Day 23, cells are maintained
in differentiation medium diluted by half with growth medium. From day 24
onwards, cells are maintained in only differentiation medium. Between Day 28
and Day 35, cells appear differentiated into two subpopulations (HepaRG
Differentiated): hepatocyte-like cells and biliary epithelial-like cells.
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Figure 4.2
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Figure 4.2 Quantitative RT-PCR analysis of CYP3A4 transcripts following
Rifampicin treatment in undifferentiated (early and late) and differentiated
HepaRG cells. RNA was isolated from cells treated with rifampicin (10μM) or
vehicle for 24 h. mRNA expression was measured by qRT-PCR using human
primers specific for CYP3A4. Gene expression was normalized to the
housekeeping gene β-Actin. CYP3A4 mRNA expression is presented as
mean Fold Change ± SE. Two-way ANOVA was performed followed by the
Bonferroni’s post-test. Asterisks (*) represent a statistical difference (p < 0.05)
between control and rifampicin treatment.
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Figure 4.3
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Figure 4.3 Effect of APAP treatment on cytotoxicity and FMO3 gene
expression in HepaRG cells. Differentiated HepaRG cells were treated with 1,
2.5, and 5 mM APAP or control. At 24, 48, and 72h after treatment, percent
LDH leakage into the medium was measured using a commercial kit. The
data are presented as mean LDH leakage (%) ± SE (A). RNA was isolated
from cells at 24, 48 and 72 h after APAP treatment or vehicle. FMO3 mRNA
expression was measured by qRT-PCR using human-specific FMO3 primers.
Gene expression was normalized to the housekeeping gene β-Actin. FMO3
mRNA expression is shown as mean Fold Change ± SE (B). Western blot for
FMO3 was performed using 10 µg microsomal protein isolated from HepaRG
cells treated with APAP or vehicle. Rabbit anti-human FMO3 primary antibody
was used to detect FMO3 protein expression. Equal protein loading was
confirmed by detection of β-actin. The data are presented as blots as well as
mean FMO3 protein expression (Fold Change) ± SE. Two-way ANOVA was
performed followed by the Bonferroni’s post-test. Asterisks (*) represent a
statistical difference (p < 0.05) between control and APAP treatment.

	
  

171	
  

Figure 4.4
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Figure 4.4 Establishment of HepaRG cells over-expressing human FMO3
(hFMO3-HepaRG). Lentiviral vector construction and transduction are
described in Materials and Methods. Luciferase activity was measured to
determine the efficiency of transduction in hFMO3-HepaRG clones (A).
Luciferase activity is presented as mean luciferase activity/mg protein (Fold
Change) ± SE. FMO3 mRNA expression in EV and FMO3 over-expressing
HepaRG clones. The data are presented as mean Fold Change ± SE (B).
Western blot for FMO3 in EV and hFMO3-HepaRG clones. Rabbit anti-human
FMO3 primary antibody was used to detect FMO3 protein expression. The
data are presented as blots (C) as well as mean FMO3 protein expression
(Fold Change) ± SE (D). Microsomes isolated from EV and hFMO3 overexpressing clones were used to measure FMO3 activity using methimazole
as substrate. Data are presented as mean Specific Activity (μM/min/mg) ±
SE. One-way ANOVA was performed followed by the Dunnett’s post-test.
Asterisks (*) represent a statistical difference (p< 0.05) compared to EV
controls.
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Figure 4.5
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Figure 4.5 Phase-contrast micrographs of HepaRG cells over-expressing
human FMO3 (hFMO3-HepaRG). Empty vector and hFMO3 over-expressing
HepaRG clones were grown and differentiated as described in Materials and
Methods and Figure 1. Representative micrographs on Day 14 (A, B, C), Day
23 (D, E, F), Day 35 (G, H, I) and Day 45 (J, K, L) are shown. Scale bar: 400
µm.
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Figure 4.6
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Figure 4.6 Expression profiles of genes involved in acetaminophen
bioactivation, detoxification, and transport in HepaRG cells over-expressing
human FMO3 (hFMO3-HepaRG). RNA isolated from untreated empty vectorand hFMO3-HepaRG clones was reverse transcribed to cDNA. The cDNA
samples were analyzed by qRT-PCR using human-specific primers and the
gene expression was normalized to the housekeeping gene β-Actin. Gene
expression of acetaminophen bioactivating enzymes (CYP1A2, CYP2E1, and
CYP3A4), detoxifying enzyme (UGT1A1), glutathione homeostasis enzymes
(GCLC and GSTM1), and efflux transporters (MRP2, MRP3 and MRP4) were
analyzed. mRNA expression are presented as mean Fold Change ± SE. Oneway ANOVA was performed followed by the Dunnett’s post-test. Asterisks (*)
represent a statistical difference (p < 0.05) compared to EV controls.
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Figure 4.7
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Figure 4.7 Relative CYP3A4 mRNA expression following Rifampicin
treatment in empty vector and hFMO3-HepaRG clones. RNA was extracted
from cells following rifampicin (10 μM) treatment or control, and cDNA was
prepared using a commercial MMLV-RT kit. The cDNA samples were
analyzed for CYP3A4 mRNA levels by quantitative RT-PCR. CYP3A4 gene
expression was normalized to housekeeping gene β-Actin. mRNA expression
after control (A) and rifampicin (B) treatment are presented as mean Fold
Change ± SE. CYP3A4 mRNA expression profiles in hFMO3-HepaRG Cells
is shown in Table (C). Two-way ANOVA was performed followed by the
Bonferroni’s post-test. Asterisks (*) represent a statistical difference (p < 0.05)
from respective EV-HepaRG cells.
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Figure 4.8
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Figure 4.8 Significance of FMO3 over-expression During APAP-induced
cytotoxicity in HepaRG cells. Empty vector, Low-, and High-FMO3 expressing
clones were treated with APAP concentrations from 1 mM to 15 mM. Percent
LDH leakage into the medium was measured 24 h later, using a commercial
kit. The data are presented as mean LDH leakage (%) ± SE (A). Two-way
ANOVA was performed followed by the Bonferroni’s post-test. Asterisks (*)
represent a significant difference (p< 0.05) compared to respective vehicle
control group and pound (#) represent a significant change (p<0.05)
compared to respective EV controls. (B) To inhibit FMO3, EV, Low-, and
High-FMO3 expressing clones were incubated with MMI (1 mM) for 30 min
before APAP (15 mM) treatment. Percent LDH leakage into the medium was
measured 24 h after APAP treatment. The data are presented as mean LDH
leakage (%) ± SE. Asterisks (*) represent a significant difference (p< 0.05)
compared to the respective vehicle treated clone, and pound (#) represent a
significant difference (p<0.05) compared to respective 5 mM APAP treated
clone.
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Figure 4.9
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Figure 4.9 FMO3 mRNA and protein expression after short hairpin RNA
interference in EV and FMO3 over-expressing HepaRG clones. qRT-PCR
analysis of FMO3 transcripts 72 h after FMO3-shRNA or scrambled-shRNA
transfection in EV, Low-, and High-FMO3 expressing clones. The data are
presented as mean Fold Change ± SE (A). Western blots for FMO3 were
performed using microsomes isolated from scrambled- or FMO3-shRNA
transfected EV and FMO3 over-expressing HepaRG clones. Recombinant
human FMO3 protein was used as a positive control indicated by “+” sign.
The data are presented as blots (B) and as mean FMO3 protein expression
(Fold Change) ± SE (C). Two-way ANOVA was performed followed by the
Bonferroni’s post-test. Asterisks (*) represent a significant decrease
compared to scrambled-shRNA transfected control.
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Figure 4.10
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Figure 4.10 Effect of FMO3 knockdown on APAP-induced cytotoxicity in
FMO3 over-expressing HepaRG clones. Empty vector, Low-, and High-FMO3
expressing cell lines were transfected with scrambled- or FMO3-shRNA for 72
h. Cells were treated with 5 mM APAP for 24 h. Percent LDH leakage into the
medium was measured. The data are presented as mean LDH leakage (%) ±
SE. Two-way ANOVA was performed followed by the Bonferroni’s post-test.
Asterisks (*) represent a significant decrease (p< 0.05) compared to
respective EV-HepaRG cells and pound (#) represent a significant increase
compared to respective APAP treated scrambled sh-RNA transfected clone.
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4.5 Discussion
Primary human hepatocytes are the most pertinent model for studying
xenobiotic metabolism and toxicity, including APAP-induced hepatotoxicity.
However, they have major drawbacks in that the availability of these cells is
limited, isolation procedures are complicated, they are expensive and due to
inter-individual variability, the drug response can vary significantly from one
batch of hepatocytes to the next (Madan et al., 2003). The lifespan of primary
human hepatocytes is short and they undergo changes in CYP expression
levels (primarily loss) over time in culture. To overcome these limitations,
immortalized liver-derived cell lines were introduced as an alternative model
for studying in vitro metabolism and cytotoxicity (Gerets et al., 2012).
Because of their unlimited availability and phenotypic stability, hepatoma cell
lines like HepG2 cells have been used extensively in toxicity studies. They
express very low CYP levels compared to primary human hepatocytes or
human liver, especially those isoforms that are involved in the metabolism of
APAP (Rodriguez-Antona et al., 2002). Their low metabolic capacity makes
them useful for toxicity testing of parent molecules and less suitable for
metabolite toxicity testing. HepaRG, a human hepatoma cell line, is a recently
developed cellular model that expresses a more normal spectrum of drug
metabolizing

enzymes.

The

mechanistic

features

of

APAP-induced

hepatotoxicity in HepaRG cells are similar to that reported for mouse
hepatocytes and mouse liver in vivo (McGill et al., 2011). Recently we
demonstrated FMO3 gene induction in an acetaminophen resistance mouse
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model termed APAP autoprotection. Although the phenomenon of APAP
autoprotection is also seen in patients exposed to supratherapeutic doses of
APAP, the mechanism is not known. Thus, the goal of the present study was
to investigate FMO3 gene induction in HepaRG cells, an in vitro model of
human hepatocytes much closer to the in vivo situation, and to also determine
the functional significance of FMO3 over-expression during APAP-induced
cytotoxicity.
Primary human hepatocytes express high cytochrome P450 (CYP)
levels and exhibit higher responsiveness to CYP inducers, such as
phenobarbital, beta-naphthoflavone and rifampicin. Constitutive and inducible
CYP3A4 mRNA expression in HepaRG cells is widely used to assess
metabolic and/or differentiation status (Aninat et al., 2006; Gerets et al., 2012;
Hart et al., 2010). Thus, HepaRG cell’s responsiveness to rifampicin was
evaluated at different growth stages. At confluence, as well as, with addition
of differentiation medium, HepaRG cells differentiate into hepatocyte- and
biliary epithelial-like cells (Gripon et al., 2002; Hart et al., 2010). Consistent
with the literature, HepaRG cells in culture progressively differentiate which is
evident from their responsiveness to rifampicin on Day 14 and Day 35. Then,
differentiated HepaRG cells were exposed to APAP concentrations ranging
from 1 to 5 mM. While 1 mM APAP treatment did not significantly increase
LDH release from cells at any of the time-points tested, 2.5 mM APAP
increased LDH leakage at 24 and 48 h. By 72 h, no difference in LDH leakage
was detected compared to vehicle treated controls. This is suggestive of mild
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cellular injury caused by 2.5 mM APAP that resolves by 72 h. On the contrary,
the cellular injury by 5 mM APAP is progressive and does not resolve by 72 h.
FMO3 mRNA levels increase at 24 h with all three doses of APAP and at 48
h, the increase is statistically significant only with 1 mM APAP. Even though
mRNA increase is seen with 1 and 2.5 mM APAP, the FMO3 protein
expression does not change. On the contrary, 5 mM APAP results in
significant increase in FMO3 protein levels at 24 and 48 h, but the levels are
significantly lower at 72 h. This observation with respect to the relationship
between degree of toxicity and FMO3 gene expression, where FMO3 gene
expression decreases during overt toxicity and mild toxicity induces FMO3
gene expression, is consistent with our previous results in vivo with various
hepatoxicants in mice (Rudraiah et al., 2014; Rudraiah et al., 2014).
The decrease in FMO3 protein expression at 72 h may be due to
production

of

H2O2.

Even

though

FMOs

form

a

relatively

stable

hydroperoxyflavin intermediate and does not contribute to production of H2O2,
during absence of NADPH, peroxyflavin can decompose to hydrogen
peroxide resulting in significant loss of enzyme activity (Cashman, 1999).
Collectively, it is notable that FMO3 gene expression is inducible by APAPinduced cytotoxicity in HepaRG cells. Although the change in FMO3 protein
expression is only by a fold-change of 1.5, the constitutive FMO3 protein
expression in HepaRG cells is very high (comparable to CYP3A4 expression).
A fold-change of 1.5, can be very large and physiologically significant.
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To further investigate the importance of FMO3 over-expression during
APAP-induced cytotoxicity, we successfully established an over-expression
system. The FMO3 over-expressing HepaRG cell lines exhibit a striking
expression level-dependent faster rate of differentiation compared to empty
vector control cells. To examine any possible difference in gene expression
profiles that might contribute to APAP-induced cytotoxicity, genes involved in
acetaminophen-bioactivation, -detoxification, and efflux transporters were
screened. Interestingly, an FMO3 level-dependent increase in expression of
CYP2E1, CYP3A4, UGT1A1 and MRP2 genes and a decrease in GCLC, are
seen. Most striking are the gene expression changes for CYPs, particularly
CYP3A4. Cashman et al. reported a concomitant increase in FMO3, FMO4
and CYP2E1 functional activity in rats on total parenteral nutrition and choline
(Cashman et al., 2004), but a correlation or interdependence between the two
was not investigated. Currently there are no reports in the literature that show
a correlation with FMO3 gene expression and CYP activity. The mechanism
of such a regulation is also not known and warrants further investigation.
To examine whether the observed phenotype of faster differentiation in
hFMO3-HepaRG cells is consistent with its responsiveness to rifampicin
treatment, FMO3-over-expressing HepaRG cells were exposed to rifampicin
and CYP3A4 mRNA levels were quantified. Consistent with the observed
phenotype of greater differentiation state, CYP3A4 induction is significantly
higher in FMO3-over-expressing cell lines compared to empty vector control.
This

	
  

suggests

that

the

HepaRG

cells
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over-expressing

FMO3

are

differentiating at a faster rate compared to control cell line and that they
respond more robustly to enzyme induction treatment. The mechanism by
which FMO3 over-expression is driving cellular differentiation is not known.
Furthermore, the percent LDH leakage into the media in Low-hFMO3HepaRG cells in response to APAP treatment is significantly lower compared
to empty vector control. In High-hFMO3-HepaRG cells, the amount of LDH
leakage by APAP is significantly lower at lower APAP concentrations, but at
higher APAP concentrations, the LDH leakage is significantly greater. This
trend where low FMO3-over-expression being protective and high FMO3over-expression combined with toxic APAP dose being more toxic is also
seen with FMO3-over-expressing hepatocyte cell line (HC-04) (Rudraiah et
al., 2014). Taken together, these data suggest that over-expression of FMO3
significantly alters susceptibility to APAP-induced cytotoxicity. It should also
be noted that the High-hFMO3-HepaRG cells express significantly higher
CYPs that metabolize APAP. The toxicity noticed may be due to over
production of toxic metabolite NAPQI or due to production of H2O2. Examining
gene

expression

and

metabolite

profiles

using

transcriptomics

and

metabolomic approaches in these cell lines could help identify signaling
molecules and pathways involved in cellular differentiation driven by FMO3.
FMO3 inhibition by MMI has been demonstrated in our lab (Rudraiah
et al., 2014). Inhibition of FMO3 activity by MMI resulted in rescue of
sensitivity to APAP toxicity. However, since MMI is not a specific FMO3
inhibitor, we used RNA interference to knockdown over-expressed FMO3 in
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FMO3-over-expressing cell lines. Transfection of sh-FMO3 resulted in a
significant decrease in FMO3 protein expression in EV- and FMO3-overexpressing cell lines. These transfection experiments and APAP treatment
were performed in a 50 to 60 % cell confluent conditions but APAP dose
response in Figure 8 was performed at a high density (100 % confluent
conditions). Because of the lower confluency as well as toxicity resulting from
transfection procedure itself, cells exhibit higher basal LDH leakage into the
media compared to experiments performed using 100 % confluent conditions.
Although the knockdown of FMO3 in hFMO3-HepaRG cells did restore the
susceptibility to APAP-induced cytotoxicity exhibited by the EV cells with
normal FMO3 levels, the scrambled-RNA transfected cells exhibit higher
toxicity compared to only APAP treated EV- and hFMO3-HepaRG cell lines.
Finally, FMO3 knockdown in hFMO3-HepaRG cells were capable of
differentiating at a rate similar to non-knockdown hFMO3-HepaRG clones
(data not shown). Furthermore, western blotting of differentiated knockdownhFMO3-HepaRG cells, failed to show low FMO3 expression compared to
differentiated scrambled-shRNA transfected hFMO3-HepaRG cells (data not
shown). Although FMO3 knockdown was successful, the lack of a selection
marker in the sh-FMO3 plasmid prevented us to control the cells repopulating
the plate after knockdown. Development of a knockdown clone can address
this problem.
In summary, we show FMO3 gene induction by APAP-induced
cytotoxicity in HepaRG cells. This is the first report demonstrating xenobiotic
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mediated FMO3 gene induction in a human hepatoma cell line. Even though
the mechanism of induction or the role of FMO3 in APAP-induced
hepatotoxicity/cytotoxicity is not clearly known, there are two potential
hypotheses for its potential role during toxicant exposure. One involving a role
for cyteamine in maintaining the cellular thiol:disulphide potential in a cell
(Ziegler et al., 1979) and the other is the possible regulation of immune cells
by an FMO3 metabolite (Bennett et al., 2013; Z. Wang et al., 2011). Strikingly,
data presented in this manuscript demonstrates a third novel dimension to
FMO3 function during toxicant exposure. Our data shows that FMO3 may be
involved in driving cellular differentiation. Although this calls for further
investigation, the potential role of FMO3 in cellular proliferation and
differentiation is consistent with the considerable lag time in gene and protein
induction seen in our mouse model of APAP autoprotection (Rudraiah et al.,
2014), where protein peaks at 72 h after a single dose APAP treatment. This
time frame is consistent with stages of repair and regeneration with APAP
toxicity.
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CHAPTER 5
Human Hepatic Flavin-containing Monooxygenase-3 (FMO3) Gene
Expression is Not Regulated by Nuclear Factor, Erythroid 2- Like 2
(NRF2/NFE2L2) Under Oxidative Stress Conditions

5.1 Abstract
The flavin-containing monooxygenases (FMOs) are important for the
oxidation of a variety of endogenous compounds and xenobiotics. The
hepatic expression of FMO3 is highly variable and until recently, it was
thought to be uninducible. In this study, human FMO3 gene regulation by the
oxidative stress transcription factor, nuclear factor (erythroid-derived 2)-like 2
(NRF2) was examined. Constitutive FMO3 gene expression is repressed in
HepG2 cells, thus this cell can be a good model for FMO3 gene regulation
studies. Over-expression of NRF2 in HepG2 cells increased NRF2 target
gene expression, heme oxygenase-1 (HMOX1) and NAD(P)H:quinone
oxidoreductase-1 (NQO1), but did not alter FMO3 gene expression. Cotransfection studies with NRF2 or its cytosolic regulatory protein, Kelch-like
ECH-associated protein 1 (KEAP1), expression vectors, along with FMO3
promoter luciferase reporter constructs of various lengths (5 Kb or 6 Kb), did
not change FMO3 reporter gene activity significantly. Furthermore, treatment
with tert-butyl hydroperoxide (tBHP) or tert-butyl hydroquinone (tBHQ) did not
alter FMO3 reporter construct activity. In summary, in vitro results suggest
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that the transcriptional regulation of FMO3 might not involve the NRF2KEAP1 regulatory pathway.
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5.2 Introduction
Flavin-containing monooxygenases (FMOs) are enzymes that catalyze
oxidation of a variety of nitrogen-, sulphur- and phosphorous-containing
xenobiotics to their respective oxides. In human liver, constitutive FMO3
expression and developmental expression patterns have been extensively
studied (Klick & Hines, 2007; Klick et al., 2008; Shimizu et al., 2008). Briefly,
Klick and Hines demonstrated that binding of transcription factors such as
nuclear factor Y (NFY), upstream stimulatory factor 1 (USF1), YYI and an
unidentified GC box to the regulatory domains upstream of the transcription
start site are important for regulating constitutive FMO3 transcription (Klick &
Hines, 2007). The pre-B-cell leukemia factor 2 (Pbx2) as a heterodimer with
an unidentified homeobox (Hox) isoform contributes to FMO3 developmentaland tissue-specific regulation (Klick & Hines, 2007). Another factor, CCAAT
enhancer-binding protein β (C/EBPβ), binding more distal to the transcription
start site, is important for the FMO3 developmental expression pattern (Klick
et al., 2008). Finally, Shimuzu et al. (2008) reported that HNF-4 and NF-Y
modulates FMO3 gene expression in the Japanese population. Because
xenobiotic-induced FMO3 gene expression was not identified, transcriptional
regulation during toxicant exposure is not well characterized.
Acetaminophen (APAP)-induced hepatotoxicity results in Fmo3 overexpression in mice (Rudraiah et al., 2014). Additionally, we also showed that
toxic alpha-naphthyl isothiocyanate (ANIT) treatment and bile duct ligation
(BDL) induced Fmo3 gene expression (Rudraiah et al., 2014). Because all
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hepatotoxicants that induce Fmo3 also induce oxidative stress, the goal of the
current study was to investigate whether oxidative stress transcription factor
nuclear factor (erythroid-derived 2)-like 2 (NRF2) might regulate FMO3 gene
expression. FMO3 Constitutive expression is repressed in HepG2 cells
making this cell line useful for studying FMO3 regulation using recombinant
FMO3 promoter-directed reporter constructs. Thus, all in vitro studies were
performed in HepG2 cells. Reporter constructs containing FMO3 promoter
sequences of various lengths (5 Kb or 6 Kb) directing luciferase expression
were used in the current study. Co-transfection studies with FMO3 promoter
luciferase reporter constructs and NRF2 or its cytosolic retainer Kelch-like
ECH-associated protein 1 (KEAP1) did not significantly alter luciferase
reporter gene activity. Subsequent promoter analysis using MatInspector
software (Genomatix, Munich, Germany), did not identify any antioxidant
response element (ARE) sites on the reporter constructs used in the current
study. These results suggest that the transcriptional regulation of FMO3 might
not involve NRF2-KEAP1 regulatory pathway.
5.3 Material and Methods
Chemicals
Tert-butyl hydroperoxide and tert-butyl hydroquinone were purchased
from Sigma-Aldrich (St Louis, MO). All other reagents were of reagent grade
or better and commercially available.
Cell Culture and Transient Transfection Reporter Gene Assay
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HepG2 cells were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10 mM glucose, 10 % fetal bovine serum and 1
% antibiotic-antimycotic (100 units/mL penicillin G sodium, 100 µg/mL
streptomycin sulfate, and 0.25 µg/mL amphotericin B) in a 5 % CO2 and
humidified environment (95 % relative humidity) at 37°C. Expression plasmids
containing variable lengths of FMO3 promoter sequences (5905bp:pRNH970
or 4908bp:pRNH1013) directing luciferase expression were prepared using a
Genome Walker Kit (BD Biosciences) as described previously (Klick & Hines,
2007). Expression plasmid p3XFLAG-myc-CMV-26 (EV26) was obtained from
Sigma-Aldrich (St Louis, MO). NRF2 or KEAP1 ORF (Open Biosystems,
Waltham, MA) was cloned into EV26. For transient transfection, HepG2 cells
were seeded in a 12-well plate at approximately 30 % confluence. The
following day, transient transfection (NRF2 or KEAP1 expression plasmids
prepared in our lab) or co-transfections (FMO3 promoter luciferase reporter
constructs and transcription factor expression plasmids) was performed using
Lipofectamine (Invitrogen) according to the manufacturer’s manual. Cells
were harvested for RNA isolation or to determine luciferase activity using the
luciferase assay system (Promega) according to the manufacturer’s protocol.
For tert-butyl hydroperoxide (tBHP) and tert-butyl hydroquinone (tBHQ)
treatment culture media (complete DMEM) was replaced with media
containing 100 μM tBHP or 100 μM tBHQ 6 h after transfection. Cells were
harvested 42 h after treatment to determine luciferase activity. If not otherwise
indicated, the amount of lipofectamine used was 2.5 μL/well, the amount of
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transfected plasmids was 0.3 μg/well for transcription factors and 0.5 μg/well
for reporter genes.
RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRTPCR)
TRIzol reagent (Life Technologies, Carlsbad, CA) was used to extract
total RNA from cells transiently transfected with expression plasmids
containing NRF2 or KEAP1. cDNA was prepared using the M-MLV RT kit
(Invitrogen, Carlsbad, CA). NRF2, KEAP1, HMOX1, NQO1 and FMO3 mRNA
expression was quantified by the ΔΔCT method and normalized to the
housekeeping gene, β-actin. Primer pairs were synthesized by Integrated
DNA Technologies (Coralville, IA) and are presented in Table 1. Amplification
was performed using an Applied Biosystems 7500 Fast Real-Time PCR
System. Amplification was carried out in a 20 μL reaction volume containing 8
μL diluted cDNA, Fast SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA) and 1 μM of each primer.
Isolation of Nuclear Fraction from HepG2 Cells
HepG2 cells were plated at 8x105 cells per dish in a 60 mm dish
overnight. The following day, cells were treated with 100 μM tBHP in serum
free DMEM for 2 h. After 2 h, cells were removed from the incubator, scraped
and collected in 1 mL cold PBS and transferred into microcentrifuge tubes.
The cell suspension was then centrifuged at 12000 g for 1 min to collect the
cells. Cell pellets were resuspended in 400 μL cold hypotonic buffer [10 mM
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HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and 0.2 mM
phenylmethylsulfonylfluoride (PMSF)] and incubated for 20 min on ice,
vortexed for 10s and then centrifuged at 1000 g for 10 min at 4°C. The
resulting pellet was again resuspended in hypertonic buffer (20 mM HEPES,
pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 0.5 mM DTT, 25 %
glycerol and 0.2 mM PMSF) and incubated on ice for 20 min for high-salt
extraction. Samples were vortexed for 10s and centrifuged at 1000 g for 10
min. The supernatant fraction containing nuclear proteins was measured for
protein concentration.
Western Blot Analysis
For western blot analysis of NRF2, 40 μg nuclear protein was mixed
with Laemmli’s buffer, incubated at 90°C for 10 min, and electrophoretically
resolved using 10 % SDS polyacrylamide gels and transblotted onto PVDFPlus membrane (Micron Separations, Westboro, MA). A custom rabbit antiHuman NRF2 primary antibody (Cell Signaling Technology, Inc. Danvers,
MA) was used to detect NRF2 with TFIIB as a loading control. Blots were
then incubated with HRP conjugated secondary antibodies against rabbit IgG
(Sigma-Aldrich, St Louis, MO). Protein-antibody complexes were detected
using a chemiluminescent kit (Thermo Scientific, IL) with visualization using
GeneMate blue autoradiography film (Bioexpress, Kaysville, UT).
LDH Leakage
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Percent lactate dehydrogenase (LDH) leakage was determined via the
Tox-7 kit (Sigma-Aldrich, St. Louis, MO) as a measure of cytotoxicity following
tBHP treatment. The assay was performed according to manufacturer’s
instructions.
Statistical Analysis
Results are expressed as mean ± standard error (SE). Data were
analyzed using the student’s t-test, one-way ANOVA with Dunnett’s post-hoc
test or two-way ANOVA followed by the Bonferroni’s post-hoc test. All
statistical analysis was performed using GraphPad Prism version 4.00 for
Macintosh (GraphPad Software, Inc., San Diego, CA). A p value of <0.05 was
considered statistically significant.

	
  

200	
  

Table 5.1 Primer Sequences for Quantitative RT-PCR
Gene

Primer Sequences
Forward: 5'- TTG TAA ATG CTA GCC CTG CC -3'

FMO3
Reverse: 5'- CTG TCT GGA AGA GGG GCT G -3'
Forward: 5'- GCC AGC AAC AAA GTG CAA G -3'
HMOX1
Reverse: 5'- GAG TGT AAG GAC CCA TCG GA -3'
Forward: 5'- TGA CAA GCT TAT GCA GCC AGA TCC CAG G -3'
KEAP1
Reverse: 5'- GTG AGG ATC CTC AAC AGG TAC AGT TCT GCT GGT -3'
Forward: 5'- GGA CTG CAC CAG AGC CAT -3'
NQO1
Reverse: 5'- TCC TTT CTT CTT CAA AGC CG -3'
Forward: 5'- GCT CAT ACT CTT TCC GTC GC -3'
NRF2
Reverse: 5'- ATC ATG ATG GAC TTG GAG CTG -3'

	
  

201	
  

5.4 Results
NRF2 and KEAP1 Over-expression Did Not Significantly Alter FMO3 mRNA
Expression in HepG2 Cells
To examine the possible role of the NRF2-KEAP1 regulatory pathway
in controlling FMO3 gene expression, FMO3 mRNA levels were quantified in
cells over-expressing NRF2 or its cytosolic regulatory protein, KEAP1. The
results in Figure 5.1 show that transfection with the NRF2 expression vector
results in a 2.7±0.2-fold change in NRF2 mRNA levels compared to empty
vector-transfected cells. Transfection with KEAP1 expression vector results in
a 1.4±0.15-fold change in KEAP1 mRNA levels compared to empty vector
controls. Over-expression of NRF2 results in significantly higher expression of
the NRF2 target genes, NQO1 and HMOX1, by 3.1±0.7-fold and 3.4±0.4-fold,
respectively, compared to the empty vector. No significant change in FMO3
mRNA expression is observed with NRF2 over-expression. In addition, no
significant change in NQO1, HMOX1 and FMO3 mRNA expression is seen
with KEAP1 over-expression (Figure 5.1).
A Subtoxic Dose of tBHP Results in NRF2 Nuclear Translocation and
Expression of NRF2 Target Genes in HepG2 Cells
In response to a 100 µM tBHP treatment for 24 h, the percent LDH
leakage from HepG2 cells did not change (Figure 5.2A). Treatment with a
subtoxic dose of tBHP (100 µM) for 2 h results in an increase in NRF2 nuclear
localization (Figure 5.2B).
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associated with significant increases in the expression of the NRF2 target
genes, HMOX1 and NQO1 by 1.8±0.3- and 1.7±0.06-fold, respectively,
compared to vehicle treated controls (Figure 5.2C and 5.2D).
Effect of NRF2 or KEAP1 Over-expression on FMO3-directed Reporter Gene
Activity
To determine whether the transcription factor, NRF2, activates FMO3
gene expression, co-transfection studies with NRF2 or KEAP1 expression
vectors and FMO3 promoter luciferase reporter constructs (pRNH1013 and
pRNH970) were performed. Co-transfection of reporter genes with NRF2 or
KEAP1 did not significantly alter FMO3-directed reporter gene activity (Figure
5.3A). Furthermore, NRF2 or KEAP1 over-expression studies also were
carried out using a subtoxic dose of the pro-oxidant and Nrf2 activator, tBHP.
Results are shown in Figure 5.3B. No significant change in reporter gene
activity is seen with KEAP1 co-transfection. However, tBHP treatment
combined with NRF2 expression plasmid and FMO3 promoter luciferase
reporter construct co-transfection, significantly decreased luciferase activity.
Effect of Pro-oxidant-induced NRF2-KEAP1 Regulatory Pathway Activation
on FMO3-directed Reporter Gene Activity
FMO3

promoter

luciferase

reporter

constructs

(pRNH1013

&

pRNH970) or empty vector were transiently expressed in HepG2 cells and
exposed to tBHP or tBHQ. No significant change in reporter gene activity is
observed after treatment (Figure 5.4).
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Figure 5.1
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Figure 5.1 Effect of NRF2 and KEAP1 over-expression on FMO3 mRNA
levels in HepG2 cells. The oxidative stress responsive transcription factor,
NRF2, or its cytosolic regulatory protein, KEAP1, were transiently expressed
in HepG2 cells. RNA was isolated from cells 48 h after transfection. cDNA
was made using a commercial MMLV-RT kit and the cDNA samples were
analyzed by quantitative RT-PCR using human NRF2, KEAP1, NQO1,
HMOX1 and FMO3 specific primers. mRNA levels were normalized to the
housekeeping gene, β-Actin. NRF2, KEAP1, HMOX1, NQO1 and FMO3
mRNA expression are presented as mean fold change ± SE. Each
experiment was done in triplicate and repeated at least three times, and
representative experimental results are shown. One-way ANOVA followed by
Dunnett’s post-hoc test was used for data analysis. Asterisks (*) represent a
statistical difference (p < 0.05) from empty vector (EV26) transfected group.
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Figure 5.2
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Figure 5.2 Effect of tBHP treatment on cytotoxicity and NRF2-KEAP1
regulatory pathway in HepG2 cells. (A) HepG2 cells were treated with tBHP
(100 μM) or vehicle for 2 h. Cytotoxicity with 100 μM tBHP was measured by
measuring LDH activity in the medium 2 and 24 h after treatment. The data
are presented as LDH leakage (%) ± SE. (B) Western blots for NRF2 were
performed using nuclear fractions from tBHP- and vehicle-treated HepG2
cells. RNA was isolated from HepG2 cells 24 h after treatment with tBHP.
cDNA samples were analyzed by quantitative RT-PCR for NRF2 target genes
HMOX1 (C) and NQO1 (D). Gene expression was normalized to the
housekeeping gene β-Actin. NQO1 and HMOX1 mRNA expression are
presented as mean fold change ± SE. Each experiment was done in triplicate
and repeated at least three times, and representative experimental results are
shown. Student’s t-test was used for data analysis. Asterisks (*) represent a
statistical difference (p < 0.05) from control treated group.
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Figure 5.3
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Figure 5.3 Effect of NRF2 or KEAP1 over-expression on FMO3-directed
reporter gene activity. Transcription factor, NRF2, or its cytosolic regulatory
protein, KEAP1, were transiently co-expressed with the FMO3 promoter
luciferase reporter constructs 5kb-length (pRNH1013), 6kb-length (pRNH970)
or the parent plasmid, pGL3 basic, in HepG2 cells. (A) Luciferase activity was
measured 48 h after transfection, using a commercial kit. Luciferase activity
was normalized to total protein and data are presented as mean fold change
± SE. (B) HepG2 cells were treated with the pro-oxidant, tBHP (100 μM), or
vehicle 24 h after transfection for 6 h. Luciferase activity was measured 42 h
after tBHP treatment. Luciferase activity was normalized to total protein and
presented as mean fold change ± SE. Each experiment was done in triplicate
and repeated at least three times, and representative experimental results are
shown. Two-way ANOVA was performed followed by the Bonferroni’s posttest. Asterisks (*) represent a statistical difference (p < 0.05) from the
respective empty vector (EV26) transfected group.
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Figure 5.4
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Figure 5.4 Effect of tBHP and tBHQ on FMO3-directed reporter gene activity.
FMO3 promoter luciferase reporter constructs (pRNH1013 & pRNH970) or
the parent plasmid, pGL3 basic were transiently transfected into HepG2 cells.
The transfected cells were treated with the pro-oxidant tBHP (100 μM), tBHQ
(100 μM) or vehicle 48 h after transfection for 6 h. Luciferase activity was
measured 42 h following treatment with tBHP or tBHQ. Luciferase activity was
normalized to total protein and presented as mean fold change ± SE. Each
experiment was done in triplicate and repeated at least three times, and
representative experimental results are shown. Two-way ANOVA was
performed followed by the Bonferroni’s post-test. Statistical comparisons
revealed no significant differences among the data sets.
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5.5 Discussion
Mammalian FMOs have long been considered non-inducible by
xenobiotics (Cashman & Zhang, 2002; Krueger & Williams, 2005). Thus, the
transcriptional regulation of FMO involving stress activated transcription
factors has not been studied. Recently, Celius et al. (2008, 2010) showed that
activation

of

the

Aryl

hydrocarbon

(Ah)

receptor

by

2,3,7,8-

tetrachlorodibenzo-p-dioxin (TCDD) induced Fmo3 mRNA expression in mice.
The authors also showed that increased Fmo3 mRNA levels in response to 3methylcholanthrene (3MC) and benzo(a)pyrene (BaP) treatment, but not by
TCDD, in Hepa-1 cells was mediated by p53 binding to a response element in
the Fmo3 promoter region (Celius et al., 2010). A gene array analysis
performed in our laboratory also identified increased Fmo3 gene expression
after APAP treatment (O'Connor et al., 2014). We have also demonstrated
enhanced Fmo3 gene expression after treatment with other hepatotoxicants
such as alpha-naphthyl isothiocyanate and after bile duct ligation (Rudraiah et
al., 2014; Rudraiah et al., 2014). Given that all three of these latter treatments
results in oxidative stress, the goal of the present study was to determine
whether FMO3 regulation under oxidative stress conditions might involve
NRF2-KEAP1 regulatory pathway activation, which is known to mediate many
oxidative-stress induced changes in gene expression.
Over-expression of NRF2 induced expression of its known target
genes, HMOX1 and NQO1 (Aleksunes et al., 2006; Aleksunes & Manautou,
2007; Aleksunes et al., 2008). With over-expression of KEAP1 we anticipated
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seeing a significant decrease in HMOX1 and NQO1 expression, but no such
changes were observed. HMOX1 has also been shown to be regulated by
hypoxia-inducible factor-1α (HIF-1α) and JNK-1 (Yeligar et al., 2010).
Similarly, AhR has been shown to regulate NQO1 (Wang et al., 2013; Yeligar
et al., 2010). It is possible that during over-expression of KEAP1, transcription
factors other than Nrf2 play a role in maintaining expression of HMOX1 and
NQO1. Over-expression of NRF2 or KEAP1 did not significantly alter FMO3
gene expression, suggesting that FMO3 gene regulation does not involve
NRF2-KEAP1. However, Klick et al. demonstrated that treatment of HepG2
cells with 5-aza-2’-deoxycytidine (DNA methyl transferase inhibitor) resulted
in detectable FMO3 expression, consistent with DNA methylation being a
major mechanism repressing HepG2 FMO3 expression (Klick et al., 2008).
The DNA methylation-mediated suppression of HepG2 FMO3 may well have
prevented any NRF2-mediated effects on this gene.
To further investigate possible NRF2-mediated FMO3 gene regulation,
co-transfection studies using two FMO3 promoter luciferase reporter
constructs (pRNH1013 and pRNH970) were performed. Co-transfection of
NRF2 or KEAP1 expression vectors along with the FMO3 reporter constructs
did not significantly alter reporter gene activity. However, co-transfection of
the NRF2 expression vector and the FMO3 reporter constructs, in addition to
activation of NRF2 nuclear translocation by a treatment with a subtoxic dose
of tBHP, did reduce reporter gene activity significantly. Although, this is
suggestive of a potential NRF2 suppressive effect on FMO3 gene
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transcription, a 6 kb promoter analysis using MatInspector software
(Genomatix, Munich, Germany), did not identify any antioxidant response
element (ARE) site on FMO3 promoter. The decrease in reporter gene activity
might be due to an indirect mechanism during oxidative stress conditions that
may or may not involve NRF2. The one other major possibility worth
evaluating is the activator protein-1 mediated regulation of FMO3. Oxidative
stress is known to alter signaling through c-Jun N-terminal Kinase (JNK) and
related pathways, thus activating AP-1 (Elsby et al., 2003; Enomoto et al.,
2001; Li & Jaiswal, 1992). In addition, promoter analysis discovered four
binding sites for AP-1 at about 0.7, 0.9, 4.9 and 5.7 kb from the transcription
start site on the human FMO3 promoter (data not shown).
FMO3 reporter construct over-expression along with NRF2 activation
by tBHP or tBHQ treatment also failed to alter reporter gene activity. The
tBHP dose used in this study increased NRF2 nuclear translocation and
expression of the known NRF2 target genes, HMOX1 and NQO1.
Collectively, these data suggest that FMO3 transcriptional regulation does not
involve the NRF2-KEAP1 signaling pathway.
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CHAPTER 6
Summary
Flavin-containing monooxygenase-3 (Fmo3) is a drug-metabolizing
enzyme involved in oxygenation of a wide variety of endogenous substances
and xenobiotics (Krueger & Williams, 2005). The importance of mammalian
FMO in xenobiotic metabolism is known, but its physiological function(s) are
poorly understood. Among all FMOs in humans, FMO3 is most studied
because mutant alleles contribute to a disease known as trimethylaminuria or
fish-odor syndrome. Until recently, Fmo3 gene inducibility by xenobiotics was
not known. Recent studies with Ah receptor agonists demonstrated increased
Fmo3 gene expression in mice livers (Celius et al., 2008; Celius et al., 2010).
A gene array analysis performed previously in our laboratory also
demonstrated increases in liver Fmo3 gene expression in the mouse model of
APAP autoprotection (O'Connor et al., 2014). Given the prevalence of APAPhepatotoxicity and the human health impact associated with the misuse of this
popular over-the-counter and prescription medication, a further understanding
of the mechanism(s) involved in such protection and the identification of new
genetic determinants of APAP toxicity is of considerable significance. The
work presented in this dissertation examines Fmo3 gene expression and
regulation during oxidative stress conditions. Our studies provide the first
comprehensive analysis of Fmo3 gene and protein expression changes, as
well as catalytic enzyme activity, in response to treatment with a xenobiotic.
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The functional significance of Fmo3 over-expression to APAP toxicity was
also investigated employing both in vitro and in vivo methods.
In Chapter 2, we examined Fmo3 mRNA and protein expression
during APAP-induced liver injury. The significance of FMO3 over-expression
was also investigated to establish a causal relationship between the Fmo3
gene expression and APAP hepatotoxicity. It is demonstrated in Chapter 2
that Fmo3 mRNA expression in response to a single dose of APAP is
accompanied by marginal increases in Fmo3 protein expression and catalytic
activity. In contrast to what was observed with a single mildly hepatotoxic
dose of APAP, both liver Fmo3 mRNA and protein expression are significantly
higher in mice treated with the APAP autoprotection regimen (pre- and postAPAP treatment). Fmo3 gene expression alteration was further confirmed by
examining protein expression by western blotting, immunohistochemistry as
well as enzymatic assay. Consistent with the protein expression analysis by
western blotting, Fmo3 catalytic activity and centrilobular zonal expression
are also significantly greater in the APAP autoprotection group. One of the
most striking finding in this study is the highly confined distribution of the
Fmo3 protein around the central vein after APAP in the APAP autoprotected
livers. Together, these studies suggest that the regulation of Fmo3 gene
expression (transcriptional and/or translational) is different under the
conditions of treatment with a single APAP dose versus an autoprotection
treatment regimen.
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The functional significance of Fmo3 over-expression during APAP
hepatotoxicity was evaluated both in vivo and in vitro. Female mice express
higher basal Fmo3 levels in liver than male mice (Cherrington et al., 1998;
Hines, 2006; Janmohamed et al., 2004), and are much more resistant to
APAP hepatotoxicity compared to males (Dai et al., 2006). MMI inhibition of
Fmo3 renders female mice highly susceptible to APAP-induced hepatotoxicity
without altering the magnitude of liver injury produced by APAP in male mice.
Results

from

hepatocyte

cell

line

(HC-04)

over-expressing

FMO3

demonstrate that enhanced expression of FMO3 confers resistance against
APAP-induced cytotoxicity. Together, our studies in Chapter 2 indicate that
Fmo3 gene is inducible following hepatotoxic APAP treatment in mice and
that FMO3 over-expression is protective against APAP-induced cytotoxicity in
cultured liver cells. These data provide the foundation for subsequent studies
aimed at unveiling the function(s) that make Fmo3 a novel genetic
determinant of APAP toxicity.
The purpose of the next set of studies presented in Chapter 3 was to
investigate Fmo3 gene induction in other mouse models of hepatic injury.
Hepatotoxicants used in this study include ANIT, CCl4 and AlOH. In addition,
BDL was used as our fourth model since it is a widely accepted surgical
intervention producing cholestatic liver injury. Since a common feature of all
these forms of liver injury is oxidative stress, the potential role of the
transcription factor Nrf2 in altering Fmo3 gene expression was also
examined. We show that toxic ANIT and BDL significantly alter Fmo3 mRNA
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expression. CCl4-mediated liver injury significantly decreased Fmo3 mRNA
expression and no change in expression is evidenced with AlOH. We also
observed a toxicity threshold for Fmo3 gene expression in APAP, ANIT and
BDL livers. Mild to moderate injury in all three models appears to be optimal
for Fmo3 mRNA induction, while no change and/or reduction in Fmo3
expression is seen with more pronounced injury. While both cholestasis
models, toxic ANIT and BDL, significantly alter Fmo3 mRNA expression,
Fmo3 protein increase is observed only with ANIT. It is possible that under
more pronounced oxidative stress conditions (as seen in cases of greater
magnitude of hepatotoxicity) some proteins involved in gene translation are
oxidized in vivo inhibiting translation (Shenton et al., 2006). The possibility of
translational inhibition during BDL should not be overlooked.
In addition, Fmo3 gene induction is still observed in Nrf2 knockout
mice in response to APAP treatment, indicating that the transcriptional
regulation of Fmo3 does not involve Nrf2 signaling. It is also possible that the
hepatocellular injury that persists at 72 h in Nrf2 KO mice most likely activates
other signaling mechanisms mediating Fmo3 gene induction. To determine
whether accumulation of bile acids is a signaling event regulating Fmo3, total
hepatic and plasma bile acid levels were measured with all hepatotoxicants.
Consistent with the literature, ANIT and BDL increased plasma and hepatic
bile acid concentrations. A high CCl4 dose did not significantly alter liver bile
acid levels, but significantly increased plasma bile acid concentration. APAP
tended to increase both hepatic and plasma bile acid concentrations, but this

	
  

218	
  

is not statistically significant. No change in plasma and hepatic bile acid levels
were observed with AlOH treatment. Because, ANIT, BDL and APAP that
induced Fmo3 gene expression also increased hepatic and plasma bile acid
levels, future studies to address the mouse liver Fmo3 gene regulation should
investigate the role of nuclear receptor farnesoid X receptor (FXR) in Fmo3
gene induction. FXR is one of the major bile acid sensors in the liver (Chiang,
2002) and plays a protective role during cholestasis development. Recently, it
has also been shown that activation of FXR induces Fmo3 protein function in
mice (Bennett et al., 2013). Furthermore, activation of FXR can protect
against APAP-induced hepatotoxicity (Lee et al., 2010). In support of all this,
we discovered using Matinspector three binding sites for farnesoid X
receptor-response element (FXRE) on the mouse Fmo3 promoter.
Similar to our APAP autoprotection mouse model, human liver can
adapt to APAP-induced hepatotoxicity (Shayiq et al., 1999; Watkins et al.,
2006). Thus, the goal of Chapter 4 was to investigate FMO3 gene induction
in a human hepatoma cell line, HepaRG cells. HepaRG cell line is a recently
developed cellular model that expresses a more normal spectrum of drug
metabolizing enzymes comparable to human hepatocytes. The mechanistic
features of APAP-induced hepatotoxicity in HepaRG cells are similar to that
reported for mouse primary hepatocytes and mouse liver in vivo (McGill et al.,
2011). Experiments in Chapter 4 demonstrate FMO3 gene induction during
APAP-induced cytotoxicity. This is the first report showing induction of FMO3
by a xenobiotic treatment in human hepatocytes.

	
  

219	
  

Furthermore, to study the functional significance of FMO3 overexpression during APAP-induced cytotoxicity, HepaRG cells over-expressing
FMO3, as an alternative in vitro system, were developed. As described
previously in this dissertation (Chapter 2), we had already established the
hepatocyte cell line HC-04 over-expressing human FMO3 (hFMO3-HC-04).
HepaRG cells differ from HC-04 cells in that the constitutive FMO3
expression is very high, which is comparable to adult human liver. FMO3
over-expression in HepaRG cells was assumed to model FMO3 overexpression during APAP treatment in human liver/hepatocytes. Consistent
with results from hFMO3-HC-04 cells, the results from hFMO3-HepaRG cells
also show that FMO3 over-expression alters susceptibility to APAP-induced
hepatotoxicity. Most importantly and highly intriguing, our data with the
HepaRG cells show that FMO3 may play an important role in cellular
differentiation. The potential role for FMO3 in cellular differentiation is
consistent with the latent profile of Fmo3 protein expression changes we
observed in vivo in our APAP autoprotection mouse model (Chapter 2). It
remains to be determined the mechanism underlying the faster rate of cell
differentiation driven by FMO3 over-expression in HepaRG cells. Future
studies that could aid in not only characterizing the functions of Fmo3 that
make it a genetic determinant of APAP hepatotoxicity, but also its potential
role in speeding cell differentiation are planned employing transcriptomics,
proteomics and possibly RNA-seq approaches. The goal of these proposed
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studies is to identify signaling pathway(s) and cellular events associated with
FMO3 function that may be relevant to the main findings of this dissertation.
Toxic APAP, ANIT and BDL induce Fmo3 gene expression in mice. A
common event for all hepatotoxicants that induce Fmo3 in mice is oxidative
stress, and activation of Nrf2-Keap1 regulatory pathway. NRF2 target gene
NQO1 induction is also reported in human liver samples obtained from
patients during transplantation following APAP overdose (Aleksunes et al.,
2006). The results in Chapter 3 with Nrf2 null mice show that Fmo3 is not
regulated by transcription factor Nrf2 but FMO3 gene regulation and promoter
sequences differ between humans and mice. Thus, the experiments in
Chapter 5 were aimed to investigate whether NRF2 regulates human FMO3
gene expression. Constitutive FMO3 expression is repressed in HepG2 cells
(Klick et al., 2008). Thus, HepG2 cells were used for all experiments in this
study. Co-transfection studies with FMO3 promoter luciferase reporter
constructs (5 kb or 6 kb) and NRF2 or its cytosolic retainer Kelch-like ECHassociated protein 1 (KEAP1) did not significantly alter luciferase reporter
gene activity. Subsequent promoter analysis using Matinspector did not
identify any antioxidant response element (ARE) sites on reporter constructs
used in the current study. Based on these results we concluded that the
transcriptional regulation of FMO3 might not involve NRF2-KEAP1 regulatory
pathway.
Although, investigating FMO3-driven HepaRG differentiation is a
potential subject of future innovative research, the possible involvement of
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FMO in maintaining cellular thiol:disulphide ratios deserves consideration also
and

should

not

be

overlooked.

The

relationship

between

cellular

thiol:disulphide ratios and the regulation of metabolic reactions is very well
documented (Barron, 1953). Cysteamine is a substrate for FMO3 oxygenation
and oxygenation of cysteamine during APAP hepatotoxicity may serve to help
control the overall thiol:disulphide redox state of the cell. This in turn may
modulate cellular metabolism and/or activate signal transduction pathway
leading to altered susceptibility to APAP (or protection). Thus, strengthening
cellular defenses and heightened toxicant tolerability. It is also possible that
oxygenation of cysteamine to cystamine by Fmo3 and transport out of the cell
also may represent a detoxication mechanism and/or protective event,
because cysteamine is toxic to cells at concentrations as low as 39 µM
through the transition metal-dependent formation of hydrogen peroxide
(Jeitner & Lawrence, 2001). To investigate whether oxygenation of
cysteamine to cystamine by Fmo3 is important during APAP hepatotoxicity,
follow-up studies will measure the total hepatic cysteamine and cystamine
concentrations in the mouse model of APAP autoprotection. Together, this
work not only supports the usefulness, but also validates the use of
transcriptomic analysis for identifying genetic determinants of diseases and
adverse reactions to chemicals (e.g. chemical-induced hepatotoxicity). Both
the in vitro and in vivo approaches used in this study represent valuable tools
for investigating the involvement of FMO3 during APAP-induced hepatic
injury.
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